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The misfolding, aggregation and accumulation of specific proteins is the overarching 
concept in protein misfolding disorders (PMDs). The microtubule associated protein tau is known 
to form insoluble filaments known as neurofibrillary tangles (NFTs) composed of 
hyperphosphorylated tau (pTau) found in a subset of PMDs called tauopathies, such as 
Alzheimer’s disease (AD) and chronic traumatic encephalopathy (CTE), among others. Misfolded 
tau engenders a structurally alternative intermediate conformation that is prone to aggregate 
having amyloidogenic properties. Formation of amyloids, such as tau aggregates, is proposed to 
follow a nucleation-polymerization model where misfolded, soluble oligomeric seeds can trigger 
native proteins to misfold and aggregate. The processes responsible for the initial formation of 
seeding competent protein aggregates is not known. One hypothesis is that an insult to the brain 
could be a trigger for developing aggregate pathology noted in PMDs. Traumatic Brain Injury 
(TBI) is a pervasive event with an estimated 10 million people worldwide being affected and is 
defined as an insult to the brain caused by an external force, which may result in impaired neuronal 
and/or physical functioning. Indeed, TBI is a strong risk factor for PMDs, and following TBI, 
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there is a detection of pathological tau early in human cases. TBI may be a trigger for the 
formation of tau seeds that can spread pathology throughout the brain. Thus, our central 
hypothesis is that TBI induces the early formation of tau misfolded seeds as well as exacerbates 
tau pathology and spreading throughout the brain by a nucleation-polymerization process, which 
will then lead to pathological changes relative to disease. Our overarching goal of this work is to 
elucidate the effect of TBI on the induction, acceleration, and spreading of tau pathology and 
clinical signs. To assess this, we induced tau transgenic mice with moderate-severe TBI or 
repetitive mild TBI (rmTBI) and examined tau pathology and spreading. Moreover, the earliest 
detected tau seeds induced following rmTBI were tested for seeding capability by in vivo bioassay.  
This proposal provides novel molecular mechanisms for these deleterious diseases, such as AD 
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Protein misfolding diseases and tauopathies 
The appropriate folding of a protein is imperative for its function. The primary structure 
of a protein consists of the amino acid sequence. The secondary structure of a protein can be 
referred to two primarily common structures – alpha helix and beta sheet, which are composed by 
the patterns of hydrogen bonds formed between amine hydrogen and carbonyl oxygen atoms as 
the backbone peptide bonds of the protein. Here, the folding of a protein into its proper native 3-
D structure can occur, and this is a well-regulated process. The information for protein folding is 
encoded in the amino acid sequence; in addition, minimization of the hydrophobic amino acid 
side chains to the soluble atmosphere is an important factor. However, events can occur that can 
cause a protein to misfold: genetic mutations, transcriptional/translational errors, failure of the 
folding/chaperone machinery, errors in post-translational modifications or protein trafficking, 
environmental changes, and induction by a seeding mechanism. Any of these actions can cause 
the misfolded state of a protein to be favored over the properly folded form. These factors can 
lead to the denaturing - disruption of the native state - of a protein where this unfolded protein 
follows lower energy levels and stability having a proclivity to thereby aggregate 1.  
If a protein does not fold into its functional structure, this can give rise to the 
malfunctioning of living systems and hence to disease, which may be caused by a loss-of-function 
and/or toxic gain-of-function; moreover, the misfolding of a protein seems to play a significant 
role in such neurodegenerative diseases (NDs) that involve protein aggregates present in affected 
tissue that can reveal altered or toxic effects. Thus, the misfolding, aggregation, and accumulation 
of specific proteins is the overarching concept in protein misfolding disorders (PMDs) (Figure 1). 
There are more than 20 PMDs including: prion diseases, Amyotrophic Lateral Sclerosis,  
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Huntington’s disease, Parkinson’s disease (PD), Alzheimer’s disease (AD), Type 2 diabetes, and 
others 2–7. Although there may be disparate clinical abnormalities and disease progression 
associated with each of these PMDs, there is common ground noted in this group of maladies, 
such as: a definitive protein adopting an alternative structure, can be age-dependent, form from 
Figure 1. Pathogenic proteins and protein misfolding disorders (PMDs). In general, 
proteins fold properly into their native conformation; however, the misfolding of a protein 
results in its aggregation and accumulation as protein deposits in diverse tissues related to 
various protein misfolding disorders (PMDs). There are more than 20 of these diseases 
regarded as PMDs including: prion diseases, Amyotrophic Lateral Sclerosis, Huntington’s 
disease, Parkinson’s disease (PD), Alzheimer’s disease (AD), Type 2 diabetes, and others 
1–6
. 
Soto C. Unfolding the role of protein misfolding in neurodegenerative diseases. Nat Rev Neurosci. 2003 
Jan;4(1):49-60. License agreement for reuse of image was obtained from Springer Nature Publishers. 
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inherited or sporadic origin, and 
can have neurodegenerative 
capacities 2. One type of PMD is 
a group of sporadic or familial 
neurodegenerative diseases that 
are designated by filamentous 
aggregates of 
hyperphosphorylated tau protein 
(pTau) in neurons and/or glial 
cells called tauopathies. 
Tauopathies consist of more than 
20 disorders and can be sub-
classified as either primary or 
secondary tauopathy depending 
on if tau pathology encompasses 
the main contribution of 
neurodegeneration or is an 
accomplice to another pathology 
in the disease 8,9 (Table 1). 
Accordingly, these tauopathies 
each have their own unique 
clinical characteristics, yet follow 
the same general common ground characteristics of PMDs as detailed above. Nonetheless, it is 
Table 1. Tauopathies. There are diverse tauopathies that 
can be classified as primary or secondary tauopathies in 
terms of pathological protein accumulation. Each of 
these tauopathies is different by symptoms and 
neuropathology, yet all of the incorporate the same 
protein aggregate – tau protein. 
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not clearly understood the exact mechanisms of how a protein in its native state, like tau, can 
misfold and aggregate and cause disease-related alterations in the brain. 
Tau protein – structure and function 
As exampled in Figure 2, the microtubule-associated protein tau gene (MAPT) is located 
on chromosome 17q21 and contains 16 exons; however, the major tau protein in the human brain 
is encoded by 11 exons. In the human brain, there are six isoforms of tau, which are produced by 
the alternative splicing of exon 2, 3, and 10 and contain 352 to 441 amino acids.  They differ by 
the number of insertions of 29 amino acids at the N-terminal (exon 2 and 3) – either zero (0N), 
one (1N), or two (2N) – as well as three (3R) or four repeat-regions (4R) at the carboxy-terminal. 
Exon 10 corresponds to the second repeat region (R2) and is absent in 3R isoforms. MAPT gene 
expression is developmentally regulated. Adult human brains consist of all six isoforms, yet fetal 
brains exhibit only the shortest isoform (3R/0N) in brain. In the adult human brain, 3R and 4R are 
Figure 2. Six microtubule associated protein tau isoforms in the adult human brain. In 
the brain, exons 2, 3, and 10 are alternatively spliced. Exon 3 (light blue) is only present with 
exon 2 (dark blue). Exon 10 (red boxes) encodes one of in overall four microtubule binding 
repeats (R1-R4). Thus, in general, exons 2, 3, and 10 give rise to six isoforms characterized by 
the absence (0N), one (1N) or two (2N) amino-terminal inserts in arranged with three (3R) or 
four (4R) microtubule binding repeats. 
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fairly similar, yet the N-terminal insertions vary as 0N, 1N, and 2N consist of ~37%, ~54% and 
~9% of total tau, respectively. Interestingly, tauopathies can also be categorized by isoforms such 
as 1) 4R only - progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), 
argyrophilic grain disease (AGD); 2) 3R only - Pick’s disease (PiD); or 3) mixed 3R/4R - AD and 
chronic traumatic encephalopathy (CTE) 8–14. 
Tau protein is a remarkably hydrophilic protein and is thought to lack a fixed or ordered 
structure in its native state, thereby being intrinsically disordered or natively unfolded, and this 
dynamic protein in its native state is not thought to have a propensity to aggregate 8,10,13,14. Studies 
using circular dichroism spectroscopy delineated tau as a random coil 15, yet tau gravitates to form 
a paperclip-like conformation, where the N-terminal, R regions, and C-terminal come in close 
approximation to each other. However, tau can become prone to aggregation when bound to an 
interacting protein or partner 10,14. Tau’s most canonical function is binding to microtubules to 
promote cytoskeletal support and flexibility, thereby aiding in axonal transport, as shown in 
Figure 3; although, it has numerous other functions. Tau proteins interact with tubulin to stabilize 
microtubules and promote tubulin assembly into microtubules. The 3R/4R repeat-regions, also 
referred to as the microtubule-binding domain, are positively charged amino acid regions that are 
important for binding to the negatively charged microtubules. 4R tau, which has the R2 region, 
displays higher propensity for microtubules and thus can affect microtubule assembly better than 
3R tau 8–14. Moreover, residues located in the microtubule binding region 269-284 and 300-310, 
which comprise two hexapeptide motifs 275VQIINK280 and 306VQIVYK311, as well as some 
adjacent regions are critical for microtubule binding and for tau aggregation 10,16. Splicing and 
missense mutations can affect the isoform ratio or microtubule-tau binding regions allowing 
disassociation of tau to the microtubule and/or propensity for aggregation, respectively. Thus, tau 
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has several ways of controlling microtubule stability – isoforms, amino acid binding domain 
regions, and phosphorylation.  
Figure 3. Physiological versus pathological tau. Under physiological conditions, tau’s 
main function is binding to microtubules to aid in cytoskeletal support and axonal 
transport. When hyperphosphorylation occurs it affects the binding properties of tau to the 
microtubule, detaching tau, and unbound tau can begin accumulating in the cytosol where 
it has the chance to form a misfolded conformation. This free tau is also suggested to 
mislocalize by arranging from the axons to the somatodendtric compartment. Tau is 
thought to begin self-templating from dimers, trimers, oligomers to a protofibril or 
filamentous structure (paired helical filaments) and finally to the insoluble amyloid 
aggregate neurofibrillary tangles (NFTs) distinguished in tauopathies. 
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Tau is a known phosphoprotein where phosphorylation plays an integral role for its 
physiological function. The number of phosphorylation sites for tau has been enumerated up to 
85 reported residues (80 serine or threonine and 5 tyrosine) with approximately 30 of these sites 
in normal tau protein 8. One example, tau in AD-derived paired helical filaments (PHFs) can be 
phosphorylated at approximately 45 residues 14. Tau is phosphorylated by numerous kinases 
including microtubule affinity-regulating kinases; cyclic AMP-dependent protein kinase; Ca2+ - 
or calmodulin-dependent protein kinase II; tyrosine kinases; proline-directed kinases like 
glycogen synthase kinase 3β (GSK-3β), cyclin-dependent kinase 5, mitogen-activated protein 
kinase, and JUN N-terminal kinase; among others 17. As tau phosphorylation and 
dephosphorylation is a dynamic process, protein phosphatases, such as protein phosphatase 1 
(PP1), PP2A/B/C, and PP5, mediate dephosphorylation of tau protein. Notably, PP2A is the most 
prominent phosphatase, accounting for ~70% of tau phosphatase activity in the human brain, and 
its activity is significantly reduced at least 20-40% in AD brains 18. It is not exactly clear if the 
excess or hyperphosphorylation of tau or individual site-specific abnormal phosphorylation of tau 
is the driver of tau pathology in diseased brains. On one side, fetal tau is much more highly 
phosphorylated compared to adult tau – approximately 7 to 2 phosphates per molecule 19. 
Likewise, hibernating animals and anesthesia-induced hypothermia exhibit tau 
hyperphosphorylation without identified aggregation 20,21. On the other hand, many tauopathies 
reveal hyperphosphorylated tau (pTau) in brain post-mortem 22. Nevertheless, the role of 
hyperphosphorylation or even site-specific phosphorylation is still not fully understood; one 
example of quandaries regarding individual site-specific phosphorylation, Ser262 and Ser396 
phosphorylation sites are phosphorylated in fetal tau, yet are also found hyperphosphorylated in 
paired-helical filaments in AD brains 23. Still, it is assumed that increasing phosphorylation of tau 
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negatively affects microtubule-tau binding and may play a role in tau aggregation and related 
disease pathology. 
Tau is known to undergo numerous modifications and has multiple functions, and these 
characteristics may be isoform- and cellular distribution-dependent. Other explored post-
translational modifications of tau include: glycosylation, glycation, deamidation, isomerization, 
nitration, methylation, ubiquitylation, sumoylation, and truncation 10,13,24–26. The 
compartmentalization of tau is suggested to be important for tau function as well. Axonal tau 
assists in cytoskeletal support by binding to microtubules and may also influence motor proteins, 
dynein and kinesin, and axonal elongation and maturation 27. A small quantity of tau has been 
detected in dendrites and dendritic spines, which may have an effect on synaptic plasticity, 
although this remains a matter of debate 8,13. Tau has also been hypothesized to be distributed in 
the nuclei of neurons and non-neuronal cells, which may protect genomic DNA, cytoplasmic 
RNA, and nuclear RNA under cellular duress 28,29. Furthermore, other novel functions of tau have 
been determined by the utilization of transgenic (Tg) mouse models, like the tau-knockout mice, 
including a role in development, neuronal activity, neurogenesis, iron export, and long-term 
depression 10.  
There are numerous molecular mechanisms that could propel normal tau protein into 
misfolding and aggregating, such as: mutations, overexpression, post-translational modifications, 
binding regulators, aging and environmental factors, dysregulation of kinases and phosphatases, 
and others 10,13,24–26. As previously mentioned, there are at least ≤80 splicing and missense 
mutations of tau that result in a loss- and/or gain-of tau function as confirmed in tauopathies in 
patients, Tg animal models harboring genetic mutations, and/or in vitro cellular assays. Presence 
of various post-translational modifications, as in hyperphosphorylation, are posited to be an early 
and critical event in tau misfolding and aggregation. In vitro, tau aggregation can be accelerated 
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by the presence of cofactors including polyanionic compounds, such as sulfated 
glycosaminoglycans like heparin, to induce aggregation of tau 24,25,30. Nevertheless, some 
mechanism described above occurs that causes tau protein to be hyperphosphorylated, which will 
then neutralize the positive charge on tau, and releasing tau from the microtubule 8,10,12–14,25. 
Without microtubule-bound tau mechanically stabilizing axonal microtubules there can be issues 
with supporting the long, extended structure of the axon, as well as the missing interaction of tau 
with motor proteins can impair axonal transport and ultimately resulting in synaptic impairment 
and axonal retraction 8. Congruently, unbound tau begins to pool in the cytosol, thereby increasing 
the critical concentration of tau. These events can facilitate the generation of a misfolded, soluble 
intermediate that instigates the aggregation process (Figure 3).   
The nucleation-polymerization model and tau protein 
It is hypothesized that amyloidogenic proteins, like tau, follow a nucleation-
polymerization model 28-32. This model posits the stages of aggregation process of amyloid 
formation – starting with a soluble protein transitioning ultimately to a fibrillary structure (Figure 
4). There is a sigmoidal time course corresponding to aggregation over time where the rate-
limiting step is the formation of oligomeric nuclei or seeds for aggregation in the nucleation phase. 
This is thought to be normally a very slow process; however, once the seed is formed, 
polymerization occurs in a rapid manner by self-templating in the polymerization or exponential 
phase, accumulating monomeric subunits to free ends of the oligomers thereby developing a fibril 
structure. In vitro, these fibrils could be fragmented thereby generating auxiliary seeds that could 
thus restart the process. With the addition of external seeds in the nucleation phase, the nucleation 
phase can be circumvented thus accelerating the overall assembly as demonstrated by an 
attenuation of time for the nucleation phase and concomitant advancement into the polymerization 
phase. The nucleation-polymerization model has also been described in other ordered processes 
11 
 
such as: protein crystallization, viral coat assembly, microtubule formation, flagellum formation, 
and sickle-cell fibril formation 32,33. The reason and mechanism for the formation of a misfolded 
nucleus or seed remains to be elucidated; however, suggestions for this engendered soluble 
intermediate include: hydrophobicity profile of amino acids, the need for stability, hydrogen 
bonding, high local critical concentration of the endogenous monomers, the “aggregation 
environment”, among others 2,14,31,32. 
  
Figure 4. The nucleation/polymerization model for amyloids. Tau is believed to follow a 
model of amyloid formation called the nucleation-polymerization model. The sigmoidal time 
course reaction for the model, which begins with the rate-limiting step that is the nucleation or 
lag phase. This nucleation phase is responsible for the initial formation of aggregates that starts 
with this misfolded intermediate. This is normally a very slow process. This is then followed 
by a rapid growth phase or polymerization phase. Here, the misfolded protein is developed 
into a fibril amyloid structure and can begin self-templating accumulating more monomers to 
create larger aggregates. With the presence of a preformed seed, we attenuate this nucleation 
phase generating this misfolded intermediate faster as well as reaching the polymerization 
phase at a quicker rate, thereby presenting the seeding-nucleation model 
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In this process, the protein undergoes secondary conformational changes generally 
comprising of oligomers to protofibrils to fibrils as revealed in Figure 3. Oligomers are seen as 
intermediates along the fibrilogenesis pathway and are soluble, small assembled misfolded 
proteins (from dimers to large multimers) that are difficult to define due to the quickness of 
aggregation and heterogeneity in preparation, and a paucity of delicate molecular techniques to 
determine the protein structure 4,10. Current research suggests that oligomeric conformations of 
amyloids are thought to be the most toxic species compared to preceding research 4,10,14,24,25. 
Protofibrils are formed by oligomers assembled into elongated linear or rod-like structures that 
may intertwine; these are referred to as PHFs or neuropil threads (NPs) regarding tau protein 
2,4,14,30. Finally, a highly ordered fibrillary structure or amyloid is formed being ~10 nm wide with 
long, generally unbranched ribbon-like structures as demonstrated by electron microscopy 1,2. 
These amyloidogenic fibrils are insoluble and resistant to proteolytic degradation, organized in a 
cross β-sheet conformation, bind to dyes such as Congo red and Thioflavin, and may be a key 
factor in PMDs. These are associated to intracellular NFTs that are formed from pTau and are 
described as closely packed, highly ordered structures that contain multiple twisting protofibrils 
with interacting side chains and characterized by classical Gallyas silver staining in tauopathies.  
As mentioned previously, in the past, NFTs were assumed to be the predominantly 
neurotoxic species as research speculated tangle regional burden in diseased-brain correlated with 
cognitive deficits and neurodegeneration 35. Conversely, current views of NFT formation from 
tau assembly suggests actually a protective cellular response in the brain. Several transgenic 
mouse models for wild-type (WT) or mutant human tau exhibit compromised synaptic impairment 
and loss, and cognitive dysfunction prior to tangle formation, while tangle-bearing neurons and 
neuronal loss show no correlation10,11. More so, NFT-laden neurons in cornu ammonis 1 (CA1) 
hippocampal area in AD could survive for about 20 years, and it has been proposed these neurons 
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may not die 36. On the other hand, NFTs could still have a deleterious effect by accruing other 
necessary cellular components and even taking up space in the cell, thereby hindering transport 
mechanisms as viewed by the somatodendritic location of NFTs. Research is still on-going to 
determine the structural components and molecular properties of tau soluble oligomers as the 
neurotoxic culprit in disease. Concurrent with the nucleation-polymerization model, experimental 
evidence has demonstrated that tau protein can be considered to have “prion-like” characteristics 
2,4,7,37–40. In humans, prion diseases (transmissible spongiform encephalopathies) are rare, fatal 
neurodegenerative disorders that include Creutzfeldt-Jakob disease (CJD), fatal familial 
insomnia, Gerstmann-Sträussler-Scheinker Syndrome, and Kuru. In prion diseases, the normal 
prion protein (PrPC) acquires an alternative conformation known as PrPSc, which can template the 
misfolding of endogenous PrPC, leading to its aggregation and accumulation in the brain, and the 
ability of PrPSc to transmit the disease in an infectious manner 2,4,7,37–40. Prions are suggested to 
spread from cell-to-cell, region to region, and between organisms 4,7,37-40. Mounting evidence 
posits that many amyloidogenic proteins, such as tau, emulate these prion-like molecular 
mechanisms for the initiation and spreading of aggregates in disease cases.  
Tau spreading 
The localization of tau within the neuron in pathological settings could play a role in 
spreading and disease and is continually being investigated. Tau protein is thought to be primarily 
axonal, yet an early pathological hallmark of tauopathies, like AD, suggested is the abnormal 
sorting of tau into the somatodendritic compartment of neurons where hyperphosphorylated tau 
can aggregate, thereby preceding neurodegeneration 10,41,42. Frandemiche et al. has shown a 
widespread distribution of tau in the dendrites, which responded to synaptic input and translocated 
to postsynaptic compartments in primary cultured cortical neurons 42. Endogenous tau was also 
determined to missort due to introduction of amyloid-beta (Aβ) oligomers 42. Moreover, in a tau 
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Tg mouse model, early tau-related deficits developed not from the loss of synapses or neurons, 
but rather from synaptic abnormalities caused by the accumulation of pTau within intact dendritic 
spines. The overall effects of this missorting remain unknown. 
Several reports indicate tau’s capability to propagate aggregation transcellularly 7,10,26,38,40. 
The exact mechanism or combination of mechanisms remain to be elucidated, but it has been 
speculated that tau spreading could occur by soluble tau traversing the cellular membrane, 
extracellular release by dead neurons or synaptic excitation, endocytosis and exocytosis, 
pinocytosis, nanotubes, passage through diffusion barriers, and others 7,10,26,38,40. Tau spreading 
can occur transynaptically as emerging evidence supports the account of pathological spreading 
by the neural connectome 2,4,7,10,13,14. Indeed, exogenous inoculation of seeding-competent tau (i.e. 
synthetic tau aggregates or brain homogenates from human tauopathies or Tg tau mice) 
demonstrates migration of pathological tau from the injection site to synaptically connected brain 
regions in humanized tau Tg mice and even in WT mice in a time-dependent manner 43–49. Studies 
utilizing microfluidic chambers and cellular assays demonstrated the cellular and synaptic 
propagation of pathological tau, as well 45,50–53. Advancements in in vivo imaging of structural 
and pathological features has divulged a general involvement of the connectome in AD and other 
neurodegenerative processes 54–56. Tg animals are useful to assess endogenous tau spreading 57–
59. rTg2510 mice express the pathogenic human tau transgene restricted to projection neurons of 
the entorhinal cortex demonstrating burgeoning tau spreading, while incorporating normal mouse 
tau into misfolding and aggregating, along functional brain connections over time 57,58. Another 
example of synaptic tau spreading is that designated by the pathological tau staging in disease, 
such as AD and CTE. As shown in Figure 5, Braak and Braak staging describes the pathological 
phases of tau aggregation in AD as following a stereotypical and temporal pattern of deposition 
emulating areas neuronally connected. I-II) NFTs spawn in the entorhinal cortex and locus 
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coeruleus; III-IV) previous areas have more robust tau deposition, and NFTs are located in the 
hippocampus, fusiform gyrus, and temporal cortex; V-VI) NFTs are abundant and spread 
throughout the cortex 60,61. However, contrary to prion disease, there is very little and debatable 
epidemiological evidence for an infectious etiology for non-prion neurodegenerative diseases. In 
these diseases, it is likely that the prion-like spreading of protein misfolding and aggregation 
operates more in the cellular-to-cellular and area-to area transmission of the pathology within the 
same individual than in the inter-individual transmission as in prion diseases 62. Overall, there is 
strong evidence that pathological tau can translocate and synaptically spread throughout the brain 
by a prion-like manner. 
Traumatic brain injury (TBI) and Relation to AD 
Figure 5. Braak staging – the spatiotemporal progression of tau pathology in 
Alzheimer’s disease (AD). The characterization of tau pathology in AD performed by Braak 
and Braak is one paragon of the “prion-like” capabilities of tau protein as revealed by 
spreading from region-to-region in the brain. The spatial propagation of tau assemblies is 
thought to follow the brain’s neural connectome. Hyperphosphorylated tau and tangles in 
AD cases seems to follow a distinct, well-organized pattern for spreading in vivo: I-II) NFTs 
spawn in the entorhinal cortex and perhaps locus coeruleus; III-IV) previous areas have more 
robust tau deposition, and NFTs are located in the hippocampus, fusiform gyrus, and 




Most PMDs like tauopathies are primarily of sporadic origin with no established 
causation; however, there are ample risk factors that could play a role in the etiology and/or 
progression of disease. Recent research has posited that traumatic brain injury (TBI) can be 
considered an environmental factor that leads to the onset of AD or dementia. TBI is the direct 
impact from an external force that may alter consciousness and have an effect on mental and 
behavioral capacities. The World Health Organization estimates that 10 million people in the 
world are affected by TBI per year. It is the leading cause of death or disability in children, young 
adults, and in industrialized cities, and it can even reduce life expectancy by 7 years 63–65. The 
severity of TBI is quantified by Glascow Coma Scale (GCS) and is distinguished in three relative 
categories: severe, moderate, and mild. Severe TBI represents head injuries that result in 
permanent or an extended period of unconsciousness, amnesia, or death following a head injury 
with a GCS of 3-8. Moderate TBI involves of a period of unconsciousness or amnesia from 30 
minutes ≥ 24 hours with a GCS of 9-12. Mild TBI (mTBI) is recognized as head injuries that 
cause a brief state of altered consciousness resulting ≤ 30 minutes of unconsciousness, though 
most mTBIs do not result in a loss of consciousness 66. Despite this interpretation, one major 
problem for researchers and clinicians regarding TBI is the high heterogeneity among injuries. 
Mild TBI represent a majority of reported cases 63. A moderate to severe TBI (sTBI) can be 
described by a car wreck, act of violence, or fall, which will more likely produce systemic 
complications following the insult and can create long-term adverse effects in the brain or even 
death. The harsher a TBI, as that of sTBI, that occurred produces a greater risk of developing AD 
64,67–69. Plassman et al. reported World War II veterans having a moderate TBI (hazard ratio: 2.32) 
or severe TBI (hazard ratio: 4.51) event had an increased risk of developing AD 70. After a TBI 
event, dementia diagnosis was found to be strongest within the first year (4-6 times) but 
maintained significance up to 30 years as well as when compared to a cohort sibling pairs with 
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opposing TBI status; moreover, the greater the TBI experience (severity or number of TBIs) 
demonstrated the higher the risk 71. Researchers in a large cohort study in Denmark reported the 
overall risk of dementia in individuals with a history of TBI was 24% higher than those without 
a history of TBI. A severe TBI increased the risk by 35%, and a single mild TBI or concussion 
augmented the risk by 17%. The risk of dementia was increased with the number of TBI events - 
33% higher for 2 or 3 TBIs, 61% higher for 4 TBIs, and 183% higher for 5 or more TBIs 72. 
Johnson and colleagues found elevated Aβ and NFTs levels by immunohistochemistry in 
approximately 1/3 post-mortem individuals that had a surviving sTBI after 1 year (between 1-47 
years) compared to controls, thus demonstrating the deleterious long-term effects of a single fatal 
TBI 73. There are multiple factors involved in regards to an individuals’ susceptibility to AD 
following a TBI including age, gender, and genetics. For example, individuals carrying the genetic 
polymorphism of apolipoprotein E epsilon 4 (APOE-ε4) have been described to have a 10-fold 
increase of AD disposition after a TBI 65,74. 
Molecular Mechanisms of TBI 
As demonstrated in Figure 6, primarily, TBI begins with an instant, irreversible initial 
blow or impact causing direct damage to surrounding neuronal and astroglial cells and 
vasculature. This primary insult can be in two modalities – either a focal or diffuse injury. A focal 
injury or blunt trauma is a direct, physical impact to an area that can be followed by a linear shift 
to the head, and it is associated with contusions and/or subdural hemorrhaging 75–78. Diffuse 
axonal injury (DAI) is an injury of literally shearing or tearing the axons caused by rapid 
acceleration and deceleration forces, mostly thought from rotational forces 75–78. This incipient 
impact can trigger a rapid necrosis due to the mechanical damage as well as systemic alterations 
in the brain such as: edema, increased intracranial pressure, and ischemia 75–78. An initiation of 
secondary mechanisms occurs in the form of multiple molecular and cellular deviations perturbing 
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the overall environment of the central nervous system including: neuronal excitotoxicity, Ca2+ 
overload, mitochondrial dysfunction, oxidative stress due to formation of free radicals, 
inflammation, and abnormal protein aggregation. These cellular and biochemical cascade 
alterations lead to synaptic dysfunction, axonal degeneration, and neuronal death ultimately 
instigating cognitive and behavioral impairments 75–78. However, it is not clear where the onset of 
diseases, like AD, would occur in this process, yet most of these aforementioned molecular 
pathways are very similar in both TBI and AD.  
TBI and tau pathology 
Tau pathology has been strongly implicated with repetitive mild TBI (rmTBI), especially 
with its connection to CTE, yet tau pathology following sTBI may not be as rampant – but does 
occur. This evidence may be due to the nature of the TBI and other variable factors 63,77,79–81. 
Hyperphosphorylated tau and NFTs are more correlated with rmTBI than sTBI, but there are 
accounts of tau inclusions after sTBI being present at higher than control levels subsequent to a 
surviving fatal TBI over long-term assessment 73. One study used the conformation specific tau 
antibody Alz50 and found neurofibrillary pathology in 8 out 27 post-mortem sTBI brains – mostly 
in the elderly, but in one case of a 16 year old male 82. Johnson et al. discovered widespread NFTs 
were present in up to a third of patients following survival of a year or more from a single TBI 73. 
Tau levels in cerebrospinal fluid (CSF) from fatal TBI patients expressed over a 1,000-fold 
increase compared to various neurological-diseased and non-diseased controls, and a cleaved and 
reduced sized form of tau protein was detected in these brain injured patients 83. Formation of tau 
aggregates after TBI is not implausible. Functionally, as noted tau protein binds to microtubules 
for cytoskeletal support; when there is physical disruption or other secondary mechanisms 
affecting microtubule dynamics, tau can detach from the microtubule and begin the misfolding 
and aggregation process 63. Moreover, other on-going activated cellular mechanisms associated 
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to TBI and disease can trigger tau aggregation including: Ca2+-induced activation of calpains and 
calcineurin which activates kinases, such as GSK-3β, triggering hyperphosphorylation of tau; Aβ 
and inflammation-induced tau aggregation; generation of cleaved tau; alterations of multiple 
protein kinases and phosphatases implicated both in TBI and AD; among others 78.  
Figure 6. Neural pathways triggered following TBI. After initial primary injury, focal 
and/or diffuse axonal injury, there can be an elicitation of secondary neural mechanisms 
including hyperexcitability, Ca
2+
 release and mitochondrial dysfunction, oxidative stress, 
inflammation, and protein aggregation. Ultimately, this leads to neuronal degradation 
accompanied by cognitive and behavioral changes. It is not known when or how 
neurodegenerative disease onset and progression could originate following TBI.  
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Mild TBI and chronic traumatic encephalopathy 
Mild TBI (mTBI) is acknowledged as head insults that cause a brief state of altered 
consciousness resulting ≤ 30 min of unconsciousness, yet most mTBIs do not result in loss of 
consciousness. The consequences of rmTBI is an important topic in research due to the fact that 
war veterans and contact sports athletes (i.e. American football, boxing, hockey, soccer, etc.) with 
TBI experiences are linked with a recently defined disease, CTE, formerly termed dementia 
pugilistica. Though the particular type of lesions resulting from mTBI are highly variable, various 
factors may play an important role in the consequences of the impact, including rotational 
acceleration and deceleration forces, fluidic pulses from the lateral ventricles generating shearing 
forces, and blow location, among others 63,77,81,84. CTE-afflicted patients display an overlapping 
and broad range of abnormal behaviors emerging mid-life that ultimately result in psychological 
issues that lead to violence and/or suicide. Following a primary TBI insult, a multitude of 
secondary mechanisms take effect causing cytopathogenesis and neurological changes within the 
brain, as indicated by an association with neurodegenerative diseases, cognitive impairment, 
seizures, sleep disorders, neuroendocrine disorders, and other complications 63,64. Interestingly, 
autopsy brain samples from CTE-diagnosed athletes and military veterans with some form of TBI 
(from teen ages to 80's) display massive accumulation of misfolded protein aggregates, mainly 
composed of tau and some cases Aβ 63,77,81,84–88. CTE is a slow-progressing disease and even if 
the trauma activity is halted the disease still proceeds long term, thereby suggesting that the 
multiple molecular pathways elicited by rmTBI have long-lasting effects. Although mTBI is 
linked to the development of neurodegenerative diseases, additional factors that may contribute 
to the development of CTE after rmTBI include: 1) age, a young brain is more plastic for recovery 
than an old brain; 2) extent, nature and timing of the trauma; 3) genetics, i.e. ApoE gene; and 4) 
other health-related factors 63.  
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Currently, a conclusive CTE diagnosis cannot be made until post-mortem. CTE is 
generally distinguishable from other tauopathies, even AD, because it consists of a unique 
distribution of pathological tau throughout the brain. Furthermore, tau accumulation is the 
predominant feature of CTE associated to rmTBI, while Aβ deposits are not very conspicuous, 
unless in more severe forms of TBI or peculiar cases. NFTs, neuropil threads, and astrocytic 
tangles form in an irregular distribution and heavy density in the frontal and temporal cortices. 
They have a proclivity to arrange near small blood vessels, ventricles, and sub-pial tissues and are 
chiefly located at cortical layers II and III 81,84,87,89. Similar to Braak staging of tau pathology in 
AD, staging of tau pathology in CTE has been described: I) NFTs are located in the depths of 
frontal cortical sulci and locus coeruleus along with gliosis and axonal loss in white matter tracts; 
II) NFTs deposit in the cortex with minimal detection in the amygdala (Amy), hippocampal area 
(HPa), and substantia nigra (SN); III) NFTs spread throughout Amy, HPa, and SN; IV) NFTs 
detected widespread through the cortex and temporal lobe 89. Despite these pathological and 
neuroanatomical differences in CTE and AD, the tau isoforms (3R and 4R) that are 
hyperphosphorylated remain identical between CTE and AD 63. It is still unclear the mechanism 
and signaling pathways implicated in NFT formation in CTE, and what the role that this 
deposition plays in CTE-specific behavior.  
Concussions and/or mTBI are some of the most common forms of neurological 
disabilities, estimating around 90% of all brain injuries recorded 63,84. The Center for Disease 
Control and Prevention reported 300,000 mTBI cases per year in contact sports, and about 
122,000 children (ages 10-19) went to the ER annually for nonfatal brain injuries 63,84,90. Studies 
involving American football players revealed that the absorbed head impacts per season rose in 
an exponential fashion: around 80 hits (ages 7-8); >240 hits (ages 9-12); >1000 hits (high school); 
and 420-2492 (college) 63,90,91. The National Football League (NFL) reported an average 
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concussion incidence of 131.2 ± 26.8 concussions per year - a rate of 0.41 concussions per game 
92. This demonstrates that an individual sport player suffers multiple damaging head blows and/or 
concussions that may produce accumulative damage over the years. However, the number and 
strength of impacts (i.e. sub-concussive versus concussive) required to lead to AD or CTE 
associated pathology remains to be elucidated. Though epidemiological studies are contentious, 
one major finding in human rmTBI cases is that the onset and severity of CTE appears to correlate 
with the length of time engaged in contact sports or military service and number of traumatic 
injuries that occur 63,65,84,92–94. A previous study stated that 17% of retired boxers developed CTE, 
yet prevalence of CTE might be underestimated possibly due to paucity of reporting or cognizance 
of even acquiring mTBI 63,65,84,92. Retired NFL players having three or more concussions were 
found to have a 5-fold increase of developing mild cognitive impairment - a stage that can evolve 
into AD or other forms of dementia 93. In addition, 68 out of 85 post-mortem individuals with a 
history of rmTBIs developed CTE pathology 84; additional studies revealed 98% CTE post-
mortem diagnosis in professional level American football players and even reported mild 
pathology in 3/14 cases at the high school level 79. Although the brain has been hypothesized to 
have the ability to recover following rmTBI, brain scans performed on high school American 
football players showed that the current in-season players versus those in off-season demonstrated 




The formation and accumulation of misfolded aggregates in various PMDs follows a 
seeding/nucleation model 28-32, and these misfolded proteins related to various PMDs are assumed 
to have prion-like properties 2,4,7,14,24,25,37–40. Many of these maladies originate sporadically with 
no clear manner of etiology. The prion-like spreading may be the molecular explanation for the 
long known - but puzzling observation - that the pathological abnormalities in neurodegenerative 
diseases progress in a stereotypical and predictable manner across anatomical connections, 
usually starting from a circumscribed area and spreading all over the brain. In this scenario, the 
key question is what factors or processes trigger the formation of the first misfolded seeds that 
then will propagate the pathology throughout the brain and progress to disease. One intriguing 
possibility is that TBI could act to trigger the formation of the first stable misfolded tau oligomeric 
seeds that then will spread the pathology in the brain by the prion principle and produce a more 
severe and faster onset of pathological alterations. Thus, our central hypothesis is that TBI induces 
the early formation of tau misfolded seeds as well as exacerbates tau pathology and spreading 
throughout the brain by a nucleation-polymerization process, which will then lead to 
neurodegenerative changes relative to disease. Our overarching goal of this work is to elucidate 
the effect of TBI on the acceleration and spreading of tau pathology and behavior. Therefore, we 
will study the effect of TBI on tau pathology by the following aims: 
1) Determine the effect of sTBI on the formation and spreading of tau pathology in vivo. 
2) Determine the generation and spreading of tau pathology and behavior following rmTBI 
in vivo. 












Determine the effect of sTBI on the formation and spreading of tau pathology in vivo. 
  
 
This chapter is based upon:  
Edwards III G.A., Zhao J., Dash P.K., Soto C., Moreno-Gonzalez I. Traumatic brain injury 
induces tau aggregation and spreading. J Neurotrauma. 2019 August 28. doi: 
10.1089/neu.2018.6348. [Epub ahead of print] 
Copyright permission was given to use the article in this thesis with credit to the Journal of 
Neurotrauma and to the publisher, Mary Ann Liebert, Inc.; New Rochelle, NY. Approval was 






Hyperphosphorylated tau aggregates generate NFTs that are considered the pathological 
hallmark of tauopathies including AD, CTE, and frontotemporal dementia (FTD), among others. 
Most tauopathies have a sporadic origin and can be associated to multiple risk factors. Traumatic 
brain injury has been suggested as a risk factor for tauopathies by triggering disease onset and 
facilitating its progression. In fact, elevated NFTs levels have been found in approximately 1/3 
post‐mortem individuals that had a surviving moderate to severe TBI demonstrating the 
relationship between tau aggregation and a single TBI 73. In addition, the diagnosis of dementia 
was significantly increased up to 30 years following TBI with the strongest association with TBI 
severity 71.  
The primary insult of a TBI can trigger systemic alterations in the brain as well as initiate 
secondary mechanisms in the form of multiple molecular and cellular deviations perturbing the 
overall environment of the central nervous system 63,65,76–78. More so, the greater the severity of 
TBI increases the risk of AD 64–66,76. The risk of CTE is also suggested to be increased when 
linked to the number of TBI events and the length of time contact sports athletes and military 
personnel are active 79,96. In these tauopathies, tau follows an explicit and predictable 
spatiotemporal pattern of deposition as described by the neuropathological staging of tau 
accumulation in AD and CTE, among others. Recently, tau aggregates have been attributed with 
prion‐like properties, including in vitro and in vivo seeding and spreading capability 97–99. It has 
been suggested that spreading can be due to tau propagating by the functional connectome in the 
brain 49,100,101. The formation of tau misfolded aggregates and progression to disease could be a 
result of TBI events. In this study, we evaluated whether moderate to severe TBI can trigger the 
initial formation of pathological tau that would induce the development of the pathology 
throughout the brain. To this end, we subjected tau transgenic mice to TBI and assessed tau 
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phosphorylation and aggregation pattern to create a spatial heat map of tau deposition and 
spreading in the brain. Our results suggest that brain injured tau transgenic mice have an 
accelerated tau pathology in different brain regions that increases over time compared to sham 
mice. The appearance of pathological tau occurs in regions distant to the injury area which are 
synaptically connected, suggesting dissemination of tau aggregates. Overall, this work posits TBI 





TBI induces rapid acceleration of tau hyperphosphorylation 
In an effort to determine the effect of TBI in the induction of tau aggregates, 3 month old 
P301S transgenic mice were subjected to TBI by controlled cortical impact (CCI) and sacrificed 
1 day, 1 week, 2 months, or 6 months post‐injury. A set of P301S transgenic mice was sham‐
induced (skin opened under anesthesia) and used as a control. To assess the effect of CCI injury 
and associative degree of tau pathology on behavior, acute neurological assessment was 
performed following CCI. Animals exposed to TBI had impairments in simple, non‐postural 
somatosensory functions and complex, postural somatosensory functions (p<0.001) indicating the 
immediate impact of CCI injury on the central nervous system (Figure 7A). Hematoma and edema 
were seen transiently after TBI in brain at 1 day and 1 week post‐operation. Later time‐points 
revealed a collapsed deformation (Figure 7B). Brains were analyzed by immunohistochemistry to 
determine the presence of pTau using AT8 antibody. We assessed burden quantification of the 
immunoreactive AT8‐positive area and generated an overall heat map of tau deposition in brain 
in both TBI‐induced mice and sham animals from early to late stage time‐points. The presence of 
AT8‐positive tau aggregates was analyzed both in the ipsilateral and contralateral hemispheres 
and in four brain areas (rostral to the impact, in the rostral impacted area, in the caudal impacted 
area, and caudal to the impact). 
Just 1 day after the TBI induction, we detected pathological tau in P301S TBI mice in 
comparison to age‐matched sham mice in primarily the overall and ipsilateral (Ipsi) area of the 
impacted side (Figure 8A‐B). We observed a significant difference of AT8 burden (percentage of 
AT8‐immunoreactive area per total area analyzed) in the cortex and amygdala (Ctx), hippocampal 
area (Hp), and brainstem (BS) (Ipsi Ctx p<0.001; overall Ctx p<0.01, overall Hp, Ipsi Hp, and BS  
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p<0.05) (Figure 8B). With this data, we created the spatial heat map of tau deposition in the brain 
of TBI versus sham mice (Figure 8C). P301S mice subjected to TBI developed AT8‐
immunoreactive tau highest in the amygdala, in particular lateral and medial amygdaloid nucleus; 
neocortical areas such as entorhinal, piriform, and perirhinal cortices; as well as brainstem 
structures, such as pons and medulla. The deposition exhibited a range from a caudal to rostral 
mosaic and ventral to dorsal approach within and near the area of impact as well as below the 
impact, mainly affecting the hippocampal formation. To determine the aggregation stage of the 
Figure 7. Traumatic brain injury (TBI)-associated impaired function and brain damage. 
(A) Mice were tested for somatosensory functions immediately after controlled cortical impact 
(CCI) or sham surgery by Mann-Whitney test (***p < 0.001). (B) Representative images of 
brain damage after CCI over the right parietal cortex in mice after one day, one week, two 
months, and six months post-operation are shown. Hematoma and edema are indicated 
transiently after impact, thereby forming a collapsed 1mm deformation in brain at later stages. 
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phosphorylated tau, we performed an ELISA test to detect the amount of insoluble tau. Brain 
homogenates from a different set of animals were ultra‐centrifuged to obtain the formic acid‐
soluble fraction. TBI‐induced animals have higher levels of insoluble tau in the ipsilateral 
hemisphere than the non‐impacted area (Figure 8D). In addition, the level of insoluble tau is 
increased in the TBI group compared to sham mice (Figure 8E). To evaluate the AT8 burden 
levels over time, we analyzed tau deposition in TBI and sham mice after 1 week. 
Immunohistochemical staining using AT8 antibody (Figure 9A) was quantified in both groups. 
TBI mice displayed a significantly exacerbated tau pathology compared to sham mice 1 week 
post‐injury in the following brain regions (Ipsi, Contra, and overall Ctx p<0.01; overall Hp and 
BS p<0.05) (Figure 9B).  
  
Figure 8. Tau aggregation is induced one day after traumatic brain injury (TBI). Tau 
hyperphosphorylation was assessed in brain homogenates and coronal tissue sections in three-
month-old P301S TBI and sham induced mice one day after the event. (A) Representative 
bright field microscopy images of AT8 immunoreactivity in TBI and sham mice brain sections. 
(B) The AT8 burden quantification was obtained by analyzing the percentage of the area 
reactive with AT8 antibody in relation to the total area analyzed in the cortex/amygdala, 
hippocampal area, and brainstem. Statistical analysis was performed by Student t test or Mann-
Whitney test for the ipsilateral (Ipsi) and contralateral (Contra) areas of impact as well as 
overall brain region. Ipsilateral and contralateral hippocampus quantifications were analyzed 
by Mann-Whitney test. (C) Semi-quantitative evaluation (lowest [0] to highest [5]) of tau 
deposition is captured in the heat map at different distance from the impacted area. The star 
denotes the estimated placement of impact. (D,E) Insoluble tau levels were evaluated by serial 
extraction and enzyme-linked immunosorbent assay performed in the formic acid fraction of 
the brains. Graphs in panels B, D, and E show the mean – standard error of the mean of the n 











The spatial heat maps revealed more sporadic tau formation in the TBI mice in comparison to 
their respective sham counterparts (Figure 9C). We observed that after 1 week, TBI mice 
projected a spatial tau pattern reminiscent of the 1 day TBI mice, but extending to the contralateral 
side of impact of the cortical and hippocampal areas, albeit at modest yet progressing levels, and 
increased compared to age‐matched sham mice. 1‐2 months after CCI induction, TBI mice 
demonstrated higher AT8 burden in the overall Ctx and BS (p<0.01) and Ipsi Hp (p<0.05) as 
observed in the representative pictures and the burden quantification (Figure 10A‐B). Both groups 
represented advancing tau pathology at 4‐5 months of age; however, TBI‐induced animals 
demonstrated higher average burden scores in comparison to sham mice as observed in the heat 
map of global tau distribution (Figure 10C). 
  
Figure 9. Spatial pattern and burden of pathological tau one week after traumatic brain 
injury (TBI). The P301S mice having either a TBI or sham surgery were assessed for tau 
aggregate formation and spreading by AT8 immunostaining. (A) Representative images of the 
TBI and sham animals using AT8 antibody are displayed. (B) The AT8 burden was evaluated 
in the cortex, hippocampal area, and brainstem in overall, ipsilateral (Ipsi), and contralateral 
(Contra) side of impact. Ipsilateral and contralateral hippocampus were evaluated by Mann-
Whitney test, while all other data underwent Student t test. (C) Four coronal areas per animal 
were assessed to recreate a heat map to navigate tau spreading after TBI. Heat map scale: 
lowest (0) to highest (5) score. The star denotes the estimated placement of impact. Scale bar: 







 TBI induces long‐term cognitive impairment and accelerated tau pathology. 
To evaluate the long‐term effect of a single moderate to severe TBI event, we induced 
CCI in Tg and WT animals and analyzed them 6 months post‐injury. Transgenic sham animals 
were also evaluated. Animals 5.5 months following either CCI or sham surgery were analyzed in 
Barnes maze to evaluate spatial learning and memory. During the learning period, TBI‐induced 
WT and Tg sham mice demonstrated their ability to learn a new task by a quicker latency to the 
escape hole over time, however Tg TBI-induced mice took longer compared to the control animals 
to learn the task (p <0.05, p<0.001) (Figure 11A). 7 days later, long‐term memory was examined, 
and Tg TBI‐induced animals revealed significant impaired memory abilities in comparison to 
controls (p< 0.01) (Figure 11B). Thus, Tg TBI mice posited impaired learning and memory 
several months after the CCI induction. Then, we evaluated tau burden and created a heat map of 
tau deposition 6 months post‐TBI. Tau pathology was more dramatic in the TBI‐induced mice in 
comparison to age‐matched sham controls as observed in representative immunohistochemical 
images. As observed in Figure 12A, NFTs‐like structures were seen profusely throughout the 
Figure 10. Tau aggregation is significantly increased two months after traumatic brain 
injury (TBI) injury. (A) Illustrative microphotography of AT8 immunopositive staining 
visually displayed growing pathologic tau aggregation. (B) The AT8 burden quantification in 
the overall, ipsilateral (Ipsi), and contralateral (Contra) impacted area in the three main brain 
regions analyzed. Ipsilateral cortex and Contra hippocampus were evaluated by Mann Whitney 
test, while all other statistical analysis was performed by Student t test. (C) The spatial heat 
map revealed increasing tau burden and presence of pathogenic tau aggregates in multiple areas 
in TBI-induced mice having more aggressive pathology compared with sham mice. Scale bar: 
100 μm. Heat map scale: lowest (0) to highest (5) score. The star denotes the estimated 
placement of impact. *p < 0.05, **p < 0.01. 
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entorhinal cortex and hippocampus both in the superficial molecular and deep polymorphic layers 
with intense staining in the pyramidal cells in CA1. Tg TBI mice display a robust tau burden in 
the isocortex and throughout the hippocampal formation. AT8 burden quantifications revealed 
significant differences between TBI and sham mice in cortical and hippocampal areas (Ipsi, 
Contra, and overall Ctx; Ipsi, Contra, and overall Hp p<0.05) (Figure 12B). The tau heat map 
shows the intrinsic tau spreading mosaic of the Tg model of the sham group that seems to be 
maintained in the TBI‐induced mice albeit with augmented dispersion and increased tau levels 
(Figure 12C). Areas that exhibited the greatest tau burden scores at this late stage time‐point were 
Figure 11. Traumatic brain injury (TBI) promotes behavior impairment in transgenic 
tau mice in the chronic stage of injury. Barnes maze test was performed on P301S TBI, 
P301S sham, and wild-type (WT) littermate TBI mice six months after controlled cortical 
impact injury. The P301S TBI mice exhibited attenuated learning and memory capabilities 
observed by the learning curve (A) and long term memory assessment (B) *p < 0.05, **p < 
0.01, ***p < 0.001. Data is expressed as means ± SEM. 
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the amygdaloid nucleus and piriform/entorhinal cortex as well as caudally in the brainstem (pons‐
medulla). 
  
Figure 12. Robust tau pathology six months after traumatic brain injury (TBI). (A) 
Example AT8 microscope images illustrate substantial tau pathology in TBI mice six months 
after injury compared with age-matched sham mice. (B) The AT8 burden quantification shows 
a significant overall increase of tau deposition in TBI mice compared with sham mice in the 
ipsilateral (Ipsi), contralateral (Contra), and overall cortex and hippocampal area. Statistics for 
brainstem were calculated by Mann-Whitney test, while all other were performed by Student t 
test. (C) The AT8 burden scores exhibited in a spatial heat map of four rostrocaudal areas in 
TBI versus sham mice. Heat map scale: lowest (0) to highest (5) score. Star denotes the 







TBI‐induced mice demonstrate tau deposition altered tropism 
To investigate whether the increase of tau burden produced by TBI is just due to an 
increase in the endogenous tau production or the induction of tau aggregation in areas where tau 
usually do not deposit, we analyzed at different time-points the brain areas where the P301S mice 
typically do not have tau deposition. Images taken 1 day post‐TBI using the AT8 antibody indicate 
the existence of tau hyperphosphorylation in the CA1 region of the Ipsi Hp, infrequent at this age 
in non‐induced P301S mice (Figure 13, left panel). The altered tropism of tau aggregation 
following TBI is also observed 1 week post‐TBI in the cortical area, close to the retrosplenial 
cortex (Figure 13, middle panel), as well as in the cerebellum 6 months after TBI (Figure 13, right 
panel). It is noteworthy that, along with the total aggregated tau burden assessment done in Tg 
TBI and Tg sham mice, no AT8 immunopositive tau was detected in WT TBI‐induced animals 
even 6 months post‐injury (data not shown). Table 2 summarizes the fold‐change for aggregated 
tau burden in brain between TBI‐ and sham‐induced mice after 1 day, 1 week, 1‐2 months, and 6 
months following the surgery. This table of tau distribution encompasses the Ctx, Hp, and BS in 
relation to the impacted area (overall, Ipsi, and Contra). In general, there is a significant fold‐
change response in the Ctx, Hp, and BS of the TBI mice compared to sham mice at the various 
assessed time‐points with a majority of the regions displaying significant increase overall and on 
the Ipsi side of impact. The largest fold‐change (21.14) is seen following 1 day after CCI impact 
in the ipsilateral Hp, followed by the more caudally impacted area in the Hp (10.14 fold‐change). 
After 1 week, the largest fold change difference that occurred following CCI was on the 
contralateral side of impact for the Hp followed by the Ctx compared to their respective sham 
group. Thus, tau aggregate formation exacerbates 1 day after TBI and spreads throughout the 
brain significantly, even to the contralateral side of impact, 1 week after. Although differences in 
tau burden fold‐change decrease at 1 and 6 months post‐TBI, these alterations are kept at 3‐8 fold‐
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increase in the Hp and Ctx over time. On the other hand, one area with the highest endogenous 
tau deposition in this animal model, the BS, is the least affected by TBI (between 2 to 3 fold 
increase).  
  
Figure 13. Altered tropism of tau deposition after traumatic brain injury (TBI). 
Representative figures of pathological tau deposition as evaluated by AT8 
immunohistochemistry in hippocampus, cortex, and cerebellar lobes in mice six months after 
TBI. Age-matched P301S sham animals revealed very low detectability using AT8 at the 
different times analyzed. Scale bar: 300 μm; insets: 100 μm. CA1, cornu ammonis 1 area; cc, 
corpus callosum; DG, dentate gyrus; Ctx, cortex; Hp, hippocampus; ml, molecular layer, gl, 








TBI has been reported to be an important risk factor for several tauopathies 71-75,81. 
Experimental models and human cases have shown formation of tau aggregates following a 
moderate to severe TBI; however, the exact linkage to deposition of pathological tau and disease 
remains to be elucidated 63,102. In this study, young P301S mice subjected to TBI were analyzed 
at short and long time‐points after the impact, and brains were assessed for tau aggregation and 
spreading. We have determined that TBI induction is able to increase tau burden as early as 1 day 
post‐TBI in the cortex/amygdala, hippocampal area, and brain stem with robust deposition on the 
ipsilateral side of the impact. 1 week after TBI, induced mice exhibited a robust deposition on the 
contralateral side of the brain compared to sham animals. Increased levels of tau following TBI 
can translate to aggravated behavior and clinical symptoms, as observed 6 months after injury. 
Overall, we have demonstrated that TBI intensifies tau pathology compared to sham transgenic 
mice in different brain regions, especially those close to the impacted area, showing a peak a few 
days later. Levels of aggregated tau have been found augmented in 6 month‐old P301L mice 1 
day after induction of CCI, thus supporting our results 103. Other moderate‐severe TBI models, 
such as fluid percussion injury 104, Feeney’s weight drop 105, and blast injury 106 have reported 
Table 2. Traumatic brain injury (TBI)-induced tau aggregates fold-change summary. The 
AT8 burden fold-change is represented in the overall, ipsilateral (Ipsi) and contralateral 
(Contra) side of impact in the hippocampal area (HPa), cortex/amygdala, and brainstem (BS) 
in relation to the respective brain areas rostrocaudally to the impacted side in TBI versus sham 
induced mice. The colored scale exhibits the lowest to highest fold change compared with 
sham brains. The fold change values displayed in red were analyzed by Mann-Whitney test 
while all other data analysis was performed by Student t test. The values below the fold change 
display the lower to upper 95% confidence interval of the mean of the TBI (top) and sham 
(bottom) groups. *p < 0.05.  
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pTau augmentation in mouse and rat models. In addition, induction of CCI in AD mouse models 
overexpressing amyloid beta, such as 3xTgAD and Tg2576, have also demonstrated increased 
pTau 107,108. However, none of the previous studies have shown the temporal distribution of pTau 
and tau aggregates after the initial insult and the spatial spreading of the misfolded tau from the 
original impacted area. 
The results obtained in our study support the idea that TBI is a risk factor for tauopathies 
and provides novel insight into the induction of pTau pathology following TBI. However, our 
study has some limitations. The PS19 (P301S mutation) model overexpresses 5‐fold the human 
mutant tau protein under the prion promoter, which may differentially alter expression of MAPT 
in different brain regions leading to ectopic endogenous expression. In addition, the human 
version of tau in this animal is 4R1N, which may influence the propensity of tau to aggregate after 
TBI, the type of aggregates that are formed, or even their tropism. Nevertheless, the PS19 model 
has been proposed as a good alternative to study acceleration of the disease and tau transmission 
109,110. The use of humanized tau models expressing wild‐type human tau may help to overcome 
these limitations. The use of animals conserving the human 3R/4R ratio will also be beneficial to 
determine the effect of TBI, specifically for AD.  
TBI‐induced mice had elevated levels of pTau compared to sham mice in the ventral 
isocortex, in particular amygdaloid nucleus, piriform and entorhinal cortices, indicating an innate 
tau progression associated to the regular tau pattern deposition in the P301S mouse model 110. 
These areas are also the first ones affected by tau pathology in early stages of Alzheimer’s disease 
6-9,23,24,56–58. When comparing the ipsilateral and contralateral sides of impact, it revealed higher 
tau burden on the impacted hemisphere, indicating the direct association between the TBI and 
increased aggregation of tau. Tau deposition was seen in the ipsilateral hippocampus, just below 
the directly impacted area, as well as less common areas that would not normally have tau 
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deposition in the naïve transgenic mouse such as the cingulate gyrus, auditory and vision cortices, 
corpus callosum, and cerebellum. In fact, cerebellar tau aggregation has been noted in the P301S 
mouse model but usually occurs at a later age than assessed here, similar to the tau pathology 
observed in AD patients 111,112. Therefore, TBI not only increases tau deposition nearby the 
impacted area, but also induces tau aggregation in distant areas that are not usually affected in 
animals not subjected to TBI. The uncommon, altered tropism of tau phosphorylation observed 
in TBI-induced animals could be due to different mechanisms such as contrecoup, where the 
ventral portion of the brain could collide on the posterior skull or by acceleration and deceleration 
forces. Consequently, the contrecoup could be playing a role in tau aggregation as the ventral 
cortex continuously displayed elevated tau burden following TBI due to the secondary brain 
injury inside the skull. Our results posit that TBI can elicit the formation of early tau aggregates 
exacerbating the ipsilateral side of impact while pathological tau propagates to other brain areas 
increasing its burden along neuronal connections causing widespread distribution of tau pathology 
over time. 
Another possibility for the increase of tau aggregation in areas distant from the impacted 
region is the spreading of pathologic tau through neuronal connections. It is already accepted that 
tau aggregates can propagate through functionally connected brain regions after the exogenous 
addition of seeding‐competent material, whether disease-associated brain homogenate or 
recombinant tau aggregates 43–49. In addition, the rTg4510 mouse model, which expresses human 
mutant P301L tau in the entorhinal cortex, is able to develop full brain tau pathology due to the 
spreading of tau pathology from the initial expression brain region to the hippocampus, neocortex, 
and amygdala over time, indicating the propagation of misfolded tau through interconnected 
regions as a mechanism for disease progression 57,58. Our results indicate that tau propagation 
seems to occur by neuronally connected areas following TBI in a stereotypical and temporal 
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pattern, and less likely by spatial proximity, since we do not see an increase in tau aggregation in 
the damaged area over time – mostly in nearby proximity. As observed in the heat maps, the brain 
regions most affected are those with direct projections to or from the impacted area including the 
entorhinal cortex, hippocampal area, amygdala, brainstem, piriform and rhinal cortices, 
hypothalamus, and septal nucleus. It is worth to mention that this study does not validate spreading 
of tau pathology by a prion‐like manner following TBI. Seeding capability of the aggregates 
formed after TBI has not been tested by techniques such as protein misfolding amplification assay 
(PMCA) or bioassays; therefore, TBI‐induced misfolded tau may or may not be seeding-
competent 113. The spreading observed here may be due to regular transport through the synapses 
or induction of tau hyperphosphorylation in different regions due to a contrecoup or associated 
inflammation maintained over time. 
The alternative spatial aggregation pattern could also be determined by the formation of 
new tau conformations after TBI. Tau can aggregate acquiring different conformations, also 
termed “strains” 113–115. Inoculation of brain homogenate from different tauopathies into mice 
induced comparable tau inclusions to that of the exogenous brain extract, thereby stably 
maintaining the specific strain assembly or conformation reminiscent of the initial pathology 
3,24,36,40-42,113. 18 tau strains have been characterized and when inoculated in P301S mice, they 
trigger strain‐specific intracellular pathology in specific brain regions, spreading, and toxicity 115. 
It is yet to be determined if TBI is responsible for generating different tau strains than those 
regularly expressed in the mouse model, and whether this phenomenon might be responsible for 
spreading the pathology to brain regions that are not commonly affected. In fact, AT8 antibody 
was utilized for assessing tau pathology after TBI, and it is able to recognize both pre‐tangle and 
tangle pathology in brain. Therefore utilization of conformational specific antibodies of tau could 
be used to determine the exact pathological tau species and their location in brain after TBI. In 
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addition, the increase in tau hyperphosphorylation may have a potential pathophysiological role 
in the progression of the disease or be simply a consequence of other effects that TBI could be 
causing, such as a modification in the kinase/phosphatase expression and activity by which 
elevation of pTau could be initiated as a response to a general damage in the brain 78. An ancillary 
factor in regards to the sequential pattern of tau deposition is a different brain regional 
vulnerability, and the existence of a variety of neuronal types that can get affected differently to 
tau pathology progression. The areas chiefly affected by tangles in AD, according to Braak 
staging, are those involved in higher-order cognitive functions, areas vulnerable in aging, as well 
as those that take the longest time for reaching maturity during development 8,9,11,60,61. TBI could 
also generate a hostile brain microenvironment facilitating tau aggregation and propagation. 
Following a TBI event, this response can therefore be intensified, stimulating early disease‐
affiliated tau aggregates leading to disease onset and irreversible progression. 
Overall, our results propose an increasing progression of tau aggregation after one single 
moderate to severe TBI, indicating that TBI accelerates tau hyperphosphorylation and aggregation 
in a time‐ and spatial‐dependent manner. The formation of tau misfolded aggregates after the 
initial TBI may further template the aggregation of additional pathogenic units, participating in 
the formation of primordial protein misfolded seeds that will template pathological features 
leading to AD, CTE or other tauopathies. It remains to be identified the conformation and 
molecular properties of pathological tau induced by TBI events and what features these de novo 












Determine the generation and spreading of tau pathology and behavior following 





The 90% of cases reported with TBI are those of a mild nature, especially strong 
prevalence in contact sports athletes and military personnel. Concussion or mTBI is a 
pathophysiological process affecting the brain induced by direct or indirect biomechanical forces 
that may include abnormal linear and rotational accelerations. With an estimated of 170 million 
adults and 38 million adolescents participating in physical activities, including sports, there is a 
high probability of a mTBI/concussion with approximately 1.6 to 3.8 million concussions 
occurring annually 116. Moreover, this number is grossly underestimated with individuals either 
not reporting the incidence or lack of knowledge a TBI event transpired. In addition, mTBIs are 
heterogeneous in nature with no determined impact threshold, can present no loss of 
consciousness, and may show no damaging effects by brain imaging; however, there may be 
exigent and short-term impairment of neurologic function 84,92,94,117. Certain neurodegenerative 
diseases such as CTE have been associated to rmTBI events by positing that a recurring insult to 
the brain may trigger a cascade of events leading to the onset of pathological abnormalities 
responsible for CTE. CTE was first described as punch-drunk syndrome or dementia pugilistica 
in studies from retired boxers, and since then, CTE has been identified in other contact sports, 
military personnel, and physical abuse cases. Evidence suggests the severity of the disease 
depends on the length of time individuals are engaged in contact sports or military service and the 
number of traumatic injuries that occur 63,77,80,84. Moreover, research suggests that following a 
mTBI event with an additional mTBI in this vulnerable time-period or so-called secondary impact 
syndrome could be much more deleterious. CTE is a slow-progressing tauopathy demonstrated 
by the unique distribution of NFTs, which are composed of aggregated tau protein, in the brain 
with other pathological changes that lead to psychiatric and cognitive alterations. Tau protein is 
assumed to following a nucleation-polymerization model of amyloidogenesis and has exhibited 
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prion-like properties in disease. Questions still remain about what number of mTBIs, energy or 
level of impact, and role of induction and progression of tau pathology occurring over time 
regarding neurodegenerative tauopathies, like CTE. This aim will assess the effect of rmTBI on 
the formation of misfolded tau seeds that will lead to early development, spreading, and 
exacerbation of tau pathology. The main goal for this aim is to determine the effect of rmTBI on 
the formation of seeding-competent tau aggregates utilizing a contact sports athlete/CTE-like 
animal model. rmTBI was induced in Tg P301S tau mice by a modified mild, closed-head weight-
drop impact model with a varied number of impacts, intervals between rmTBI, and ages upon 
evaluation. Neurobehavioral sequelae was assessed utilizing various behavioral tasks 
longitudinally to analyze the changes due to rmTBI and aggregate formation. Tau pathology was 
assayed by histology using various conformational specific methods and biochemical techniques 






Four mTBIs were administered in 1 day (denoted as 1 round) over the head emulating 
multiple mild impacts or “second impact” syndrome. As a control, sham mice were anesthetized 
and experienced the same fall through the platform but with no impact. P301S and WT littermate 
mice were placed in experimental groups as noted in Figure 14, which included: P301S with 
rmTBI, P301S sham, WT with rmTBI, and WT sham (n = 9-1l for each time period). The 
described groups were exposed to the modified mild, closed-head weight-drop / sham treatment 
Figure 14. Experimental design for 
repetitive mild TBI. rmTBI was performed 
using a modified weight-drop method similar 
to the Wayne State method. 4 mTBIs were 
administered in 1 day (denoted as 1 round) 
over the head. As a control, sham mice were 
anesthetized and experienced the same fall 
through the platform but with no impact. 
Experimental groups were impacted at 1 
month, 5 days old with varied rmTBI rounds 
over different time-points. Animals were 
sacrificed at: 1 hour (1 rmTBI round); 1 day (1 
rmTBI round); 1 week (1 rmTBI round); 3 
months (2 rmTBI rounds); or 6 months (3 
rmTBI rounds) post-rmTBI event (Groups 1-
5). Longitudinally studied mice sacrificed at 
8.5 months of age had 4 rounds rmTBIs (16 
total mTBI impacts in time) spread over time 
to assess exacerbation of tau pathology in an 
active athlete paradigm (Group 6). The groups 
(n = 9-11) assessed were P301S rmTBI, P301S 
sham, WT rmTBI, and WT sham mice. 
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at 1 month, 5 days and sacrificed at 1 hour (1 rmTBI round); 1 day (1 rmTBI round); 1 week (1 
rmTBI round); 3 months (2 rmTBI rounds); 6 months (3 rmTBI rounds); or 8.5 months (4 rmTBI 
rounds) post-rmTBI event. No animals exhibited any gross anatomical disturbances, i.e. skull 
fractures or edema/hematoma when sacrificed, verifying the mild impact treatment. 
Neuropsychiatric behavioral tests (Splash test, Nesting, and Open field test), motor testing 
(RotaRod), and learning and memory assessment (Barnes maze, reversal learning) were 
performed before sacrifice. Tau pathology was determined by histology targeting different tau 
conformational structures and quantification in distinct brain regions as well as biochemical 
ELISA for insoluble tau levels from hemisected brains. 
rmTBI triggers transient behavioral impairments along with augmented tau aggregation at 
early time-points 
Following 1 round of rmTBI or sham induction, naïve P301S and WT were sacrificed 1 
hour (hr), 1 day (d), or 1 week (wk) following impacts. Respective behavioral examinations were 
performed before sacrificing the groups, and tau pathology was assessed by histological and 
biochemical methods. Figure 15A reveals P301S and WT rmTBI mice impaired artificial 
grooming 1 hour and 1 day after rmTBI, yet there was no significant difference after 1 week (1hr 
and 1d, p < 0.05; 1wk, p > 0.05). P301S and WT rmTBI displayed lower overnight nesting scores 
1 day and 1 week after rmTBI compared to controls (p < 0.05), respectively (Figure 15B). There 
was no difference in rmTBI and sham mice with latency to fall in RotaRod after 1 week after 
treatment (p > 0.05) (Figure 15C) as well as in percentage of time in the open field for open field 
testing (data not shown). When assessing the 1 hour, 1 day, and 1 week P301S rmTBI groups by 
ANOVA in grooming performance, the 1 week P301S rmTBI mice performed significantly better 
than the 1 hour and 1 day groups (p < 0.0001) (Figure 15D). 1 hour WT rmTBI mice exhibited 
significantly lower grooming time compared to the 1 day and 1 week post-rmTBI groups 
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comparing within the groups (p < 0.0001). There was no difference within the different time-point 
group analysis of the P301S sham and WT sham mice in Splash test (data not shown). The general 
neurobehavioral reaction from 1 hour to 1 day following rmTBI event may be due to the direct 
effects of the initial impact or a post-concussive like syndrome as both P301S and WT rmTBI had 
lowered performance, despite genotype. However, WT rmTBI mice may improve neuro-
functionally slightly better following concussion in comparison to P301S rmTBI mice assayed by 
within group analysis of Splash test. P301S and WT rmTBI mice appear to begin an eventual 
recovery in behavior by the 1 week mark. Overall, these results suggest that rmTBI causes early, 
transient behavioral changes, independently from tau aggregation, hinting recovery may be slower 
in Tg tau mice as well as a progressive recovery in behavior at about 1 week post-rmTBI.  
Figure 15. Behavioral examination of early time-point rmTBI-induced 
P301S and WT Mice. (A) P301S (*) and WT rmTBI ($) mice reveal impaired 
artificial grooming 1 hour and 1 day after rmTBI (1hr and 1d, p < 0.05; 1wk, p > 
0.05). (B) P301S and WT rmTBI display lower nesting scores 1 day and 1 week 
after rmTBI compared to controls (p < 0.05). (C) There was no difference in 
rmTBI and sham mice with latency to fall in Rota-Rod after 1 week after 
treatment (p > 0.05) (D) P301S rmTBI mice may potentially recover slower 
following rmTBI treatment as within group analysis posits both 1 hour and 1 day 
time periods show significant differences to the 1 week mark (p < 0.001); 
however, WT rmTBI only show significant difference at the 1 hour time-point (p 








  Astonishingly, when assessing these young rmTBI Tg tau mice by histology, we were able 
to detect a small, but detectable amount of tau aggregates in brain with more prevalence than age-
matched sham mice. Representative images unveil positive and morphologically pertinent tau by 
AT8, MC1, and Gallyas silver staining in P301S rmTBI mice 1 hour (Figure 16A), 1 day (Figure 
16B), and 1 week (Figure 16C) after TBI induction compared to respective age-matched P301S 
sham mice in similar undetected areas. Pathological tau accumulation was detected in the piriform 
and rhinal cortices, entorhinal cortex, cingulate gyrus/retrosplenial granular cortex, hippocampal 
area, hypothalamus along with dorsal areas of the thalamus, midbrain/pons, and tegemental area 
of the medulla in P301S rmTBI mice. Interestingly, some reactive tau was proximal to ventricles, 
such as 4th ventricle or Sylvian aqueduct, and a fair amount of deposition was noted in the dorsally 
located cingulate gyrus/retrosplenial granular cortex – brain regions just below the impacted 
closed-head skull. When the cortex and amygdala (CTX), hippocampal area (HPa), diencephalon 
(Di), and brain stem (BS) were quantified using AT8 for pTau in 4 distinctive coronal areas, 
P301S rmTBI mice exhibited elevated tau deposition compared to P301S sham animals: 1 hour 
(fold change (FC) in CTX: 7.72*; p < 0.05), 1 day (FC in CTX: 3.78*, HPa: 8.01, BS: 9.83*; p < 
0.05), and 1 week (FC in CTX: 2.93*, HPa: 1.72, BS: 5.28*; p < 0.05) following rmTBI induction 
(Figure 17A). MC1 immunostaining revealed elevated conformational-dependent PHF tau in 
P301S rmTBI in comparison to P301S sham mice following: 1 hour (FC in CTX: 40*, HPa: 1.60; 
p < 0.05), 1 day (FC in CTX: 6.03*, HPa: 3.70, BS: 9.41*; p < 0.05), and 1 week (FC in CTX: 
5.27*, HPa: 5.17, BS: 6.07*; p < 0.05) time-points (Figure 17B). AT8 and MC1 immunostaining 
revealed no detected tau in the diencephalon in the early-stage P301S sham mice; in addition, 
there was no detected NFT formation by Gallyas silver staining in any brain region in the 1 hour, 
1 day, and 1 week P301S sham mice. Finally, the opposite hemisected brain was homogenized 
(10% w/v), ultra-centrifuged to retrieve the formic acid, insoluble protein fraction, and assayed  
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by ELISA. As  shown in Figure 17C, each early time-point P301S rmTBI group displayed 
approximately ±1.5-fold increase of insoluble pathological tau in comparison to their respective 
age-matched P301S sham group (1hr FC: 1.63**, 1d FC: 1.44*, 1wk: 1.44*; *p < 0.05, **p < 0.01).  
Thus, these results speculate that rmTBI can trigger accelerated tau deposition, as early as 1 hour 
along with the presence of different tau conformations, in comparison to sham animals by 
histological and biochemical analysis. 
 
  Figure 17. Histological and biochemical quantification of tau pathology 
in 1 hour, 1 day, and 1 week P301S rmTBI mice. (A) Quantification of AT8 
burden at 1 hour, 1 day, and 1 week in P301S rmTBI and P301S sham mice. 
(B) P301S rmTBI and age-matched P301S sham mice MC1 burden 
quantifications at early time-points. (C) Early stage P301S rmTBI and P301S 
sham mice insoluble tau was analyzed by ELISA. ND: not detected. (*p < 
0.05, **p < 0.01). 
Figure 16. Histological analysis of tau pathology in P301S rmTBI mice 1 
hour, 1 day, and 1 week subsequent to rmTBI. Representative images of AT8 
(left panel), MC1 (middle panel), and Gallyas silver staining (right panel) in 
P301S rmTBI and sham mice 1 hour after rmTBI induction (A), 1 day after 
rmTBI (B), and 1 week after rmTBI (C) versus age-matched P301S sham 






 Recurrent rmTBI intensifies cognitive impairment and tau aggregation over time 
 In addition to assessing the possibility of early triggered tau formation following rmTBI, 
we investigated the effect of multiple rmTBI events on tau pathology over time in brain and on 
behavior. P301S rmTBI, P301S sham, WT rmTBI, and WT sham groups (n = 9-1l for each time 
period) were subjected to a modified closed-head, mild weight-drop model at varied times and 
intervals and sacrificed at 3 months (3m) with 2 rmTBI rounds, 6 months (6m) with 3 rmTBI 
rounds, or 8.5 months (9m) with 4 rmTBI rounds (Figure 14). Behavioral assessment, histology, 
and biochemical analysis was performed as stated previously. One ancillary phenotypic 
characteristic of the Tg tau P301S mouse model is the probability of a fairly rapid hindlimb 
paralysis at later ages 110. 8.5 month old P301S rmTBI mice exhibited 4 mice with hindlimb 
paralysis, which presented an inability to utilize their hindlimbs, hunch-backed posture, and 
difficulty feeding, with only one mouse having paralysis in the sham group; animals were 
immediately sacrificed upon paralysis discovery and not utilized for behavioral testing. Therefore, 
8.5 month old P301S rmTBI mice had more paralytic animals than age-matched sham animals. 
Approximately 2 weeks after the final rmTBI/sham treatment, non-cognitive assessing 
tasks (Splash test, Nesting, Open Field test, and RotaRod) was performed before sacrificing at 
either 3 months, 6 months, or 8.5 months. Splash test assessment by one-way ANOVA showed a 
lowered performance in P301S rmTBI at 3 months (p < 0.05), 6 months (p < 0.05), and 8.5 months 
(p > 0.05, ns) (Figure 18A). Nesting scores revealed lowered nesting abilities at the later stage 
time-points, as well (3m, p > 0.05; 6m, p > 0.05; 9m, p < 0.05) (Figure 18B). There was no 
significant difference in groups at any time-point for the percentage of time spent in the open field 
in Open Field testing (data not shown). Motor function by RotaRod testing was noted to be 
attenuated in P301S rmTBI at 3 months (p < 0.01), 6 months (p < 0.01), and 8.5 months (p < 0.01) 
(Figure 18C). However, despite diminished behavioral performance in these non-cognitive 
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associated tasks by the P301S rmTBI mice at later time-points, there was no significant difference 
between P301S rmTBI and WT rmTBI. Thus, progressing tau aggregation and rmTBIs over time 
revealed lowered neuropsychiatric and motor functions yet may not be the absolute definitive 
factor in non-cognitive behaviors. 
Following neuropsychiatric and motor assessment, spatial learning and memory was 
tested by Barnes maze and reversal learning in all groups before sacrificing at 3 months (2 rmTBI 
rounds), 6 months (3 rmTBI rounds), and 8.5 months (4 rmTBI rounds). All groups at all time-
Figure 18. Psychiatric and motor behavior of late stage P301S and WT mice subjected to 
rmTBI or sham. Splash test, Nesting, and RotaRod was performed in all groups before 
sacrificing 3 months, 6 months, and 8.5 months. (A) Splash test assessment exhibited an overall 
lowered performance in P301S rmTBI at 3 months (p < 0.05), 6 months (p < 0.05), and 8.5 
months (p > 0.05, ns). (B) Nesting scores revealed lowered nesting abilities at the later stage 
time-points (3m, p > 0.05; 6m, p > 0.05; 9m, p < 0.05). (C) There was a difference in motor 
performance by rmTBI treatment with P301S rmTBI demonstrating a significant impairment 
versus sham treated mice at 3 months (p < 0.01), 6 months (p < 0.01), and 8.5 months (p < 
0.01). (*p < 0.05, **p < 0.01, ***p < 0.001). Data is expressed as means ± SEM. 
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points improved performance in the training process over time in Barnes maze (p < 0.0001). 
Figure 19A demonstrated impaired navigation abilities in P301S rmTBI mice at the later time-
points compared to aged-matched controls by analyzing the Barnes maze learning curve, 
respectively (3m, p < 0.001; 6m, p < 0.01; 9m, p < 0.001). Furthermore, in Figure 19B, 3 days 
after the final maze trial, P301S rmTBI revealed exacerbated long-term memory (LTM) by 
demonstrating a longer time to discover the escape hole in comparison of P301S sham, WT 
rmTBI, and WT sham mice at 3 months (p < 0.01), 6 months (p < 0.001), and 8.5 months (p < 
0.001). Example traces of LTM assessment corresponding to the average primary latency of each 
group at each time-point are shown in Figure 20. P301S rmTBI mice revealed an approximately 
more randomized search pattern as compared to the other groups showing a more serial or spatial 
search pattern. When the escape hole was placed approximately 180 degrees from the previous 
static quadrant, late stage P301S rmTBI animals had a more difficult time disassociating the 
preceding escape hole and discerning the location of the novel escape hole by reversal learning 
(3m, p < 0.05; 6m, p > 0.05; 9m, p < 0.01), despite no significant difference as a function over 
time (p < 0.0001) (Figure 19C). In addition, 3 months and 6 months old P301S rmTBI engendered 
more total errors while navigating the arena compared to controls (data not shown). Moreover, 
there was no significant difference among the groups at each time-point examined measuring 
velocity (mm/sec) in the learning curve of the Barnes maze suggesting successful removal of 
paralyzed P301S mice and comparable locomotor activity (p > 0.05, ns; data not shown). These 
results suggest that the combinatorial effect of rmTBI and progressing tau deposition over time 
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Figure 20. Example traces of Barnes maze 
LTM of later stage rmTBI and sham-treated 
mice.  The average primary latency was used 
to obtain example traces of P301S rmTBI, 
P301S sham, WT rmTBI, and WT sham mice 
groups sacrificed at 3 months (A),  6 months 
(B), and 8.5 months of age (C).  
Figure 19. Cognitive assessment of late stage P301S rmTBI mice. (A) P301S rmTBI 
demonstrated impaired learning in the Barnes maze compared to age-matched controls 
at later time-points (3m, p < 0.001; 6m, p < 0.01; 9m, p < 0.001). (B) P301S rmTBI 
mice had impaired memory when assessed in long term memory versus age-matched 
controls at later time-points (3m, p < 0.01; 6m, p < 0.001; 9m, p < 0.001). (C) P301S 
rmTBI mice exhibited impaired performance when the escape hole was reversed 
compared to controls at later stages after rmTBI (3m, p < 0.05; 6m, p > 0.05; 9m, p < 
0.01); (*p < 0.05, **p < 0.01, ***p < 0.001). 
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Tau pathology was determined following rmTBI induction at later time-points by 
histological analysis utilizing AT8 for pTau, MC1 for conformational-dependent PHFs, and 
Gallyas silver staining for NFTs. 3m (Figure 21A), 6m (Figure 21B), and 9m P301S rmTBI mice 
(Figure 22) presented robust and progressive tau pathology in 4 distinct coronal brain sections 
compared to their respective age-matched controls.  
 
Figure 21. Tau histology in P301S rmTBI and P301S sham mice at 3 and 6 months of age. 
Demonstrative images of AT8, MC1, and Gallyas silver staining of P301S rmTBI and P301S 
sham mice at 3 months, 2 rounds of rmTBI (A), and 6 months, 3 rmTBI rounds (B). Scale bar: 







In Figure 23A-D, cortex/amygdala, hippocampal area, diencephalon, and brain stem were 
quantified for total percentage burden of AT8, MC1, and Gallyas silver staining in all later stage 
Tg tau groups. Following 2 rmTBI rounds, 3 month old P301S rmTBI mice demonstrated 
augmented pathological tau conformers compared to age-matched P301S sham mice by AT8 (FC 
in CTX: 1.83*, HPa: 4.55*, Di: 2.27, BS: 2.30*; *p < 0.05), MC1 (FC in CTX: 2.17*, HPa: 4.58*, 
Di: 4.29**, BS: 3.83*; *p < 0.05, **p < 0.01), and Gallyas silver staining (FC in CTX: 2.53*, HPa: 
4.06*, Di: 7.45**, BS: 7.57**; *p < 0.05, **p < 0.01). Six month old P301S mice treated with 3 
rmTBI rounds had elevated pathological tau AT8 burden versus age-matched sham animals (FC 
in CTX: 3.30*, HPa: 5.87*, Di: 2.26*, BS: 2.05*; *p < 0.05), MC1 burden (FC in CTX: 2.71*, HPa: 
3.29*, Di: 2.47*, BS: 1.85**; *p < 0.05, **p < 0.01), and Gallyas silver staining (FC in CTX: 2.69**, 
HPa: 1.57**, Di: 2.29*, BS: 3.54**; *p < 0.05, **p < 0.01). Indeed, P301S rmTBI sacrificed at 8.5 
months old with 4 rmTBI rounds exhibited the most grandiose tau pathology compared to their 
respective Tg sham mice by histological analysis of AT8 (FC in CTX: 1.31, HPa: 2.75*, Di: 1.43, 
BS: 2.62*; *p < 0.05), MC1 (FC in CTX: 1.92, HPa: 2.92*, Di: 1.71, BS: 2.73*; *p < 0.05), and 
Gallyas silver staining (FC in CTX: 1.81*, HPa: 2.64**, Di: 2.24, BS: 2.58*; *p < 0.05, **p < 0.01). 
Thioflavin S (ThS) positive-staining was also identified and followed the same trend as the silver 
staining (Figure 22); moreover, WT rmTBI and WT sham animals in all groups did not display 
any positive, morphologically-relevant tau staining using the same techniques here (data not 
shown). Supporting our histopathological results, hemisected brains were homogenized by 10% 
Figure 22. Tau histology in P301S rmTBI and P301S sham mice at 8.5 months 
of age. Example images of AT8 (top panel), MC1 (second panel), Gallyas silver 
staining (third panel), and Thioflavin S staining (last panel) in brain of P301S 
rmTBI and sham mice at 8.5 months of age. P301S rmTBI animals exhibit a much 




w/v and ultra-centrifuged to obtain the formic acid fraction to assay insoluble tau levels by pS199 
ELISA from the 3m, 6m, and 9m P301S rmTBI/sham treated mice (n = 10/time-point and group). 
Insoluble tau aggregates were seen to be exacerbated in P301S rmTBI mice compared to age-
matched P301S sham mice at 3 months (FC: 1.21, p < 0.05), 6 months (FC: 1.53, p < 0.01), and 
8.5 months of age (FC: 1.49, p < 0.05) (Figure 23D). Ultimately, P301S rmTBI mice at later time-
points displayed burgeoning and amplified pathological tau of disparate structural conformations, 
such as pTau, PHFs, and NFTs, by histological quantifications and insoluble tau levels by ELISA 
in brain in comparison to age-matched P301S sham rodents. 
  
   
Figure 23. Assessment of tau pathology in P301S rmTBI mice over time. 
Quantification of images of AT8, MC1, and Gallyas silver staining in cortex/amygdala 
(CTX), hippocampal area (HPa), diencephalon (Di), and brain stem (BS) of P301S rmTBI 
and sham mice over time. (A) Late-stage P301S rmTBI mice display exacerbated 
hyperphosphorylated tau AT8 burden in brain compared to P301S sham mice. (B) MC1 
burden was augmented following rmTBI in P301S mice at 3 months, 6 months, and 8.5 
months of age. (C) Quantification of Gallyas silver staining for NFTs revealed higher 
levels in brain in the late stage P301S rmTBI mice compared to age-matched P301S sham 
animals. (D) Insoluble pathological tau was noted to be intensified in P301S rmTBI mice 
compared to age-matched P301S sham mice at 3 months, 6 months, and 8.5 months old. 





P301S rmTBI mice have elevated insoluble tau aggregates and accelerated model-related 
aging consequences 
Additionally, if the insoluble tau ELISA levels from all of the groups are plotted over time 
comparing P301S rmTBI and P301S sham animals using linear regression, there is an 
approximate 1.5-fold increase of insoluble tau per month following the rmTBI paradigm as 
performed here (p < 0.001; F (1,112) = 12.41) (Figure 24A) – assuming animal survival and 
continuous aggregation, i.e. not reaching a plateau phase. Incorporating the slope of the P301S 
rmTBI and sham animals indicates an overall accretion of insoluble tau levels thereby increasing 
the predicted age of the P301S rmTBI mice compared to sham mice. Moreover, analyzing the 
difference of the slopes for AT8 (Figure 24B), MC1 (Figure 24C), and Gallyas silver staining 
(Figure 24D) for the total summed burden of all groups, P301S rmTBI exhibit significant 
differences in MC1 (p < 0.01; F (1,118) = 10.64) and Gallyas (p < 0.01; F (1,118) = 8.75) overall 
burden, while AT8 overall burden showed a trend (p > 0.05; F (1,118) = 2.75), as compared to P301S 
sham rodents over time. The auxiliary table revealed significant differences in the slopes of P301S 
rmTBI and sham mice in individual quantified brain regions with the most noteworthy differences 
seen among MC1 and Gallyas silver staining along with HPa and BS regions. Finally, the P301S 
Tg mouse model has reported neuronal loss at 9-12 months of age as studied previously 110; thus, 
neuronal loss in 9m P301S rmTBI and sham mice was assessed by immunohistochemistry by 
anti-cleaved caspase-3 antibody, an apoptotic marker of cell death, and quantified in the prior 
described brain regions to study the potential acceleration of the Tg mouse model due to rmTBI. 
As described in Figure 24E, P301S rmTBI rodents at 8.5 months old had worse neuronal cell 
death in comparison to age-matched P301S sham mice (FC in CTX: 2.01*, HPa: 3.21*, BS: 3.67*; 
*p < 0.05). These concomitant results posit aggravated insoluble tau levels along with accelerated 
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Figure 24. Neuropathological consequences of rmTBI manifest in transgenic tau mice 
over time. Collected data was plotted as a linear regression, and the slopes of the P301S rmTBI 
and P301S sham mice were compared. (A) Assessing insoluble pathological tau, P301S rmTBI 
mice had approximately 1.5-fold increase of tau aggregates over time compared to P301S sham 
(p < 0.001). Moreover, the predicted age in terms of this deposition of the P301S mice was 
elevated due to rmTBI treatment. Quantification of all groups of the specific brain regions were 
summed and plotted along with the slope of the line for burden of AT8 (p > 0.05) (B), MC1 (p 
< 0.01) (C), and Gallyas silver staining (p < 0.01) (D). Additionally, distinct brain region data 
for AT8, MC1, and Gallyas silver staining was tested by linear regression, and the significance 
between the slopes of the P301S rmTBI and P301S sham mice was compared as shown in the 
ancillary table. (E) Anti-cleaved caspase-3 antibody was used to assess apoptotic cell loss in 
8.5 month old P301S rmTBI and sham mice. Tg tau rmTBI rodents displayed a significant 
amount of neuronal loss compared to sham mice. Not detected (ND); (*p < 0.05, **p < 0.01). 


















The seeding-nucleation polymerization process has been reproduced in vivo in various Tg 
animal models of AD by bioassay, even using minute amounts of pre-formed seeds 43–49,118. This 
method of assaying seeding capability by in vivo bioassay originated with prion diseases 
following the prion principle. One efficient way to study seeding capabilities of a certain substrate 
is to inoculate the material containing pre-formed misfolded seeds in vivo into naïve mice and 
examine the acceleration and/or deposition of pathology and clinical symptoms compared to 
animals that were not challenged. Exogenous infusion of tau seeding-competent material, whether 
synthetic or homogenized brain inocula, into rodent models to evaluate seeding capability, 
spreading, and further tau pathology has been performed previously 43–49. In this study, brain 
homogenate collected from the previous P301S rmTBI and control mice were intracerebrally (i.c.) 
injected into naïve mice to sensitively assay the seeding ability of rmTBI-induced tau aggregates. 
Results from previous experiments dictated the earliest time-point (1 hour) of triggered tau 
formation and a canonical, tau-laden brain region (entorhinal cortex) that provided the inocula for 
the bioassay. Moreover, the extracted entorhinal cortex (EC) homogenate from the 1 hr grouped 
mice was i.c. injected into 2.5 month old hTau mice, which express non-mutated, normal human 
tau 119. Utilizing different EC inocula, hTau injected mice were then assayed in animal behavior 
and histology as done above to examine the effect of specific tau seeds in inducing and 




Inocula for the in vivo bioassay was selected from the earliest determined time-point tau 
deposition was identified from previous experiments, which was 1 hour post-rmTBI. The EC, an 
area that displayed detectable tau pathology by histology and is acknowledged as an initial 
affected region of tau deposition in AD 60,61, was excised from the hemisected frozen brain (n = 
3) and homogenized (10% w/v) for i.c. injection into 2.5 month old normal humanized tau (hTau) 
mice (n = 5/group). Thus, the following experimental groups for the in vivo bioassay included: 1) 
hTau mice injected with 1hr P301S rmTBI EC homogenate, 2) hTau mice injected with 1hr P301S 
sham EC homogenate, 3) hTau mice injected with 1hr WT rmTBI EC homogenate, and 4) hTau 
mice injected with Aged P301S (10-11 months old / n = 3) EC homogenate as a positive control. 
Unilateral 10 uL hippocampal injections of the various inocula was performed in naïve hTau mice 
and sacrificed at 9 months old. Behavioral examinations and tau histology was completed, as done 
previously. Thus, by the sensitive method by in vivo bioassay of early rmTBI-induced tau seeds, 
we evaluated the seeding competency of rmTBI-induced tau seeds in hTau mice. 
 
Results 
hTau-Aged P301S and hTau-P301S rmTBI inoculated mice reveal impaired learning and 
memory. 
Naïve hTau mice were inoculated with: Aged P301S EC substrate (hTau-Aged P301S), 
1hr P301S rmTBI EC substrate (hTau-P301S rmTBI), 1hr P301S sham EC substrate (hTau-P301S 
sham), or 1hr WT rmTBI EC substrate (hTau-WT rmTBI). Anxiety/depression-like behavior was 
tested by Splash test, Nesting, and Open Field test starting at about 6 months after the injection. 
Figure 25A-B shows no significant difference among the different inoculated hTau mice for 
Splash test and nesting abilities (p > 0.05, ns), respectively; furthermore, there was no significant 
difference in Open Field testing, as well (p > 0.05, ns; data not shown). Motor function assessment 
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was examined by RotaRod thereafter, and there was no significant difference among the groups 
(p > 0.05, ns) (Figure 25C). Remarkably, hTau-Aged P301S and hTau-P301S rmTBI mice 
revealed impaired spatial navigation learning abilities in the Barnes maze learning curve 
compared to their respective controls (Figure 25D) (p < 0.05). All groups displayed significant 
learning abilities during the training process as a function of time (p < 0.0001). Long-term 
memory assessment of primary latency and total errors made during the trial revealed significant 
impairments of hTau-Aged and hTau-P301S rmTBI mice particularly to hTau-WT rmTBI mice 
(Figure 25E-F) (p < 0.05; p < 0.01, respectively). When the platform was placed in a novel area 
180 degrees from the previous position for reversal learning assessment, hTau-Aged P301S and 
hTau-P301S rmTBI mice demonstrated impaired ability to finding the novel escape hole as 
compared to hTau-P301S sham and hTau-WT rmTBI mice (Figure 25G) (p < 0.01). Overall, 
hTau-Aged P301S and hTau-P301S rmTBI inoculated mice presented impaired learning and 
memory compared to respective control groups. 
  
Figure 25. Behavioral testing of inoculated 9 month old hTau mice. Anxiety/depressive-
like behavior, motor function, and cognition was examined in hTau-Aged P301S, hTau-P301S 
rmTBI, hTau-P301S sham, and hTau-WT rmTBI mice. There was no significance in 
performance in Splash test (p > 0.05) (A), Nesting (p > 0.05) (B), or RotaRod (p > 0.05) (C) 
among the injected hTau animals. (D) hTau-Aged P301S ($) and hTau-P301S rmTBI mice (*) 
had impaired spatial navigation learning abilities as shown in the Barnes maze learning curve 
compared to their respective controls (p < 0.05). LTM primary latency (p < 0.05) (E) and total 
errors (p < 0.01) (F) demonstrated impairments in recalling the escape hole in hTau-Aged 
P301S and hTau-P301S rmTBI mice. (G) Reversal learning of the escape hole showed that 
hTau-Aged P301S and hTau-P301S rmTBI animals could not sufficiently discover the novel 
escape hole as compared to hTau-P301S sham and hTau-WT rmTBI mice (p < 0.01). (*p < 






hTau-Aged P301S and hTau-P301S rmTBI mice demonstrate exacerbated AT8 and MC1 
tau burden. 
After sacrificing all groups of 9 month old hTau inoculated animals, 6.5 months following 
EC homogenate injection, AT8 and MC1 immunohistochemistry was performed in 5 distinct 
coronal sections, and overall immunopositive burden was quantified in CTX, HPa, Di, BS, and 
cerebellum (Cb). Figure 26A illustrates AT8 (left panel) and MC1 (right panel) in hTau-Aged 
P301S, hTau-P301S rmTBI, hTau-P301S sham, and hTau-WT rmTBI mice. In all mouse groups, 
faint or weak AT8 and MC1 immunostaining could be detected chiefly in: piriform cortex and 
claustrum, superior cortex, entorhinal cortex, amygdala, hippocampal area, diencephalon, 
brainstem, and cerebellum. In the CA1/pyramidal layer of the HPa, among other areas, a plethora 
of diffuse AT8-positive punctates and thread-like structures were seen to be more robust in hTau-
Aged P301S and hTau-P301S rmTBI compared to hTau inoculated P301S sham and WT rmTBI 
mice. Yet, some AT8 immunostaining similar to the classical somatodendritic tau morphology 
was seldom detected – mostly in hTau-Aged P301S mice - as seen in the enclosed inset from the 
hippocampal CA3 stratum lucidum (Figure 26A, inset). In the right panel, hTau-Aged P301S and 
hTau-P301S rmTBI mice revealed an interesting, yet aggravated MC1 immunostaining mostly in 
the granule layer of the cerebellum as compared to controls. This faint staining and morphology 
may resemble early tau aggregate processes or a pre-tangle state, and the cellular location of these 
pTau inclusions seems to emulate distal segments of basal dendrites, apical dendrites, and 
proximal dendrites making its way to the neuronal soma as described previously 120. AT8 and 
MC1 abnormal tau, although a little more intense, was noticed in neuronal cell bodies in the brain, 
as well, in areas such as in basolateral amygdala and brain stem regions.  
Furthermore, when quantifying these brain regions for AT8 and MC1 burden, hTau-Aged 
P301S and hTau-P301S rmTBI mice showed elevated pTau and conformational-dependent PHF 
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immunostaining, respectively. One-Way ANOVA assessment of AT8 immunostaining revealed 
significant overall differences in CTX (p < 0.01), HPa (p < 0.01), and BS (p < 0.05) (Figure 26B). 
Post-hoc analysis measured elevated pTau in hTau-Aged P301S versus hTau-P301S sham (FC in 
CTX: 3.51**, HPa: 6.27**) and hTau-WT rmTBI (FC in CTX: 3.12**, HPa: 5.64**, BS: 1.80*), and 
hTau-P301S rmTBI mice had significant AT8 tau compared to hTau-P301S sham (FC in HPa: 
5.39*) and hTau-WT rmTBI (FC in HPa: 4.85*, BS: 1.68*) (Figure 26B). Moreover, Figure 26C 
shows MC1 burden quantification estimated significant overall differences in CTX (p < 0.001), 
HPa (p < 0.05), BS (p < 0.05), and cerebellum (p < 0.01). Multiple comparison testing confirmed 
hTau rodents inoculated with Aged P301S EC inocula had augmented MC1 burden in comparison 
to hTau-P301S sham (FC in CTX: 2.87, HPa: 3.59) and hTau-WT rmTBI mice (FC in CTX: 
2.80**, HPa: 3.62*, Cb: 3.60*). The hTau-P301S rmTBI group also had higher MC1-positive 
staining against hTau-WT rmTBI in the cerebellum (FC: 2.87*). Overall, hTau-Aged P301S mice 
were determined to have a more aggressive tau pathology followed by animals inoculated with 
the 1 hour P301S rmTBI EC homogenate as compared to 1 hour P301S sham and WT rmTBI 
inoculated hTau animals by AT8 and MC1 immunohistochemistry in brain. 
Figure 26. AT8 and MC1 tau immunohistochemistry and quantification in inoculated 
hTau rodents. (A) Example images utilizing AT8 and MC1 antibodies for hTau-Aged P301S, 
hTau-P301S rmTBI, hTau-P301S sham, and hTau-WT rmTBI mice in hippocampus. (B) 
Quantification of AT8 burden % revealed significant overall differences in CTX (p < 0.01), 
HPa (p < 0.01), and BS (p < 0.05) in hTau animals, yet hTau-Aged P301S and hTau-P301S 
rmTBI mice yielded significant differences in distinct brain regions by post-hoc analysis. (C) 
Quantification of MC1 burden % in brain presented significant overall differences in CTX (p 
< 0.001), HPa (p < 0.05), BS (p < 0.05), and cerebellum (p < 0.01). Animals injected with 
Aged P301S inocula had significant increase in MC1 immunostaining compared to hTau-
P301S sham and hTau-WT rmTBI mice, while hTau-P301S rmTBI had a significant increase 
in the cerebellum compared to hTau-WT rmTBI mice. (*p < 0.05, **p < 0.01). Scale bar: 100 






Tau seeds from Aged P301S and P301S rmTBI material demonstrate efficient seeding 
ability.  
Finally, all inoculated hTau groups were assessed for tangle pathology induction following 
injection by classical Gallyas silver staining in various coronally sliced sections. All hTau injected 
mouse groups, although not all animals, displayed Gallyas positive staining in CTX around the 
inoculated area as exampled in hTau-P301S sham mice (Figure 27A). Interestingly, these 
argyrophilic inclusions in the surrounding CTX histopathologically bear resemblance to glial tau 
pathology found in certain 4R-specific tauopathies, such as progressive supranuclear palsy (PSP), 
corticobasal degeneration (CBD), and argyrophilic grain disease (AGD) 121–123. Figure 27B shows 
the corpus callosum (cc) separating the CTX and HPa in hTau-P301S rmTBI mice having an 
argyrophilic collection of numerous, irregular-shaped grains or particles along the white matter 
fibers. This was mostly seen in Aged P301S and P301S rmTBI inoculated mice – only one mouse 
exhibited this type of pathology in the hippocampal alveus and cc in the hTau-P301S sham 
animals. Figure 27C further supports the presence of glial tangles as argyrophilic coiled bodies as 
well as rod or thread-like deposits were located in abundance in the fimbria fornix of mostly hTau-
Aged P301S mice followed by hTau-P301S rmTBI animals. This type of silver impregnation 
reaction was not seen in the Tg tau sham or WT rmTBI hTau-inoculated mice. Despite glial-like 
tau pathology, hTau-Aged P301S (Figure 27D) and hTau-P301S rmTBI mice (Figure 27E) 
revealed Gallyas-positive silver staining neuronal tangles within the HPa. No argyrophilic tau 
pathology, whether neuronal or glial, was found by silver impregnation in the HPa in hTau-WT 
rmTBI mice (Figure 27F); additionally, 10 month old untreated hTau mice (n=3) also displayed 
no argyrophilic tau pathology in brain (Figure 27G). Silver staining burden in the HPa was 
determined to be significant among the groups (p < 0.05), while hTau-Aged P301S mice had 
significantly enhanced Gallyas silver staining (p < 0.05) with a strong trend in the hTau-P301S 
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rmTBI mice (p = 0.0524) in comparison to hTau-P301S sham mice as shown in Figure 27I. To 
further validate the presence of neuronal tangles in hTau-Aged P301S and hTau-P301S rmTBI 
animals, Thioflavin S (ThS) staining was performed in all hTau injected groups. Structures 
delineated as glial tangles in 4R-related tauopathies – and as viewed in this study – are thought to 
be ThS-negative 122,124,125, while neuronal tangles still are ThS-reactive. Figure 28A-B indicate 
ThS-positive neuronal aggregates in the hippocampus of hTau-Aged P301S and hTau-P301S 
rmTBI mice, while hTau-P301S sham and hTau-WT rmTBI animals exhibit ThS-negative 
reactivity in HPa and even in cortical areas that typically reveal Gallyas silver staining (Figure 
28C-D). All together, these results suggest uniquely induced tau pathology in the HPa that exhibits 










Figure 27. Gallyas silver staining in injected hTau mice. (A) In some of the experimental 
hTau animals, there was silver-positive inclusions that were similar to glial tau pathology 
noted in 4R-related tauopathies, such as PSP, CBD, and AGD. Argyrophilic staining, as 
exampled by irregular rod or thread-like structures (white arrows) and microglia-like 
morphological deposits (black arrow), was detected around the injected cortical area as 
shown in a hTau-P301S sham mouse. (B) Argyrophilic inclusions or irregular grains (white 
arrowheads) infiltrate the white matter tracts of the corpus callosum (cc) and alveus of the 
hippocampus (HPa) as shown in a hTau-P301S rmTBI mouse, which was more prevalent 
in hTau-Aged P301S and hTau-P301S rmTBI animals. (C) Associated glial tau pathology, 
which resembled threads (white arrows) and coiled bodies (black arrowheads), could be 
detected in the fimbria fornix (ff) as displayed in a hTau-Aged P301S mouse. This occurred 
only in the hTau-Aged P301S and –P301S rmTBI mice. Only hTau-Aged P301S (D) and 
hTau-P301S rmTBI mice (E) generated neuronal tangle pathology as observed in the 
hippocampus. (F) This induced tau pathology was not identified in the HPa of hTau-WT 
rmTBI, nor any argyrophilic staining was detected in aged untreated hTau mice (G). (H) 
Human brain affected with AGD exhibit glial and neuronal tangle pathology; the NFT here 
is morphological very similar to the NFT pathology found in hTau-Aged P301S and hTau-
P301S rmTBI mice. (I) Gallyas quantification in the HPa posited a significant difference 
among the groups by one-way ANOVA (p < 0.05), while hTau-Aged P301S mice had a 
significantly higher burden compared to hTau-P301S sham mice with hTau-P301S rmTBI 
exhibiting a strong trend (p = 0.0524). (DG) = dentate gyrus; (ND) = not detected. (*p < 
0.05). Scale bar: 300 μm, 100 μm, 50 μm. Data is expressed as means ± SEM. (H): Ferrer, 
I., Santpere, G., van Leeuwen, F.W., 2008. Argyrophilic grain disease. Brain 131, 1416–1432. 
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Figure 28. Thioflavin S (ThS) staining in injected hTau mice. Further support 
for the presence of neuronal tau aggregate pathology induced in hTau mice from 
the Aged P301S and P301S rmTBI EC homogenate was performed by ThS 
staining. Glial tangles are suggested to be negative for ThS staining. ThS-positive 
staining could be identified in the targeted inoculation area of hTau-Aged P301S 
(A) and hTau-P301S rmTBI mice (B) as shown in the hippocampal granule cell 
layer. Cortical areas of hTau-P301S sham mice (C) and hTau-WT rmTBI mice (D), 
which generally proved argyrophilic, do not display ThS staining, as well.  Scale 













 There have been copious assertions of TBI as a strong risk factor for neurodegenerative 
diseases involved with protein misfolding, aggregation, and accumulation, such as AD and CTE. 
Indeed, the molecular mechanistic effects of both TBI and neurodegenerative diseases resemble 
very similar properties. Anomalous tau and tau aggregates have been detected following TBI 
events and is canonical in diverse tauopathies in brain. More so, recent research implicates 
multiple, continuous traumatic impacts, perhaps those involved in contact sports and military 
settings, to tauopathies, like AD and CTE. Neuropathological tau is believed to consist of 
characteristics redolent of the prion protein in prion diseases and has been suggested to be “prion-
like”. Moreover, tau is posited to follow a nucleation-polymerization process to ultimately form 
NFT amyloid structures composed of hyperphosphorylated tau as well as tau can spread through 
the brain transsynaptically through the brain functional connectome. A paragon for tau spreading 
assessing the degree of intensity and kinetics of disease-related tau has been described in AD by 
Braak staging and in CTE from the McKee laboratory, previously. In this current study, we 
assessed the effect of repetitive mild TBI in engendering early pathological tau formation as well 
as exacerbating tau aggregation in brain with additional rmTBIs over time and subsequent 
neurobehavioral consequences; moreover, we addressed if these initial rmTBI-tau aggregates 
represented seed competency by in vivo bioassay.  
In the early time-point assessed groups (1 hour, 1 day, and 1 week post-induction), Tg and 
WT naïve animals treated with rmTBI exhibited altered neurobehavioral performance by 
measurement of artificial grooming in the Splash test - specifically 1 hour to 1 day after. 
Particularly, 1 hour after rmTBI not only was the grooming time attenuated, but overall 
participation in the task was diminished as measured by distance travelled and immobility (data 
not shown). This result was most likely due to the effect of the direct impacts presenting short-
term impairment in neurological function evidenced by immobility, perhaps due to pain, or even 
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a dazed state / dizziness in some animals. This response can be found in concussed individuals 
and is known to be resolved in days’ time 117. However, the 1 day Tg and WT rmTBI mice 
revealed lowered performance in artificial grooming, not due to a lack of participation in the task 
(data not shown), as well as overnight nesting. This may be explained by the residing or lingering 
effect of the TBI initiating a post-concussion-like syndrome in the rmTBI animals. In TBI cases, 
this syndrome consists of headache, dizziness, fatigue, irritability, and principally compromised 
memory and concentration, but its exact frequency is not known 78,80,94,126,127. These symptoms 
may persist longer than the transient symptoms, as seen in the 1 hour rmTBI mice, and may reflect 
altered neurotransmitter function and generally correlate with the duration of post-traumatic 
amnesia 128. 
Nevertheless, rmTBI-induced animals then begin to progressively recover to normal 
behavioral function after 1 week as indicated by Splash test, Nesting, open field, and RotaRod. 
One week P301S rmTBI mice did demonstrate lowered performance among the groups in 
artificial grooming and nesting and no significant difference in motor capabilities. Although 
recovery rates are assuredly individualized, there appears to be a 7-10 day period of a heightened 
susceptibility to re-injury, thus activities with high concussion exposure are recommended to be 
avoided for at least 1 week 117. When assessing the P301S and WT rmTBI with-in subject testing 
over these times, only P301S rmTBI revealed a significant difference between the 1 day and 1 
week mark perhaps indicating a rate of slower recovery as compared to WT rmTBI and respective 
sham controls, yet more experimental emphasis is warranted. Moreover, additional behavioral 
results at later time-points (3m, 6m, and 9m) in P301S mice following rmTBI attested to the 
presence of tau aggregation and may have a more substantial role in learning and memory, which 
should be assessed at the early time-points. Still, no full recovery, or even a slower recovery, from 
symptoms 1 week after mTBI may occur, as indicated even at the high-school age level 129, and 
86 
 
the triggered TBI-induced secondary neuro-molecular events, such as the formation of 
pathological tau, may be associated with symptom recovery rate.   
 Further, our study assessed the early formation of tau deposition in P301S mice at 1 hour, 
1 day, and 1 week with or without rmTBI events by histological and biochemical methods. For 
histological analysis, four coronal sections, which included regions as CTX, HPa, Di, and BS, 
were assayed utilizing AT8, MC1, and Gallyas silver staining. AT8 recognizes specific 
phosphorylation sites that is associated to pre-tangle or tangle hyperphosphorylated tau. MC1 
detects a distinct conformation of tau, believed to be pre-tangle PHFs, by targeting the N-terminal 
(amino acids 5-15) and the third microtubule binding region (amino acids 312-322) of tau, and 
Gallyas silver staining is a classical technique canonical for NFT and NP thread detection. P301S 
rmTBI mice did exhibit a small, but detectable and elevated amount of conformation-specific tau 
aggregates in the quantified CTX, HPa, Di, and BS regions by AT8, MC1, and Gallyas silver 
staining histological procedures. Following a two-step fractionation and obtaining the insoluble 
formic acid fraction from brain homogenate, biochemical ELISA demonstrated that each early 
time-point P301S rmTBI group displayed approximately ±1.5-fold increase of insoluble 
pathological tau in comparison to their respective age-matched P301S sham group. Overall, these 
results suggest that rmTBI can trigger early and accelerated tau formation in brain following 1 
hour, 1 day, and 1 week.  
Primarily, tau deposition was seen to follow what normally transpires spatiotemporally in 
the P301S mouse model (i.e. piriform and rhinal cortices) regardless of treatment. Conversely, 
P301S mice with rmTBI did demonstrate more tau deposition just below the area of impact (i.e. 
cingulate gyrus/retrosplenial cortex) and in regions not detected typically in the P301S mice at 
this young of age (i.e. the hypothalamus in the diencephalon), as exampled by the Tg sham mice 
here. An explanation for this could be described by an altered tropism due to the direct effect of 
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the rmTBI, where it produced tau assemblies in regions not distinctly identified in a naïve P301S 
mouse resulting in spontaneous tau formation. Although, it may be debatable if this mild of 
impacts could produce a pertinent contrecoup injury to engender tau formation in a ventral portion 
of the brain such as the hypothalamus after impact. Tropism can be distinguished by the 
localization of proteinaceous deposits within the brain and by the pattern of disease that is 
produced, which may lead to functional clinical symptoms, and this has been well described in 
prion diseases where distinct prion strains dictate different tropisms in brain and peripheral organs 
130–134.   
Alternatively, the result of multiple mild traumas to the head may create a thriving cellular 
microenvironment that can aid in the accelerated formation and spreading of tau through the 
functional synapses in the brain. Therefore, the intrinsic Braak-like staging and spreading of tau 
in the P301S mouse model could be accelerated. Areas canonical for the origination of 
pathological tau seeds, described by Braak and Braak such as the EC and/or BS 60,61,120, could 
form seeding competent tau much earlier, as discovered in this study, which spread much more 
thoroughly and effortlessly following rmTBI. For example, tau seeds generated in the EC could 
very well travel by functional neuronal efferent projections, such as cingulate cortex, 
hippocampus and amygdala (both which also project to the hypothalamus) and others, at a more 
exigent rate following rmTBI – all brain regions exhibiting tau deposition by histology in the early 
time-point P301S rmTBI mice. It has been posited that seeding may actually be an earlier event 
in pathology by assessing different Braak stage brains and seeding ability 111. To further 
complicate the issue, since this is a dynamic phenomenon, these results could be a concomitant 
effect of both spontaneous formation and accelerated spreading. An example, while the intrinsic 
spatiotemporal pattern of tau in the P301S mouse model is commencing, rmTBI-induction was 
seen to engender pathological tau just above the impact area, the cingulate and retrosplenial 
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cortices, which could then have tau spread to functional neuronal connections, such as deep layers 
of the EC and HPa, among others. Remarkably, early tau deposits can be usually detected in more 
superficial layers (layers II-IV); however, pathological tau could be found in deep layers of the 
EC, even at 1 hour post-rmTBI.  Thus, the molecular mechanism responsible for the divergent 
neurotropism of tau formation and spreading following rmTBI remains to be elucidated and more 
clarifying experiments are warranted.      
 In addition to the spontaneous formation and/or accelerated spreading of pathological tau 
subsequent to rmTBI in brain parenchyma, there could be release and/or generation of tau seeds 
in the periphery that could then propagate tau aggregation and spreading in the brain. This may 
be evidenced by the finding of pathological tau in early stage P301S rmTBI mice appearing in 
areas proximal to ventricles, i.e. abnormal tau immunopositive staining in layers V-VI in the EC 
or in the oriens layer of the hippocampus near the ventrally extending lateral ventricles (Figure 
16A, P301S rmTBI AT8) or in the hypothalamus where the 3rd ventricle would be present. The 
interstitial fluid (ISF), cerebrospinal fluid (CSF), and blood plasma collectively make up the 
extracellular fluid of the brain and spinal cord. The brain parenchyma is surrounded by ISF 
together with related vasculature and tissues as well as CSF that fills the ventricles within the 
brain and the spaces on its outer surfaces, and the ISF/CSF has multiple functions for the brain 
from solute volume and osmolality regulation, waste clearance, and buoyancy and cushioning, 
and others, respectively 135. Indeed, detectable protein aggregates, such as Aβ and tau, are found 
in these biological fluids and are currently being assessed as a diagnostic marker for PMDs, like 
AD 74,75,83,136–143. Alongside detection and diagnosis for diverse PMDs, biological fluids are being 
targeted in TBI cases, as well; one study demonstrated that tau levels in CSF from fatal TBI 
patients expressed over a 1,000-fold increase compared to various neurological-diseased and non-
diseased controls, and a cleaved and reduced sized form of tau protein was detected in these brain 
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injured patients 83. Tau found in ISF and CSF may be independent from cellular death and is not 
known if it is released in a free, soluble form or if it is packaged into small membrane vesicles, 
such as exosomes 144. 
Moreover, proteinaceous deposits may be removed from the brain by various clearance 
systems, including: transport across the blood-brain barrier, astroglial-mediated ISF bulk flow or 
also known as the glymphatic system, and the meningeal lymphatic vessels. Impairments in this 
waste clearance system has been described in Aβ 145,146 and tau 147,148 in rodent models, even after 
TBI. Following TBI, glymphatic pathway function was dramatically reduced to around 60%, and 
knock-out of aquaporin-4, astroglial water channels important for CSF-ISF exchange and 
clearance, in mice subjected to TBI revealed impaired glymphatics, promotion of tauopathy, 
neuroinflammation, and neurodegeneration 148. The initial formation of tau in peripheral fluids, 
like CSF, ISF, and blood plasma, after rmTBI is not unfathomable. In CTE, the irregular and 
patchy tau distribution, which is disparate from tauopathies like AD, is identified early in the 
sulcal, perivascular and periventricular, and subpial depths – all areas associated with CSF/ISF 
flow and glymphatic/lymphatic systems 63,79–81,84,89,94. Thus, the presence of tau in biological 
fluids following TBI can be detected and perhaps promoted by such mechanisms as impaired 
circulating fluid clearance. 
Additionally, one theory that may occur following TBI is a slosh effect of CSF/ISF in the 
head; the concept of slosh has been investigated in liquid dynamics and is the motion of a given 
liquid’s free surface within a container, where energy transfer occurs among the various 
boundaries. The CSF that surrounds the brain may act as a safeguard converting focally applied 
external stress to compressive stress because the fluid follows the outlines of the sulci and gyri of 
the brain and distributes the force in a uniform fashion, but the CSF is unable to wholly prevent 
shearing forces from being transmitted to the brain, especially when rotational forces involved. 
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The slosh effect could be mitigated by the tension of neck muscles, such as omohyoid muscle, 
bracing for an impact; this can be thought of when a professional boxer is prepared to sustain a 
force of enormous magnitude by tightening the neck muscles, but an unexpected blow may lead 
to more deleterious consequences, perhaps such as that from a hook punch 149. Reduction of a 
slosh effect can also be described in nature as woodpeckers, although somewhat controversial 
150,151, are thought to have protective mechanisms from the effects of repetitive TBI by possible 
shock absorbing anatomical structures, i.e. hyoid bone and a unique tongue 149.  The significant 
and/or continuous stresses of a slosh effect could play a role in tau aggregation as exampled by 
the discovery of CTE pathology in instances that may not involve direct allisions or collisions to 
the head, such as military personnel affected by IED explosions or head bangers associated to 
heavy metal music 84. Certainly, if complications such as sleep deprivation and wakefulness and 
epilepsy demonstrate increased ISF/CSF tau, then it is reasonable to assume that ISF/CSF tau 
would be augmented in the severity spectrum of TBIs 152,153. Thus, it cannot be ruled out that the 
first misfolded tau seed could occur in the ISF/CSF, perhaps due to fluid dynamics from the injury, 
and penetrate into the brain parenchyma and spread through the functional connectome; this could 
explain the unique distribution of tau pathology in CTE (i.e. detection in subpial and sulci tissue 
in early stages). Future studies will be performed to detect pathological tau in CSF following TBI.  
In all likelihood, tau, whether in a pathological state or not, may be released by diffuse 
axonal injury (DAI) after repetitive mild TBI and make its way into the circulating fluids and/or 
parenchyma. Whether by primary or secondary effects, this DAI may be due to the literal shearing 
of axons and axoskeleton components or from axonal swellings or bulbs that consequently burst 
after injury. Ultimately, both can result in impaired axonal transport and buildup and/or lysis of 
proteins and enzymes leading to accumulation of neuropathological substrates and toxicity along 
with axonal disconnection and synaptic issues. Axonal injury due to trauma can be measured by 
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amyloid precursor protein (APP) and neurofilament proteins (NFs). APP is present in axons at 
high concentrations and is transported by fast axonal transport, and NFs, which are coassembled 
of light, medium, or heavy chain corresponding to molecular weight, are important structural 
scaffolds for neurons providing mechanical stability and shaping axonal diameter through the 
number and spacing of NFs 63–65,74–78,102,154. DAI is thought to be an early event in TBI as in vitro 
dynamic stretch injury of cortical axons revealed microtubule disruption as early as 2 minutes 
followed by axonal varicosities hours later 152; in addition, detection for axonal injury has been 
identified in adult human tissue within ~6-10 hours after head injury 155–157 and as early as 35-45 
minutes in children following a motor vehicle accident 158. Axonal injury by APP has been seen 
to persist even up to 1 year along with Aβ deposits by fluid percussion injury in rats 159. 
Nevertheless, the formation of Aβ perhaps due to DAI is very common in TBI cases, even 
appearing 2 hours after an incident 160, and may be attributed to an over-accumulation or a 
reservoir of the substrates known to generate toxic Aβ that then are easily lysed from the dilated 
bulb and into the brain parenchyma – tau could follow this same event 63,65,74,78,102,154,159. 
Interestingly, some research suggests that experimental rotational head injury is proportional to 
the extent of rotational head motion, severity of DAI (particularly in the BS), and, in turn, the 
duration of coma as well as degree of neurological impairment; thus, it may be needed to study 
loss of consciousness in TBI and tau pathology for future studies 161,162. Nevertheless, DAI could 
be an early molecular mechanism that allows tau protein to be unbound to microtubules and 
expelled into the extracellular space to enter circulating fluids or spread through the brain 
parenchyma. 
Next, we asked the question if rmTBIs were continual over time as the animal aged what 
would happen to pathological tau progression and resultant neuro-behavior. Naïve P301S and WT 
animals were rmTBI or sham-treated at varied impact numbers and intervals and sacrificed at later 
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stages: 3m (2 rmTBI rounds), 6m (3 rmTBI rounds), and 9m (4 rmTBI rounds). Behavioral 
examination was assayed using tests that would emulate some of the clinical aspects of CTE; thus, 
tasks associated to non-cognitive behavior (Splash test, Nesting, Open field, and RotaRod) as well 
as cognitive assessing behavioral tasks (Barnes maze with reversal learning) were performed in 
P301S rmTBI, P301S sham, WT rmTBI, and WT sham mice before sacrifice. Once again, 
histology using AT8, MC1, and Gallyas silver staining was implemented for assessing tau 
pathology in different brain regions as well as measurement of insoluble pathological tau levels 
in brain by ELISA. First, the P301S mouse model is known to exhibit prompt hindlimb paralysis 
accompanied by a hunch-backed posture and difficulty feeding at later ages; at least 80% are 
noted to die by 12 months of age 109,110. Following 4 rmTBI rounds, 8.5 month old P301S rmTBI 
mice had more paralyzed mice (4) compared to age-matched P301S sham animals (1). There can 
be difficulties when assessing rodent behavior in mouse models of AD; however, this is a 
fascinating result because it mimics what is seen in prion diseases, human and animal cases, where 
infection is substantial and fatal resulting in death, thus rmTBI seems to accelerate this canonical 
phenotype of paralysis that would lead to its demise. 
When assessing the psychiatric and motor aspects of the animals treated with or without 
rmTBI over 3m, 6m, and 9m, P301S rmTBI mice had lowered performance in the Splash test and 
Nesting assessment for anxiety/depressive-like behavior. Likewise, One-way ANOVA revealed 
worsening motor function by RotaRod in late stage P301S rmTBI mice, even showing 
significance versus P301S and WT sham mice from 3m to 9m. However, there was no significant 
difference in these psychiatric and motor tests between P301S rmTBI and WT rmTBI mice at any 
age. These results posit that rmTBI-induced tau may not be the only underlying factor for this 
type of behavior, yet it is not known if these results would be sustained if various experimental 
features were altered, such as: an extended age, augmenting impact force or number, shorter 
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interval from impacts, among others. Thereafter, all animals and groups were examined by 
utilizing the medial temporal lobe-dependent Barnes maze task. P301S rmTBI at 3m, 6m, and 9m 
of age demonstrated impaired learning when investigating the primary latency to the escape hole 
over time compared to controls, and when LTM was measured 3 days after training, the P301S 
rmTBI mice at all late time-points exhibited significant impairment remembering where the 
escape hole was statically placed compared to all age-matched P301S sham, WT rmTBI, and WT 
sham controls. Representative images of the trace for all groups emulate the average primary 
latency to the escape hole in LTM. P301S rmTBI exhibited a randomized search pattern, while 
the control animals followed a more serial or spatial approach. Further, when the escape hole was 
moved to a novel area, the Tg tau rmTBI animals once again had difficulty discovering the newly 
placed escape hole, thereby indicating an impairment to disassociate the previously learned 
information and apply this to a novel context as in reversal learning.   
Since developed by Carol Barnes in 1979, the Barnes maze is one of the most widely used, 
standard tasks to assess rodent spatial reference memory and hippocampal/medial temporal lobe 
(MTL) function 163–165. Studies of the canonical patient H.M., effect in aging or diseases such as 
AD, and multiple animal lesion and imaging studies verify that the HPa and MTL are imperative 
for memory function 163,164,166,167.  The Barnes maze results explored in this study determine that 
the combinatory effect of burgeoning tau accumulation and rmTBI induction diminish spatial 
learning and memory signifying impairment in the hippocampus and MTL brain regions in the 
P301S rmTBI mice, even as early as 3 months of age. Moreover, in the reversal learning, where 
the escape hole position is changed to 180° from its previous testing location, the animal then has 
to learn that the former is no longer rewarded and adjust their strategy to resolve the issue. If an 
improvement in performance is not observed, this means that cognitive flexibility is distorted 
163,168. Studies that address reversal learning discovered involved brain regions are the 
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oribitofrontal cortex, medial prefrontal cortex, nucleus accumbens, and perhaps basolateral 
amygdala 168. Once more, P301S rmTBI animals spent a longer time identifying the novel-situated 
escape hole compared to age-matched controls referring to disturbed cognitive flexibility and 
executive function. Notably, these are mostly all brain regions that are intimately neuronally 
connected and where tau accumulation can generally appear in tauopathies, as well as in the 
experiments performed here. 
The significant difference between P301S rmTBI and the respective controls in the 
cognitive-associated Barnes maze with reversal learning task relay that rmTBI along with 
progressing tau pathology may play a more deleterious role in learning and memory. Tau 
aggregates in brain have been noted to correspond with clinical outcomes, neuronal degeneration, 
and disease severity better than Aβ aggregation in AD 169, yet other intricacies could be involved 
that lead to the behavioral consequences: time exposed to pathological tau protein, levels of the 
protein, the structural state or mislocation occurrence, and other factors. Seeding ability of tau has 
been correlated with a higher Braak stage and negative Mini-Mental State Exam 111. Indeed, 
current AD therapy studies are shifting targets from Aβ to tau protein to hopefully delay or prevent 
AD 170. Compounds directed to tau aggregates or anti-tau immunotherapy have shown to lower 
tau aggregates in brain and improve behavior 170,171. Tau reduction by anti-sense oligonucleotides 
alleviated tau inclusions and seeding as well as neuronal loss in Tg tau mouse 172. Cheng et al. 
demonstrated that complete ablation or partial reduction of tau prevented deficits in spatial 
learning and memory after a repeated mild frontal impact TBI model 173. 
Tau protein could play a large role in neuronal networks as neuronal/synaptic activity can: 
stimulate the release of tau and spreading of tau pathology, induce tau phosphorylation, and 
relocate tau to the dendritic spines 42,174–176. Reduction of tau protein prevented cognitive decline, 
synaptic impairment, and spontaneous epileptiform activity from the synergistic effect of Aβ and 
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Fyn in multiple hAPP mouse models as well as ameliorated seizure activity induced in Aβ/Fyn 
overexpressing mice 177,178. The absence of tau protein prevented Aβ-induced impairment of long-
term potentiation (LTP) with involvement of the GSK-3β kinase in hippocampal cultures 179. 
Hyperphosphorylated tau was elevated in the dentate granule cells and mossy fibers in 
pharmacologically epileptic-induced 3xTg-AD mice compared to controls 180. Over-expressed 
hTau-A152T tau Tg mice demonstrated abnormal brain oscillations that was corrected by genetic 
ablation of the MAPT gene and doxycycline inducible-expression 181.  Neuronal vulnerability, 
which could transpire to even brain region susceptibility, could be an issue along with pathological 
tau and spreading affecting neuronal types differentially182 and may be amplified following TBI; 
two possibilities could occur: 1) the selective vulnerability is due in part to its intrinsic properties 
or 2) vulnerability may be due to their connectivity 183. This could be why, agreeing with Braak 
staging, specific brain regions are compromised in disease, such as AD, and some are spared of 
neuropathological repercussions.   
In AD, brain areas predominantly affected by tau pathology are those involved in higher-
order cognitive functions, areas/neuronal connections vulnerable in aging, as well as those that 
take the longest time for reaching maturity during development 8,9,11,60,61. A repetitive form of TBI 
may well engender a deleterious microenvironment, or even accelerating age-related molecular 
mechanisms, in the brain that can facilitate tau aggregation and propagation. Tauopathies are age-
related and progressive, where tau pathology sequentially spreads over time, yet a TBI event could 
form tau pathology in a short time – or even in children – and these early tau aggregates could 
lead to disease onset and irreversible progression. Widespread protein insolubility and 
aggregation has been suggested as a natural part of aging 184,185, which could influence PMDs, 
and this reaction could be accelerated after TBI beginning with tau due to tau’s response to 
damage and/or stress in brain. 
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 To study the effect of varied rmTBI induction on tau pathology, histological procedures 
utilizing AT8, MC1, and Gallyas silver staining were employed. Although tau pathology was 
advancing along with age, Tg tau rmTBI mice showed a more robust pathology in brain as 
compared to Tg tau sham mice at 3, 6, and 8.5 months of age. P301S mice displayed positive 
staining with classical somatodendritic morphology as well as punctate and thread-like tau, which 
seemed more advanced in the assessed regions following rmTBI; for example, at 8.5 months old, 
P301S rmTBI mice had interesting infiltration of Gallyas-positive staining in the dentate hilus 
compared to sham mice (Figure 22, Gallyas inset). Thioflavin S staining of the groups exhibited 
the same trend in Gallyas silver staining. Overall quantifications demonstrated exacerbated and 
disseminated tau pathology, including various distinguished structures, in the P301S rmTBI mice 
compared to age-matched P301S sham mice at later stages, as denoted by fold-change (FC) 
evaluated below:         
 AT8:  
 3 months, 2 rmTBI R (FC = 1.83-4.55) 
 6 months, 3 rmTBI R (FC = 2.05-5.87)  
 8.5 months, 4 rmTBI R (FC = 1.31-2.75) 
 MC1:  
 3 months, 2 rmTBI R (FC = 2.17-4.58) 
 6 months, 3 rmTBI R (FC = 1.85-3.29) 
 8.5 months, 4 rmTBI R (FC = 1.71-2.92) 
 Gallyas silver staining:  
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 3 months, 2 rmTBI R (FC = 2.53-7.57) 
 6 months, 3 rmTBI R (FC = 1.57-3.54) 
 8.5 months, 4 rmTBI R (FC = 1.81-2.64) 
For the most part, HPa and BS show some of the higher fold-changes by histology, which may 
translate to what is revealed by the Barnes maze results as well as the increased paralysis in the 
9m rmTBI group. Finally, following fractionation protocols of 10% brain homogenate to obtain 
the formic acid, insoluble protein fraction, biochemical ELISA measurements determined 
significant augmented pathological insoluble tau in P301S rmTBI mice versus P301S sham mice 
at 3 months (FC = 1.21), 6 months (FC = 1.53), and 8.5 months of age (FC = 1.49). There was no 
measurements detected in WT rmTBI and WT sham mice tested at 8.5 months old by pS199 ELISA 
(data not shown). 
 Transgenic tau rmTBI and sham results were assessed from all early and later time-point 
groups by insoluble tau ELISA levels and summed brain areas of histology using linear regression 
and determining the effect of rmTBI on tau pathology as well as the potential equivalent age to 
P301S sham mice by the slope of the line. There was an approximate 1.5-fold increase of insoluble 
tau by ELISA per month – assuming animal survival and continuous aggregation; moreover, the 
predicted age of the P301S rmTBI mice compared to sham mice showed an accretion in age, 
following the rmTBI paradigm as executed in this study. The difference of the slopes for AT8, 
MC1, and Gallyas silver staining for the total summed burden of all groups demonstrated P301S 
rmTBI had differences as compared to P301S sham rodents over time. Breaking the overall burden 
back down to individual brain regions, P301S rmTBI mice revealed significant differences to 
P301S sham animals with noteworthy differences seen among MC1 and Gallyas silver staining 
along with HPa and BS regions. These results determined that P301S rmTBI had more aggregated 
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PHF/NFT tau pathology in the brain. The HPa and BS may be more vulnerable areas to tau 
pathology or even act as a hub for tau propagation and spreading as well as correlate with the 
behavioral and phenotypic results following rmTBI over time. The P301S mouse model is 
reported to have neuronal loss at 9-12 months of age 110. Quantification of anti-cleaved caspase-
3, one apoptotic marker of cell death, determined that P301S rmTBI mice sacrificed at 8.5 months 
old, earlier than the 9-12 months mark, had more neuronal degeneration in comparison to age-
matched P301S sham mice. Higher levels were seen in the HPa and BS, once again, which may 
correlate to tau aggregates and behavior. These results posit intensified insoluble tau levels along 
with accelerated model/age-related neuropathology following rmTBI events over time. 
 If we extrapolate these data, following the rmTBI paradigm studied here, there is an 
elevated presence of aggregated tau and neuronal death in the brain, markedly in the HPa and BS, 
which may then translate to the observed learning and memory deficits and paralysis in the P301S 
rmTBI animals. It has been suggested that tau spreading and aggregation is age and brain region 
dependent. For example, the Hyman laboratory deduced that mice, virally expressed with human 
tau in the EC, had more tau spreading in the hippocampus and adjacent cortical regions and EC 
neurons in older mice than young, yet viral vector introduction in the striatal caudoputamen (CPu) 
left the mice unaffected by tau spreading, despite the age 186. As conferred previously, these results 
hint to region/neuronal vulnerability, where there may be an integral difference in neuronal 
populations in the EC versus CPu that may promote tau aggregation and spreading, or the regional 
environment / cell autonomous conditions, as there is a difference in tau kinases and phosphatases 
in the EC versus CPu 186. TBI could very well magnify these aspects related to tau misfolding and 
aggregation, but it is yet to be determined if the formation of a pathological tau seed strictly in an 
anomalous region, not prominent for tangle pathology, could occur and spread throughout the 
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brain. It still cannot be ruled out that some regions/neuronal cells may have the ability to degrade 
tau longer before succumbing to tau accumulation.  
Moreover, could TBI, as in the association of rmTBI with CTE, actually engender the 
formation of multiple types of seeds or conformers as delineated by different tau strains?  The 
“strain” terminology in terms of proteopathies originated from prion diseases where the self-
propagating PrPSc protein can have differing structural heterogeneity (i.e. size and conformation) 
or conformational variants that results in maladies with diverse features: clinical symptoms, 
affected brain regions, seeding or sequential spreading, preference to specific cells to affect, 
and/or toxicity  4,7,34,38,99,113,115,130–132,134. This could be one explanation for the various tauopathies 
and atypical sequential pattern of tau neuropathology, distinguished tau morphology, and clinical 
symptoms. Clavaguera et al. was able to recapitulate the corresponding pathological lesions from 
inoculated tauopathies (AD, tangle-only dementia, AGD, PSP, CBD, and Pick’s disease) in 
ALZ17 mice and were able to serially propagate this seeding material in vivo 43. The laboratory 
of Marc Diamond measured tau seeding by the Förster resonance energy transfer (FRET)-flow 
cytometry tau biosensor cell assay from multiple brain regions and Braak stages in human AD 
samples and observed extensive seeding activity, noticeably in regions projected to unaffected by 
pTau deposition, and in detergent-insoluble fractions that were not detected by tau ELISA 111. 
Thus, this implies there may be multiple types of soluble and insoluble tau seeds in the diseased 
human brain; moreover, this too could be happening in TBI cases. Purified and synthetic tau 
oligomers and PHFs have been used to seed endogenous tau in rodents, as well 46,47,51,100. Indeed, 
recent research utilizing cryo-microscopy at high resolution has discovered that CTE (3 cases) 
demonstrated distinct filamentous structures from AD and PiD cases, and over 97% of the CTE 
protofilaments comprised of a conserved fold were different from AD and PiD 71,187–189. Thus, 
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manifestation and dissemination of distinct conformers of assembled tau may underlie different 
tauopathies and could be present following TBI events.  
 The discovery of prions acting virtually alike to a virus with infectious properties and as 
a causative agent of prion diseases, or transmissible spongiform encephalopathies, was a 
transformative innovation in the scientific field. Subsequently, this idea was translated to various 
PMDs that were thought to have a transmissible component or shared “prion-like” mechanisms. 
This could be demonstrated in animal models by an in vivo bioassay where the seeding-nucleation 
model could be propagated in vivo by inoculation of seed-containing material (i.e. an aberrant 
proteinaceous brain homogenate) and generate similar pathologic features or a significant 
attenuation of the nucleation or lag phase of seeding in the circumstance if there is endogenous 
components in the animal model. Thus, seeding is observed as a significant shortening of the 
incubation period or acceleration in the onset of the inherent arising disease. Akin to prion 
diseases, seeding assessment of AD by in vivo bioassay was performed originally in marmosets 
followed by intensive evaluation in rodent models; these results gave strong support for the 
protein-only hypothesis in disease 34,37,190,191. Indeed, exogenous inoculation of a tau seeds (i.e. 
synthetic tau or brain homogenates from human tauopathies or transgenic tau mice) determined 
resultant tau deposition was not limited to the injection site, but had spread beyond to functionally 
connected brain regions in human tau transgenic mice and even in non-genetically modified WT 
mice 43–49.  Seeding could also be detected in parallel by serially diluted amyloidogenic Aβ brain 
homogenate in vivo 118.  
To address if the earliest rmTBI-induced tau (1 hour post-rmTBI) was seeding competent, 
we excised and made an entorhinal cortex brain homogenate and inoculated mice expressing 
normal human tau (hTau) to analyze any acceleration of endogenous pathology or induction of 
insoluble tau in vivo. Results from the prior experiments dictated the earliest time-point (1 hour) 
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of triggered tau formation and a canonical, tau-laden brain region (entorhinal cortex) that provided 
the inocula for the bioassay. The EC is an area canonical for tau pathology and as an initial 
affected region of tau deposition in AD 60,61. The extracted EC homogenate from the 1 hr P301S 
and WT rmTBI or sham-grouped mice was i.c. injected into 2.5 month old hTau mice; these 
animals observe progressive formation of soluble tau over time, not as robust as the P301S model, 
but no tangle formation 119. EC inoculated hTau injected mice were then assayed in animal 
behavior and histology as done previously to examine the effect of rmTBI-induced tau seeds in 
prompting NFTs and exacerbating tau pathology at 9 months of age. The following experimental 
groups for the in vivo bioassay included: 1) hTau mice injected with 1hr P301S rmTBI EC 
homogenate, 2) hTau mice injected with 1hr P301S sham EC homogenate, 3) hTau mice injected 
with 1hr WT rmTBI EC homogenate, and 4) hTau mice injected with Aged P301S EC 
homogenate as a positive control.  
 As completed previously, hTau-EC injected animals were assayed in psychiatric and 
motor abilities. There was no significant difference in performance among the groups for Splash 
test, Nesting, Open field test, or RotaRod suggesting the different EC homogenates had no effect 
on these relative behaviors. Nonetheless, examining Barnes maze with reversal learning, hTau-
Aged P301S and hTau-P301S rmTBI revealed impaired cognitive capacities compared to controls 
in Barnes maze learning curve, LTM (primary latency and errors), and primary latency to the 
novel escape hole in reversal learning, respectively. These results were similar to what was seen 
beforehand that tau combined with rmTBI may play a more deleterious role in learning and 
memory and cognitive-associated brain regions as specific EC homogenates (Aged P301S and 
P301S rmTBI) were able to alter behavior in hTau mice evaluated by Barnes maze with reversal 
learning. Immunohistochemistry using AT8 and MC1 antibodies in hTau-Aged P301S, hTau-
P301S rmTBI, hTau-P301S sham, and hTau-WT rmTBI mice was performed. All mouse groups 
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presented a faint or weak AT8 and MC1 immunostaining, which could be detected essentially in: 
piriform cortex and claustrum, superior cortex (deep cortical layers), entorhinal cortex, amygdala, 
hippocampal area, diencephalon, brainstem, and cerebellum, respectively. Soluble pre-tangle tau 
pathology is primarily non-argyrophilic and non-fibrillar; this weakly immunostained droplet-like 
inclusions in the hTau groups may be in a prefibrillar and pre-tangle state at 9 months of age. 
Immunopositive nuclei was also detected with better intensity in regions such as the amygdala 
and BS. This weak staining of AT8 and MC1 seems to be an intrinsic property of the hTau mouse 
model as missorting of tau has been reported at about 6 months of age utilizing the PHF-1 anti-
tau antibody 119 and as older 10 month old untreated hTau mice exhibited the same type of 
immunoreaction (data not shown). Thus, abnormal tau seemed to be located in the distal dendritic 
segments / proximal dendrites as noticed by Braak et al 192 and therefore may exhibit a 
mislocalization of tau as an early step in tau pathogenesis. Some classic somatodendritic aberrant 
tau with AT8/MC1 immunostaining, as that of in the P301S mouse model, could be found in the 
HPa of hTau-Aged P301S mice, which had been reported much later (12-18 months) previously 
119, thereby positing an acceleration of tau pathology in the hTau mice following Aged-P301S EC 
inocula.  
Protein assemblies may be viewed in post mortem tissue and reveal visually striking 
pathological aggregates, yet this end-point result may not convey the conclusive pathogenic 
alteration of the specific protein. As in the case with tau protein, pre-tangle or oligomeric 
structures or precursor events may be directly responsible for the neurotoxicity accompanied with 
behavioral changes in disease. Soluble oligomers appear to be an intermediate on the pathway to 
fibrilization and/or amalgamate together to form fibrils, yet oligomers could lead to a different 
“off pathway” system - disparate from the nucleation-polymerization pathway; however, there is 
much difficulty determining the nature of protein misfolded intermediates/oligomers due to 
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unfavorable energy context resulting in a transient structural change. Mechanisms of oligomer 
toxicity suggested are: direct binding to molecules, pathway activation, oxidative stress, 
recruitment of cellular factors, generation of membrane permeating pores or binding to receptors, 
and/or overload of proteostasis machinery. Research has demonstrated that there is an inverse 
relationship between oligomer size and toxicity and have hydrophobic patches exposed, which 
may make them more capable seeders. Yet, there may be different types of oligomers (i.e. 
amorphous or disordered aggregates) with different: fates, stability, mechanisms of toxicity or 
even lack thereof, and propagation properties 4,14,193–195. It cannot be ruled out that rmTBI could 
trigger the formation of “on-or-off pathway” neurotoxic tau oligomers, which are able to 
propagate in vivo, and can result in behavioral consequences as shown here in this study. 
These samples were carefully quantified for AT8/MC1 burden intensity, and hTau-Aged 
P301S mice demonstrated the most significant effect with AT8 staining higher in CTX, HPa, and 
BS, and MC1 staining elevated in CTX, HPa, and Cb as compared to hTau-P301S sham and hTau-
WT rmTBI mice, respectively. Hyperphosphorylated tau, indicated by AT8 immunostaining, was 
augmented in the HPa of hTau-P301S rmTBI mice as compared to hTau-P301S sham and hTau-
WT rmTBI mice and in the Cb versus hTau-WT rmTBI mice by MC1 immunostaining. MC1 
immunoreactivity was surprising in the Cb, mostly localized to the granular cell layer, but may 
be from the inherent characteristic of the hTau model, as untreated 10 month hTau mice had 
similar immunostaining; however, this also could serve as a portent for cerebellar motor-related 
issues as even later-aged hTau mice observe altered gait. These results are indicative of the 
amount and perhaps type of de novo tau seeds inoculated in the hTau mice having a deleterious 
effect by accelerating AT8/MC1-stained aberrant tau pathology in the hTau model. Aged-P301S 
inoculated hTau mice exhibited a more robust hyperphosphorylated tau and MC1-PHF pathology 
in brain, yet hTau-P301S rmTBI had elevated pTau in the hippocampal area, but significantly 
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only by AT8 immunostaining, representing significant, but early pathological changes, compared 
to respective controls. Longer incubations may be necessary to observe significant differences of 
PHF tau and/or other brain regions in hTau-P301S rmTBI.   
Astonishingly, Gallyas silver staining of the injected hTau mice presented fascinating 
results. All groups, although not all animals, displayed argyrophilic Gallyas positive staining in 
the CTX proximal to the injected area and likely where the homogenate may have dispersed. This 
staining resembled glia-like morphology that was rod-like and punctate structures and some 
ameboid morphologies. Argyrophilic grain-shaped staining could be detected more often in hTau-
Aged P301S and hTau-P301S rmTBI mice in the corpus callosum and trickling into the alveus of 
the HPa – although this occurred in one hTau-P301S sham mouse. Only hTau-Aged P301S and 
hTau-P301S rmTBI mice exhibited abnormal Gallyas positive staining similar to coiled bodies 
and neuropil thread-like structures in the fimbria fornix and stria terminalis. Argyrophilic staining 
could be examined in the hippocampal-targeted area much higher in hTau-Aged P301S rodents 
followed by hTau-P301S rmTBI mice, and no Gallyas staining in the internal hippocampal 
structures was noted in hTau-P301S sham and hTau-WT rmTBI mice and even 10 month old 
hTau untreated mice. The staining in the HPa of hTau-Aged P301S and -P301S rmTBI animals 
was ThS-positive and resembled neuronal morphology. The argyrophilic staining identified here 
can be determined from the inocula that produced an induced reaction, utilized in this study, as 
older untreated hTau mice do not show Gallyas positive tau or fibrillar tau as stated previously. 
When quantifying Gallyas staining threshold density in the targeted HPa of the groups, 
hTau-Aged P301S animals had elevated Gallyas silver staining in the HPa as compared to hTau-
P301S sham (one mouse) and undetected in hTau-WT rmTBI mice, whereas hTau-P301S rmTBI 
mice exhibited a very strong trend against hTau-P301S sham mice (p = 0.0524). It is evident that 
inoculation with the hTau-Aged P301S EC substrate, which most likely contains an exorbitant 
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amount of tau seeds and is seeding competent as seen in previous studies, provoked the formation 
of argyrophilic structures shown as an amalgamation of glial and neuronal tangles in vivo, while 
hTau-P301S rmTBI mice presented a similar effect at a lower level. It could be expected that the 
1hr P301S sham inocula could reveal some seeding activity since there could still be capable and 
available endogenous tau seeds as conveyed in the P301S mouse model, as seeding activity could 
be reported earlier than previously expected in this Tg tau mouse model 45. It is imperative to 
point out that only the hTau-Aged P301S and hTau-P301S rmTBI animals demonstrated what 
looked like soma-filled, neuronal argyrophilic inclusions (as well as ThS-positive) below the 
corpus callosum and alveus of the hippocampus, i.e. in the hilus of the dentate gyrus or CA1 
regions of the HPa. In prion studies of zoonotic potential, the transmission barrier can manifest as 
a subsequent delay of etiology and/or as an incomplete attack rate which may predominantly be 
determined by the percentage of similarity between the prion PrP sequence and the novel host’s 
PrP sequence; thus, this could be occurring in our experimental study in terms of different tau 
isoforms. This could explain why there was not a uniform attack rate among the groups, as well 
as individual mice showing a more robust reaction than others, when the P301S mouse (4R1N 
isoform) was introduced into the host hTau mouse (4R2N isoform); moreover, the amount levels 
and/or engendering of a different tau strain and/or folded conformation cannot be ruled out, as 
well. Ultimately, these results together posit successful seeding capability of the Aged-P301S and 
1hr P301S rmTBI inocula demonstrated by an augmentation of AT8/MC1 tau pathology and 
induction of glial and neuronal tangle pathology – normally not present in the hTau mouse model. 
Most significantly, argyrophilic inclusions were generated by EC inoculation in normal 
human tau mice, which has not been described in this mouse model 119, and, indeed, these silver-
positive deposits attained in the injected hTau mice highlight intriguing results. Gallyas silver 
staining is a very useful staining technique in that it is able to react to PHF/NFT-tau and has been 
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determined to be a vital staining for tauopathies, like AD, and stated to react to only 4R tau 
isoforms, yet it has been a significant staining method for identifying glial fibrillary tangles 
(GFTs) and astrocytic inclusions (i.e. tufted astrocytes, astrocytic plaques) and glial cytoplasmic 
inclusions (GCIs) in related 4R tauopathies such as PSP, CBD, FTD, and AGD, and other NDs, 
like Multiple System Atrophy, respectively 196. Incredibly, inoculation of EC substrate in the hTau 
mouse model generated what can be described as GFTs, much more aggressively in hTau-Aged 
P301S and hTau-P301S rmTBI mice, emulating some of the same silver impregnated, 
morphological neuropathology denoted in these particular 4R tauopathies 122,196–198. Some of the 
glial tangles detected in these mice are described below. GCIs are composed of a meshwork of 
randomly arranged, loosely packed filaments with cross-sectional diameters of 20-30 nm; can 
entrap cellular organelles; are Thioflavin S-negative; and may reveal weak or negative 
immunostaining with various anti-tau and anti-PHF antibodies 196,199. Argyrophilic thread-like 
structures or interfascicular threads can be seen as long, thin, wavy, and/or corkscrew-shaped 
filaments as well as may be oligodendroglial in nature 196. Coiled bodies are composed of 
accumulations of fibrils measuring 10–20 nm in diameter ultrastructurally and appear as a fine 
bundle of filaments coiled around the nucleus 196,198,200,201. Scattered inclusions and/or grains are 
small, about 4–8 microns, spindle shaped, rod-like, button-like or round protrusions in the 
neuropil and are thought to be located in dendrites and dendritic branches 122,196,197,200. Fairly 
similar results have been described as post-mortem brains from PSP and CBD cases were 
inoculated in non-Tg mice, and only these particular 4R tauopathies induced astroglial and 
oligodendroglial tau inclusions 202. It is not necessarily known which 4R isoform composes these 
described silver-responsive pathologies, but immunoreactivity of argyrophilic grains, coiled 
bodies, and pre-tangle neurons to non-phosphorylation-dependent antibodies to N-terminal and 
C-terminal tau suggest that full length tau (4R2N) is contained in these structures 203.  
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However, despite the presence of GFTs in the injected hTau groups, only hTau-Aged 
P301S and hTau-P301S rmTBI mice revealed neuronal NFT formation in the targeted HPa as 
demonstrated by argyrophilic neuronal morphology, as well as Thioflavin S-positive staining in 
hippocampal structures - below the corpus callosum and alveus of the hippocampus. ThS-
positivity was not as rampant as that of the Gallyas silver-stained pathological consequences, but 
indication of Thioflavin S reactivity in the Aged P301S and P301S rmTBI injected hTau animals 
posits the occurrence of neuronal tangles, as glial-related tangles are dictated as ThS-negative 
122,124,125. It can be presumed the deleterious effect from the glial tau inclusions as argyrophilic 
deposition in the corpus callosum or alevus may alter axonal transport or could have an effect 
related to the learning and memory impairments exhibited as solely the hTau-Aged P301S and 
hTau-P301S rmTBI had glial tau in the fimbria fornix, which has been suggested to play a role in 
memory.  It cannot be ruled out that these substrates may have transferred or even generated a 
novel strain of tau that may have involved different astroglial populations or triggered a distinct 
astroglial response. AT8/MC1 immunohistochemistry did not robustly detect these tau astroglial-
like pathologies, which normally do show AT8/MC1-positive GFTs and GCIs in the various 4R 
tauopathies 124. These argyrophilic inclusions may be later aggregation events where the AT8 
epitope and MC1 detecting region may be rendered inaccessible or proteolytically degraded. 
Remaining experiments are to determine if this type of neuropathological response is an 
endogenous reaction that may be induced by really any kind of homogenate - as well as defining 
if this is indeed a novel tau strain by utilizing the diverse anti-tau antibodies that target specific 
phosphorylation sites of tau. Nevertheless, hTau-Aged P301S and –P301S rmTBI injected hTau 
mice reveal an induced Gallyas-positive neuronal and glial tauopathy, reminiscent of 4R-affiliated 
tauopathies, which therefore suggests a prolific seeding capability – even at estimated minute 
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quantities as predicted in the 1 hour P301S rmTBI EC homogenate - as compared to controls, yet 
transsynaptic spreading may occur more rampantly at much later ages. 
 Although tau exists principally in neurons, tau has been suggested to be present in 
astrocytes, microglia, and oligodendrocytes in lower levels, yet this same tau protein is reported 
to be involved in proteinaceous astrogliopathies in NDs related to protein misfolding and 
aggregation. More so, CTE is described to have neuronal and astroglial tau neuropathology in 
brain 84,89. Thus, glial tangles may appear in a spectrum of morphologies in disease, but it is not 
uncommon or extraordinary in NDs. Astrocytes and glia are important for the neuroinflammatory 
response, among other functions, and has been suggested as an early pathological event and might 
promote the progression in NDs.  A neuroinflammatory response to damage-associated molecular 
patterns can occur immediately following injury, and this response balances on a fine line between 
beneficial and deleterious. Following a TBI, inflammation is activated, yet can persist, as seen 
even in some human cases of up to 17 years 65,75,78,204–206, producing more harm. Other than 
responding to injury, astroglial cells could play a role in the transcellular spread of tau or may 
even react with neuronal tau pathology. Depleting microglia reduced tau propagation in vitro and 
in vivo 207. Extracellular tau oligomers have been detected to abundantly and promptly accumulate 
in astrocytes where they disrupted intracellular Ca2+ signaling and Ca2+-dependent release of 
gliotransmitters, especially ATP, and induced synaptic dysfunction 208. Moreover, these results of 
tau uploading from astrocytes required APP 208, which could be altered from TBI events as in 
DAI or APP-filled axonal bulbs. Oligodendrocytes, which insulate neuronal axons with myelin 
sheaths, were seen to be involved in tau seeding and spreading; Ferrer et al. introduced various 
brain homogenates from diverse tauopathies into the corpus callosum in mice, and phospho-tau 
deposition, resembling coiled bodies and threads, was able to spread from the ipsilateral injection 
site to the contralateral side 209. The results discovered here call for an understanding of this glial 
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tangle pathology that is found in various tauopathies, and the role of astroglial cells involvement 















  The effect of TBI on tau pathology was assessed in vivo over time following a 
moderate-severe TBI using the classical controlled cortical impact method and by rmTBI by 
means of a closed-head modified weight drop method emulating sub-concussive or concussive 
impacts. In addition, the seeding capability of the earliest generated rmTBI-induced tau seeds was 
assayed by in vivo bioassay. The central hypothesis of this study was that TBI would induce the 
early formation of tau misfolded seeds as well as exacerbate tau pathology and spreading 
throughout the brain by a nucleation-polymerization process, which would then lead to 
neurodegenerative changes relative to disease. In this study we observed: 
Chapter 2: Determine the effect of moderate-severe TBI on the formation and spreading of tau 
pathology in vivo. 
 TBI is involved in the early formation and spreading of pathological tau that could 
accelerate the progression and even induce the onset of tauopathy. 
 TBI is able to induce tau deposition as early as 1 day post-TBI most significantly on the 
impacted side of the brain. 
 TBI generates pathogenic tau aggregates than can spread from the initial impacted-site to 
the contralateral side of the impacted brain as tau pathology is observed 1 week after the 
event. 
 Tau load continuously increases over time (1-2 months and 6 months post-TBI) indicating 
a progressive and spreading pathology - not just a local and restricted event. 
 Tau spreading followed progression along the functional connectome of the brain 
suggesting the neuronal transport of tau aggregates from one brain area to another. 
 Tg P301S tau mice demonstrated impaired learning and memory 6 months post-TBI, 
manifesting the effect of increased aggregated tau on clinical signs. 
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 TBI induced an altered tropism in tau deposition suggesting the possibility of a new tau 
strain that aggregates in a brain area that is usually not affected in P301S mice. 
Chapter 3: Determine the generation and spreading of tau pathology and behavior following 
repetitive mild TBI in vivo. 
 rmTBI causes early, transient behavioral changes, in both WT and Tg mice, due to the 
effects of the direct impact and/or a post-concussion syndrome. Normal functional 
recovery is slower in Tg mice compared to WT suggesting that tau aggregation may be 
involved in post-concussive pathology. 
 There is a small, detectable amount of tau pathology of different conformations triggered 
as early as 1 hour after rmTBI, which is augmented compared to respective age-matched 
sham mice noted by histology and ELISA. 
 Following multiple rounds of rmTBI, anxiety and motor coordination impairment are 
exacerbated in the P301S rmTBI mice, although the presence of tau may not be the only 
underlying factor, as there was no significant difference compared to WT rmTBI mice.  
 Late stage P301S rmTBI mice (3 months, 6 months, and 8.5 months) displayed 
exacerbated tau pathology in brain by histological and biochemical assessment as 
compared to age-matched controls. Thus, multiple mTBI events were seen to 
exponentially intensify tau aggregation and spreading in all the brain regions analyzed. 
 Our data indicates that insoluble tau levels in the P301S rmTBI mice increases over time, 
higher than in Tg control mice, augmenting age-associated deposition. Also, neuronal loss, 
another age-related neuropathology of the P301S mouse model, was exacerbated in P301S 
rmTBI suggesting rmTBI-induced tau aggregates cause cell death. 
Chapter 4: Investigate the seeding capability of rmTBI-induced seeds by in vivo bioassay. 
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 hTau mice inoculated with Aged P301S or rmTBI-induced P301S extract showed learning 
and memory impairments, positing the deleterious effect of tau on behavior and suggesting 
the presence of tau aggregates in rmTBI-induced P301S mice. 
 hTau bioassayed mice displayed increased abnormal aggregated tau burden in brain 
compared to controls corroborating the induction of tau aggregation in the inoculated 
samples, and its seeding capability in the host . 
 hTau-Aged P301S and –P301S rmTBI injected mice reveal a remarkable induction and 
elevation of neuronal and glial tauopathy, reminiscent of 4R astroglial human tauopathies, 
which suggests seeding and spreading depends on the host model and the inoculum.   
 
Altogether, based on these data, following TBI there can be an early triggering of 
pathological tau that can alter and/or accelerate the spatiotemporal progression of aberrant tau 
in the brain, which can lead to disease-associated manifestations. Indeed, TBI-induced tau 
seeds, even as early as 1 hour post-TBI, were seen to be seeding capable demonstrated by 
elevated abnormal tau burden and induction of argyrophilic glial and neuronal tau pathology 
by in vivo bioassay.   
114 
 
There are few translatable animal models that impeccably emulate a mild head 
impact/concussion-induced athlete or military personnel. This problem may stem from the 
deliberations on defining mild impacts/concussions, problems reporting and diagnosing, and 
heterogeneity of the TBI itself; however, animal models for mild TBI are expanding. Edwards III 
et al. described various experimental models for repetitive mild TBI and the effect of these on Aβ 
and tau pathology 63. Depending on multiple reported elements, the research somewhat had 
consistent results demonstrating higher pTau deposition following mTBI; however, there is a need 
to explore and pool these models and results in detail to answer tenuous questions, i.e. the number 
of mTBIs to induce pathology, differences in the placement of impacted areas of the head, effect 
of loss of consciousness, age of onset, and more. In addition, novel animal models of TBI are still 
being investigated such as the modCHIMERA, which allows rotational acceleration to a cradled 
animal tested at 1.7 and 2.1 joules 210. Moreover, post-mortem assessment of former military 
personnel engaged in blast exposure or military-related concussion as well as animal models of 
blast exposure indicate tau pathology after TBI suggesting that diverse injury types can provoke 
tau pathology in brain 77,94,106.   
Nevertheless, to initiate rmTBI in this study, mice were treated by a modified, closed-head 
weight drop method, similar to the Wayne State weight drop animal model. This model fulfills 
mostly all criteria emulating a CTE-like/contact sports animal model with no severe damaging 
effect or invasive procedure as well as implementation of acceleration/de-acceleration and 
rotational forces due to a free-flowing head movement 63,211–214. Free-flowing head models are yet 
to thoroughly explore tau deposition especially utilizing Tg animals. Angular acceleration may 
be more deleterious for the brain than straight linear forces 127, and a study on professional boxers 
revealed that hook punches, where the head is turned laterally, caused more concussions than 
parallel blows (i.e. jab punch) 215. We used the lowest reported mass to our knowledge as our 
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method of mild, sub-concussive rmTBI induction in naïve anesthetized animals. This approach 
was scaled to previous studies that enumerated human concussions to rodents 126. Four mTBIs 
were administered in 1 day (denoted as 1 round) over the head at varied time-points, consisting 
of 1 to 4 totaled rounds, reflecting multiple mild impacts and/or “second impact syndrome”. This 
syndrome transpires following a concussion head injury or worse accompanied by a second head 
injury before symptoms associated with the first have cleared and can be cataclysmic for the brain 
127. Moreover, CTE diagnosis is highly associated to rmTBI signifying that the repeated exposure 
to brain trauma could be an enormous factor in tau development and progression.  Indeed, in our 
study, consecutive mild impacts generated over time were seen to trigger early tau formation, 
exacerbate neuropathology over time, and impair learning and memory in P301S Tg tau mice. 
This novel experimental approach contributes to on-going mTBI/concussion studies, yet more 
studies are warranted at different combinations of ages of induction and intervals, augmenting 
weight forces and number of impacts, comparison of disparate impacted areas, methods of mTBI 
and animal models, and more.  
As previously mentioned above, this study utilized the PS19 strain (P301S mutation) Tg 
mouse model for assessing tau aggregation. Although an acceleration and worsening of tau 
pathology can be measured, as performed in this study, this mouse model is non-physiological in 
nature as there is an overexpression of the human P301S mutant tau protein and 4R/1N tau isoform 
on the prion promoter, which may alter expression of MAPT in different brain regions. This model 
does not fully recapitulate human tauopathy maladies, although no animal model does so 
faithfully. Future rmTBI studies could incorporate: transgenic tau mice with green fluorescent 
protein (GFP), such as the T40PL-GFP Tg mouse from the laboratory of Virginia Lee, where 
pathological tau induction and propagation could be measured by tracking GFP following TBI 
induction 216; Tg mouse models that express wild-type or normal human tau, which do not exhibit 
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tangle accumulation 109,119,217,218; and a tau knock-in (KI) mouse, such as the KI of P301L 
observed at physiological levels of expression 219 with comparison to tau knock-out (KO) mice. 
Moreover, just as CTE and AD have a close 3R/4R tau isoform ratio, there could likely be 
different molecular conformers composed of both 3R/4R and solely 3R or 4R tau isoforms 
following TBI; thus, rmTBI studies could analyze models of various tau isoforms and/or mice 
including all putative 6 isoforms of tau 220,221. In addition, future studies could include more 
natural mammalian models that could comprise some of the relevant brain morphology emulating 
humans, such as present sulci and gyri, since CTE-related tau is primarily detected in the depths 
of sulci and gyri in human cases. 
 Although we demonstrate that there is triggered formation and elevation of abnormal, 
seeding-capable tau deposition following rmTBI very early on that is able to uninterruptedly 
remain exacerbated over time complemented with cognitive impairment, the initial molecular 
mechanism remains to be elucidated. Figure 6 shows general molecular cascades that may be 
altered following TBI, whether resulting from the primary impact and/or secondary initiated 
pathways, such as neuronal excitotoxicity, Ca2+ overload, mitochondrial dysfunction, oxidative 
stress due to formation of free radicals, inflammation, and abnormal protein aggregation. The 
force from the direct, primary insult can perturb the cellular membrane, thereby spilling its 
contents into the extracellular space shocking the microenvironment and chronically triggering 
multiple, overlapping downstream pathways that begin to exhaust the brain. There are 
impairments in a myriad of neurotransmitter systems linked to mental and behavioral function 
including: glutamate, gamma-Aminobutyric acid (GABA), acetylcholine, and dopamine 78. The 
activation of the glutamatergic system is a typical component following TBI. The brain is 
estimated to consume 20% of energy stores in the body, and neurons depend on a steady transport 
of glucose facilitated by glucose transporters (GLUTs), especially GLUT-1 and -3. Alteration in 
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GLUT-1 and -3 is reported in TBI 222; a deficiency of GLUT-1 and -3 is noted in AD brains and 
correlates with hyperphosphorylation of tau and the density of NFTs 135,223. After TBI, there is 
damage to the neuronal cell, which causes ionic imbalance by an efflux of K+ and influx of Na+ 
and Ca2+ as well as impaired glutamate release and re-uptake, in so doing causes an energy 
conundrum in the cell. This results in excessive extracellular glutamate which engenders an 
amplified and chronic membrane depolarization activating specific excitatory channels such as α-
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPA) and N-methyl-D-
aspartate receptor (NMDA) as well as opening of Ca2+ channels. This chronic hyperexcitability 
due to copious glutamate downregulates glutamate receptors which can impair LTP and induce 
long-term depression, among other problems 76,78. With the unrestrained Ca2+ influx and constant 
release of intracellular stores, there can be the over-production and over-activation of various 
phospholipases (i.e. calcineurin), proteases (i.e. calpains and caspases), and transcription factors 
(i.e. c-Jun and NOS). These molecules along with elevated Ca2+ can cause cytoskeletal demolition 
and dendritic spine shrinkage by: neurofilament compaction and microtubule disassembly; 
mitochondrial impairment, which can occur rapidly and persist (from less than 1 hour to 14 days) 
and where there is additional release of Ca2+ stores; oxidative stress from the formation of free 
radicals like reactive oxygen species and nitric oxide; formation of aggregate proteins such as 
pTau/NFTs and Aβ; and activation of neuronal cell death 78,224,225.  
As discussed prior, neuroinflammation can respond immediately after TBI. Following TBI 
and/or a disturbance of the blood brain barrier (BBB), astrocytes and microglia can migrate and 
activate chemokines and cytokines to remove injury by-products and offer neuroprotection; 
however, this is another example of a mechanism that can become activated for too long and 
producing insidious effects. Indeed, pro-inflammatory cytokines - tumor necrosis factor, 
interleukin 1β, and interleukin-6 – were initiated within hours in a TBI mouse model 78,226, and 
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this negative inflammatory response can endure even up to 17 years after TBI 65,75,78,204–206. To 
add to the complexity, various kinases and phosphatases entwined in tau phosphorylation are 
altered in TBI and tauopathies like CTE and AD, as well 227–229. In addition, the incorporation 
and/or interaction of molecular cofactors and enzymes may play a role as estimated by the 
ultrastructural assembly of CTE filaments, which revealed a dense, hydrophobic cavity, not found 
in AD and PiD cases 187. Future auxiliary immunohistochemistry utilizing APP and/or 
neurofilament-light will be performed to analyze the effect of axonal injury as an early 
pathological event and role in tau pathology following rmTBI, as noted in Figure 29.  
Neurofilaments serve as major components of the axonal cytoskeleton, being the most 
abundant fibrillary piece of the axon, and are built by the intertwining of 3 protofibrils – one being 
68-70 kDa neurofilament light chain (NF-L). NF-L is found highly in neurons of the brain, in 
particular the cortex and cerebellum, while also detected in the periphery. Importantly, NF-L has 
been studied as a marker of axonal injury and researched as a biomarker of damage in the brain 
for TBI and neurodegenerative brain disorders 227–231. In Figure 29A, preliminary results utilizing 
anti-Neurofilament L antibody reveal normal immunofluorescent staining throughout the brain, 
as exampled by the CTX here, in both the 1 hour P301S rmTBI and sham mice. However, various 
brain regions, such as CTX and BS (inset), did identify NF-L positive ovoids or varicosities in 
the 1 hour P301S rmTBI mice prominently in the age-matched sham mice (Figure 29B). 
Interestingly, when assaying subcortical white matter of the corpus callosum (cc), 1 hour P301S 
sham exhibited no aberrant NF-L staining or morphology (Figure 29C), but 1 hour P301S rmTBI 
mice had prominent NF-L positive compacted beads or varicosities along the cc white matter 
tracts (Figure 29D) reminiscent to axonal damage as observed with such antibodies for DAI like 
APP or SMI-34 83,155,157,204,210,233. This immunoreactivity was not seen in 1 hour P301S sham mice. 
These preliminary results show impairments in axonal structure by NF-L immunofluorescent 
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staining of DAI in brain 1 hour after rmTBI in P301S mice. However, further studies are necessary 
to evaluate auxiliary molecular mechanisms involved in the results demonstrated in this study. 
  
Figure 29. Early axonal injury detected by neurofilament light chain (NF-L) 
immunofluorescence in 1 hour P301S rmTBI mice. Anti-Neurofilament L antibody was used 
to determine presence of axonal injury 1 hour following rmTBI in P301S mice. (A) NF-L was 
highly identified in areas such as the cortex (CTX), as shown here, and cerebellum in rmTBI and 
sham-treated P301S mice. (B) 1 hour P301S rmTBI mice exhibited more prominent abnormal 
NF-L immunopositive large ovoids or varicosities (white arrowheads) in CTX and midbrain 
(inset). (C) NF-L staining was seen to be at WT control levels and show unbroken white matter 
tracts in the corpus callosum (cc) of 1 hour P301S sham mice. (D) 1 hour P301S rmTBI animals 
demonstrated NF-L positive varicosities akin to axonal injury all along the cc much more 
prevalently. HPa = hippocampal area. Scale bar: 100 μm, 30 μm.  
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Moreover, tau pathology is seen only in a subset of TBI cases - not unanimously; other studies 
are warranted to assess perhaps what pathways are involved or not involved in individuals that 
are resilient to the effects of TBI versus those that succumb to deleterious consequences in the 
brain. 
We believe that an assortment of injuries and/or stresses to the brain can drive tau 
pathology, yet we inadequately know the exact biochemical profile of tau following injury – the 
effect of disparate and heterogeneous injuries, inclusion types formed, precise phosphorylation 
sites involved, the effect of the various tau isoforms, among others. Along with neurodegenerative 
tauopathies, TBI is a risk factor for diverse NDs and dementia and is associated to other protein 
aggregates, as well; thus, TBI could be classified as a polypathological trauma 235. For example, 
TBI generated a higher incidence of PD in patients with TBI of all severities (0.58%) and even 
mTBI (0.47%) as compared to patient controls 236. A unifying feature of TBI is the abnormal 
accumulation and potential concomitant accumulation, as within the same brain, of pathological 
proteins associated with NDs – tau, Aβ, alpha-synuclein, and TDP-43 235. Amyloid-beta 
deposition resembling early AD, diffuse plaques has been demonstrated in human TBI cases, even 
at younger ages, which indicates that TBI can reduce the age of when amyloid generation is 
typically observed 160,235. Stein et al. analyzed 114 deceased athletes and veterans with CTE, 
which revealed Aβ accumulation increasing 2.7-fold for every decade in age for 52% of the 
subjects. In addition, CTE patients with Aβ had a trend for greater amount of concussions 
reported, elevated CTE stage prognosis, and higher frequency of dementia than CTE subjects 
without Aβ 66,87. Other factors following TBI upon pathological protein accumulation and related 
NDs could include: injury severity and repetitive nature, survival time, patient age at injury 
induction, genotype (i.e. APOE genetics), and cognitive reserve 63,235. Nevertheless, the 
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independent and dependent effect and/or interaction of these pathological proteins subsequent to 
TBI and risk to disease remain to be elucidated and could provide interesting future studies.    
 Could rmTBI be facilitating earlier and more aggressive neuronal tau mislocalization and 
spreading? Some of the early time-point P301S rmTBI mice revealed more punctate and thread-
like tau immunoreactivity in brain, such as in apical dendrites in the EC. Undoubtedly, the 
classical soma-filled tau was detected in brain, as well, and yet as rmTBIs and time progressed, 
so did this punctate and thread-like tau pathology – especially in the EC and HPa. At the 8.5 
month old age, some P301S rmTBI mice had this similar pathology as compared to age-matched 
P301S sham mice. Representative images of the EC utilizing AT8, MC1, and Gallyas staining of 
8.5 month old P301S rmTBI mice reveal more robust punctate and thread-like positive tau 
compared to age-matched P301S sham mice (Figure 30A). This particular histological positive 
morphology could be area/region or cell type specific; for example, irregular punctate tau 
pathology was detected more often in the lateral EC and hilus of the dentate gyrus, while more 
thread-like, most likely due to axonal projections, was seen in CA1/CA3 of the hippocampus. The 
mislocalization of tau to the dendritic compartment is noted as an early pathological event in AD 
and has been provoked by Aβ accumulation and associated with dendritic degeneration 
8,10,13,25,42,119,120,174, yet it is interesting to see this type of pathology so early on and even robustly 
at the late-stage in the P301S rmTBI mice. Initial tau-related deficits may develop as a result of 
synaptic aberrations caused by the accumulation of hyperphosphorylated tau within intact 
dendritic spines, where it disrupts synaptic function by impairing glutamate receptor trafficking 
or synaptic anchoring as shown by Hoover et al 41. Indeed, this pathological dendritic tau could 
be a much more potent seeder and be a key cog in the spatiotemporal progression of tau in disease-
afflicted brains. With the repetitive head impacts occurring over time, pathological tau, perhaps 
even localized in the axon or soma, could be fragmented engendering more available seeds, which 
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translocate to the dendritic compartment, or it cannot be ruled out that axonal injury or shearing, 
as shown in Figure 29, could allow free extracellular tau in the brain parenchyma, which may be 
up taken by neurons and begin the misfolding and aggregation process. Nevertheless, future 
studies are aimed to determine the compartmental localization of tau aggregates in rmTBI-treated 
and sham animals by double-labeled immunohistochemistry in consecutive slides using: 
AT8/NeuN (neuronal soma); AT8/MAP2 (neuronal axons); and AT8/anti-total tau (dendrites). 
Additional approaches to isolate the synaptosomes in the brain and detect number and tau levels 
by biochemistry will be done in parallel, as well. 
  
 
Figure 30. Potential mislocalization of tau following rmTBI. Example images show 8.5 
month old P301S rmTBI mice reveal more robust punctate and thread-like positive tau 
compared to age-matched P301S sham mice by AT8, MC1, and Gallyas silver staining. Future 




 Additionally, in terms of tau seeding capability, an ultrasensitive and specific FRET-based 
flow cytometry (fc) biosensor assay as a method to examine in vitro tau seeding has been 
developed in the laboratory of Dr. Marc Diamond at the University of Texas Southwestern 
(UTSW) in Dallas, TX 45,52,115,237–239. This assay discriminates to tau seeds and shows sensitivity 
to ~300 fM of added tau seeds 45. Previously, monoclonal FRET biosensor HEK293T cells were 
engineered to stably express the repeat domain P301S mutation that was fused to either cyan 
fluorescent protein (CFP) or yellow fluorescent protein (YFP), and when exposed to exogenous 
tau seeds (i.e. synthetic tau or disease-associated homogenate), this leads to tau reporter protein 
aggregation which emits a FRET signal and can be detected by fc. In the absence of proteopathic 
seeds, the cells maintain tau as a soluble monomer, and have no substantial background FRET 
45,52,115,237–239. Accordingly, while performing a visiting rotation at UTSW in the Diamond 
laboratory, we assessed the earliest time-points pathological tau was determined following rmTBI 
(1 hour and 1 day) in the P301S mice by the FRET-based fc biosensor assay. A novel generation 
of HEK cells that express the tau repeat domain P301S mutation fused to GFP/Pacific Blue were 
optimized for codon usage to diminish truncation of the tau protein (NK cells, unpublished) were 
utilized here. Permission for further presented results and usage (Figure 31) was obtained directly 
from Dr. Marc Diamond at UTSW. 
 Under a sterile fume hood, for usage, NK cells were trypsinized using 3 ml of trypsin-
EDTA (0.25%) for 5 minutes (min), quenched with 9 ml of aspirated warm culture medium 
(DMEM+10% FBS), and transferred to a 15 ml conical tube after gentle re-suspension/washing. 
Ten μl of the cells sample along with trypan blue was loaded into a TC20 automated cell counter 
(Biorad, Hercules, CA) to obtain cell count measure. Cells were centrifuged at 1,000 x rpm for 5 
min at room temperature (RT), and the cell pellet was resuspended in warm culture medium. A 
master mix of cells (culture media + Penstrep antibiotic) was made so that each well of two 96 
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well plates would contain 35,000 cells in 130 µl media. The NK cells were allowed to settle by 
leaving the plate undisturbed for 8 min at RT and then incubated overnight (o/n) at 37 °C, 5% 
CO2. The following day, when tau biosensor cells were 60-65% confluent, NK cells were treated 
with 1 hour P301S rmTBI (n = 5), 1 hour P301S sham (n = 5), 1 day P301S rmTBI (n = 5), and 1 
day P301S sham (n = 5) randomly selected 10% mouse brain homogenate. All samples were 
performed in triplicates and blinded to experimenters. Since standardized characterization of the 
novel NK cells to P301S brain homogenate was limited, a “naked” seeding assay was performed 
by serially diluting homogenates of 8 μL, 4 μL, and 2 μL in 1x PBS split between the triplicate 
wells. Seed transduction complexes were created by: incubating appropriate volume of 
Lipofectamine (Lipo) + Opti-MEM at RT for 5 min; 35 μL of this solution was placed in each 
diluted sample tube and incubated for 30 min at RT; 10 μL of Lipo + Opti-MEM was added in 
triplicate biosensor cell control wells; and 50 μL of samples was added per well for each triplicate. 
Cells were then incubated for 36 hours at 37 °C, 5% CO2.  
The next day cells were harvested for FRET-fc by first trypsinizing cells (50 µl) for 5 min 
in 37 °C incubator, quenched with 150 µl of aspirated culture media, and after resuspension, 
centrifuged at 1,000 x rpm for 5 min at RT. Media was carefully removed to not disturb the pellet, 
and 200 μL of 2% paraformaldehyde was incubated for 10 min at RT then re-centrifuged and 
paraformaldehyde removed. Cells were resuspended in 200 μL flow buffer for FRET-fc 
thereafter. FRET-fc was ran using BD LSR Fortessa instrument (special order - BD Biosciences, 
Haryana, India), and gating strategies utilized as explained in previous publications 45,52,115,237–239. 
AmCyan signal appears in response to tau seeding with these NK cells. FCS files were obtained 
and analyzed by fc analysis programs FlowJo (FlowJo, LLC, Ashland, OR) and Community 
Cytobank 240. Briefly, compensation was performed to avoid fluorescence spillover, and cell 
populations were taken through the appropriate gates to remove any debris, doublets, and false-
125 
 
positives, as shown previously 237. A FRET-positive polygonal gate was obtained by plotting the 
empty liposome-treated GFP/Pacific Blue cells on a FRET-positive (AmCyan) vs GFP bivariate 
plot, and this gate excluded most cells (~99%), such that background FRET was  ≥ 1% of cells. 
Any events that shifted into this gate were considered FRET-positive and expressed as percentage 
of FRET-positive cells as indicated in Figure 31. 
  Thus, tau seeding by the FRET-based flow cytometry biosensor assay was performed in 
the earliest rmTBI and sham-treated P301S (1 hour and 1 day) diluted brain homogenates. As a 
whole, the tau seeding effect was not robust; however, minute tau seeding could be detected only 
in the early time-point P301S rmTBI-treated animals. The 8 μL brain homogenate dilutions, in all 
cases, seemed to produce a more toxic effect to the cells as noted under the microscope and debris 
identified by FRET-fc analysis. This has been reported to be cognizant of seed volume, as too 
high of crude sample volume may be toxic to these biosensor cells 237. Cells treated without seed 
material (i.e., empty liposomes) revealed diffuse fluorescence, whereas cells treated with seed 
material had punctate and reticular intracellular inclusions as noted in the 4 μL and 2 μL dilutions 
having healthier cells and producing a better seeding effect. In Figure 31A, top panel, in the 1 
hour P301S rmTBI and P301S sham mice (n = 5/each group), one P301S rmTBI mouse 
demonstrated prolific tau seeding at the 4 μL (average of triplicates = 0.68%) and 2 μL (average 
of triplicates = 0.73%) dilutions. This FRET-positive population was above FRET background 
and occurred in all triplicates with sufficient FRET events, while no seeding was detected in any 
1 hour P301S sham mouse (data not shown). The 1 day-P301S examined groups once again 
revealed tau seeding activity in three 1 day P301S rmTBI mice in the 4 μL and 2 μL dilutions in 
all triplicates, as exampled by Figure 31A (2 mice shown, middle panel), while no reputable tau 
seeding occurred in any 1 day P301S sham mice (Figure 31A, lower panel). Although tau seeding 
did not occur in all early-staged P301S rmTBI mice, the number of FRET-positive events reported 
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was higher in P301S rmTBI versus sham animals, and when the average percentage of FRET-
positive cells was quantified for the 1 day P301S rmTBI and sham mice, Student t-test 
demonstrated a significantly higher reported FRET-positive cell % in both 4 μL (p < 0.05) and 2 
μL (p < 0.05) dilutions for the 1 day P301S rmTBI animals, respectively (Figure 31B). Thus, these 
preliminary results posit minute levels of seeding capable tau in the 1 hour and 1 day post-rmTBI 
P301S mice by the FRET-based fc biosensor assay. Further experiments are warranted to optimize 
this assay to assess the degree of tau seeding in P301S rmTBI and sham mice at the earliest time-
points, such as: reducing the number of cells per well and extending the temporal measurement, 
identification of the best homogenate dilution or fraction, increasing the n-value of the groups, 
among others. Despite this, with the expected low levels of pathological tau seeds in the naïve 
P301S rmTBI and sham mice 1 hour and 1 day after induction and “naked” tau seeding assay 
approach taken here with these novel NK biosensor cells, these results are promising and support 
our hypothesis of the formation of exigent rmTBI-triggered and seeding proficient tau seeds.  
Figure 31. In vitro FRET-based flow cytometry tau biosensor assay of 1 hour and 1 day 
post-rmTBI P301S mice. After following standard flow cytometry-gating methodology, a 
FRET-positive (AmCyan) versus GFP bi-variate plot was generated, and a FRET gate was 
constructed from empty liposome-treated cells, such that the background FRET is ≤ 1%. A 
cell population shift into the FRET gate would appear following treatment with tau seed-
containing material. (A) Results show example plots of 4 μL and 2 μL brain homogenate (BH) 
dilutions, which demonstrate FRET-positive tau seeding in the 1 hour P301S rmTBI mice (top 
panel) and 1 day P301S rmTBI mice (middle panel), while no reputable tau seeding was 
detected in early time-point P301S sham mice (lower panel). (B) Student t-test was performed 
for the 4 μL and 2 μL dilutions of the 1 day P301S rmTBI and sham mice. Each dilution 
presented significantly higher percentage of FRET-positive cells in the 1 day P301S rmTBI 
mice compared to sham animals (p < 0.05), respectively. Data is expressed as means ± SEM. 








The results of the inoculated hTau animals exposed unexpected and intriguing findings. 
Indeed, the hTau injected animals used here demonstrated faint AT8 and MC1 immunostaining 
along with more punctated and thread-like morphology of tau, and yet these animals produced 
robust argyrophilic staining, which closely resembles glial tau pathology seen in tauopathies such 
as PSP, CBD, and AGD, in some arrangement. However, penetration into the targeted HPa of the 
inoculated material seemed to be better suited for the Aged P301S and P301S rmTBI EC 
homogenate, thereby generating GFT neuropathology, but also what may possibly be neuronal 
Gallyas and ThS-positive induced tau pathology in the normal human tau-expressing rodent. The 
seeding event examined in this study could very well be a combination of the host’s intrinsic 
response and provided intracerebral inoculated substrate. Tauopathies show unique and 
heterogeneous clinical symptoms and neuropathology, despite the commonality of pathological 
tau protein distinguished post-mortem in each of these diseases. These features could be due to 
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tau aggregates forming distinctive structural conformations or strains, and this cannot be ruled out 
in this case. Future studies will look to illuminate these suggestions, such as the use of different 
phospho-tau antibodies that target different epitopes (i.e. AT100, AT180, AT270, etc.) as the 
distinct recognition by anti-tau antibodies of the seeded pathology is indicative of tau strains.             
Finally, in recent publications, Dr. Claudio Soto’s laboratory has shown promising results 
for technique, similar to what is achieved in PCR, for amplifying the nucleation-polymerization 
process in vitro by a method called protein misfolding cyclic amplification (PMCA). Results for 
an Aβ-PMCA for AD and α-synuclein PMCA for PD using human CSF posited this diagnostic 
approach to have high specificity and selectivity 241,242. This same technology is being applied to 
tau protein with encouraging results. PMCA uses the functional property of misfolded oligomers 
that catalyze the polymerization of the monomeric protein as a way to amplify and detect them 
over time. Briefly, tau monomers are incubated with a tau-seeding component (i.e. synthetic 
oligomers or tauopathy homogenate or collected biological fluid), along with respective controls, 
and with Thioflavin T (ThT). Seeding efficiency of tau is then measured following multiple 
rounds of intermittent shaking/sonicating while over time ThT interacts with the polymerizing 
fibrils, thus shifting the ThT emission peak monitoring the kinetics of fibrillogenesis, as shown 
previously 241,242. If the material is seeding-competent, tau-PMCA should display an attenuated 
nucleation phase, thereby demonstrating faster aggregation kinetics compared to controls. The 
main overall goal is to utilize the tau-PMCA as a diagnostic method or predictor for tau-affiliated 
NDs. In Figure 32A, preliminary results demonstrate an attenuation of the nucleation phase of tau 
fibril formation in vitro by a concentration-dependent manner. With a higher concentration of 
added pre-formed synthetic tau seeds, the reaction occurs faster thereby exigently reaching the 
exponential or polymerization phase measured by ThT fluorescence over time. This provides 
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good concentration separation and superior sensitivity that will be instrumental when assessing 
affected disease–related and TBI samples. 
The goal of this future study is to efficiently detect tau aggregates after TBI by tau-PMCA 
in available brain and biological fluids, including CSF and blood plasma, to monitor the 
progression of tau pathology with disease onset. It is noted following a TBI event and in 
tauopathies, like AD, that tau levels are aberrant in biological fluids such as CSF 66,76,136,138,139,243. 
Thus, the rmTBI-treated mice and respective controls indicated in Chapter 3 will be assessed by 
tau-PMCA utilizing brain, CSF, and blood collected at various time-points following impacts, 
different intervals between impacts, and age of termination (Table 3) to investigate whether 
rmTBI results in an increase of seeding-capable tau protein aggregates. Brain and CSF samples 
were collected from P301S rmTBI, P301S sham, WT rmTBI, WT sham mice at different ages at 
the terminal endpoints following rmTBI: 1 hour, 1 day, 1 week, 3 months, 6 months, and 8.5 
months with varied rmTBI rounds. CSF extraction occurred by withdrawal from the cisterna 
 
  
Table 3. Blood plasma and CSF collection in P301S and WT mice for future studies. This 
table shows a synopsis of the P301S and WT rmTBI and sham treated groups for fluid 
collection with varied number of rmTBIs, ages, and time after rmTBI. CSF will be collected 
through the cisterna magna in all groups at 1 hour, 1 day, and 1 week post-1 round rmTBI, 3 
months after 2 rounds rmTBI, 6 months after 3 rounds rmTBI, and 8.5 months after 4 rmTBI 
rounds, respectively. In addition, to these points as well as the others listed, blood plasma was 
obtained by submandibular withdrawal and cardiac puncture as final collection technique. 
Blood was collected in 0.5 M EDTA and immediately centrifuged then snap frozen. Essentially, 
using these various time-points we can assess blood plasma following differing numbers of 
TBIs, ages, and time after TBI events focusing on early detection by tau-PMCA without over 





magna as described previously 244. Blood samples were collected by submandibular withdrawal 
longitudinally and at terminal points by cardiac withdrawal at: before any TBI event as baseline, 
at 1 hour, 1 day, 1 week, 1 month, 2 months (1 rmTBI round), 3 months (2, 3 rmTBI rounds), 4 
months (3 rmTBI rounds), 5 months (2 rmTBI rounds), 6 months (2, 3 rmTBI rounds), and 8.5 
months (4, 5 rmTBI rounds). For plasma collection, whole blood was centrifuged at 3,000 rpm 
for 15 minutes, and the supernatant collected and snap frozen until use. Once again, tau monomers 
and ThT will be incubated with the biological fluids collected from all mice in SA2. During 
interval shaking fluorescence will be measured by fluorimeter over time. Overall, we will 
compare the detection of misfolded tau oligomers in brain, CSF, and blood in the absence or the 
presence of rmTBI by tau-PMCA and correlate associated histology, biochemical ELISA, and 
behavioral results to tau-PMCA detection. These results can assist to pinpoint an estimated time 
tau seeds form after rmTBI induction, levels of peripheral and parenchymal seeds, the number of 
TBI events initialized, the level of tau pathology and behavioral state of the animal at that stage. 
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Potentially, together this could give a diagnostic window in which treatments could be used to 
intervene following TBI.  
Furthermore, future studies will aim for a translational approach by detection of abnormal 
tau seeds or aggregates in biological fluids in TBI and AD human samples. The detection of tau 
levels in biological fluids may show promise as a pertinent biomarker in individuals suffering 
from TBI and act as a portent for deleterious maladies to come. Diagnostic methods are warranted 
for TBI cases; furthermore, the tau-PMCA technology may demonstrate the capability to be used 
as an early indicator for other known tauopathies. Here, we will collect human biological samples 
of CSF and blood plasma taken from various individuals with a history of TBI and assess levels 
of tau seeds utilizing tau-PMCA. Samples will be obtained in collaboration with: Dr. Paul Schulz, 
the Director of the Memory Disorders and Dementia Clinic at UTHSC; Dr. Andrew Goldfine, 
Neurologist, Assistant Professor and Director of the Neurorehabilitation clinic after Traumatic 
Brain Injury at Stony Brook, New York; and Dr. Anat Beigon, Professor of Neurology at Stony 
Brook Neurosciences Institute. Samples will be collected from AD cases (with or without TBI), 
severe and mild TBI cases, and healthy controls (age 50 and under). Younger, healthy controls 
should have lower amounts of tau circulating in fluids compared to TBI affected patients that 
should produce a measurable effect of tau seeds. We will attempt to establish a relationship with 
TBI severity level and time since TBI, along with known confounding factors, to estimate whether 
misfolded tau protein oligomers correlated with a history of TBI at a cross-sectional population 
level. Preliminary results demonstrate the tau-PMCA’s capability to detect tau seeding in P301S 
versus WT mice in brain (Figure 32B). When assessing human TBI, AD and CBD, and control 
CSF, the tau-PMCA indicated more accessible tau seeds in human TBI and tauopathy-related CSF 
as compared to control CSF comparing the rate of the aggregation curve (Figure 32C). This assay 
will provide high sensitivity in comparison to other assays that will aid in targeting tau seed 
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formation in relation to TBI and neurodegenerative diseases and is continually being optimized 
for future diagnostic capabilities. 
We expect that the addition of biological fluids from P301S mice following rmTBI will 
contain pre-formed seeds that can accelerate the misfolding and aggregation reaction in tau-
PMCA exhibited by an attenuated nucleation phase compared to control material and normal 
aggregation rates. We expect that using the specific and sensitive tau-PMCA,  we can detect the 
earliest time-point in CSF and plasma following rmTBI that is seeding capable and correlate this 
to the animal’s age, number of mTBIs, pathology by histology and biochemical assays, and 
behavior, thereby making a well-rounded diagnostic supposition. If our hypothesis is correct, the 
acceleration in tau pathology would indicate that rmTBI can initiate the formation of seed-
competent tau aggregates that can propagate misfolding and aggregation in a “prion-like” manner 
and can use this to detect early aggregate formation and track disease progression by tau-PMCA. 
As we initiate trials and take a translational approach utilizing human samples, this will generate 
a significant impact in the TBI and tauopathy field. This will bring novelty to the field as no other 
study to our knowledge has measured tau levels following multiple rmTBI events longitudinally 
in CSF and blood to detect the formation of tau seeds and correlate this with clinical symptoms 





Figure 32. Potential diagnostics for 
TBI and tauopathies utilizing Tau-
PMCA. Tau-PMCA was performed 
using tau monomers, synthetic tau seeds 
(A), transgenic or WT brain 
homogenate (B), or human CSF 
samples (C), and ThT while using 
cyclic agitation over time. Aggregation 
was followed over time by ThT 
fluorescence. (A) Tau-PMCA displays 
prominent detectability and 
concentration dependence using 
synthetic tau seeds. (B) Tau-PMCA 
demonstrates the capability to detect tau 
seeds in mouse brain homogenate. (C) 
Tau-PMCA detected misfolded tau 
seeds in human patient TBI CSF 
generating a quicker aggregation curve 
along with Alzheimer’s disease (AD) 
and Corticobasal syndrome (CBS) CSF 
than the respective controls measured 
over time. All assays were performed in 
duplicates. Experiments and figures 
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P301S transgenic mice (Prnp‐MAPT*P301S P301SVle/J, Jackson Laboratory, Bar 
Harbor, ME) express the P301S mutant human microtubule‐associated protein tau (MAPT) under 
the control of the mouse prion protein (Prnp) promoter. These animals accumulate pTau and NFT 
formation that can be detected around 6‐9 months of age 109,110. The expression of the mutant 
human MAPT is five‐fold higher than the expression of the endogenous mouse MAPT. P301S Tg 
mice were used for Chapters 2 and 3. For Chapter 4, normal or WT human full length tau (4R/2N) 
hTau mice expressed on the Thy1.2 promoter were used to assess seeding capability by in vivo 
bioassay. hTau mice exhibit somatic mislocalization of tau at 6 months and have reported 
hyperphosphorylated tau that is increased with age (12-18 months), but no tangle formation 119. 
Mice were double genotyped for all chapters. Animals were housed in groups of up to 5 in 
individually ventilated cages under standard conditions (22°C, 12h light–dark cycle) receiving 
food and water ad libitum. All animal experiments were carried out in accordance with the NIH 
regulations and approved by the committee of animal use for research at the University of Texas 
Health Science Center at Houston, McGovern Medical School. 
Induction of TBI 
For Chapter 2, groups of 3 month old P301S mice and wild‐type (WT) littermates were 
anesthetized with isoflurane, placed on a stereotaxic apparatus with a face mask, and prepared for 
controlled cortical impact (CCI), as done previously to induce moderate to severe TBI 63,245,246. 
Briefly, a midline incision was made, and a 5‐mm‐diameter craniotomy was performed on the 
right parietal cortex, midway between the Bregma and the Lambda with the medial edge of the 
craniotomy 1.0 mm lateral to the midline. A pneumatic impact device (Custom Design and 
Fabrication, Richmond, VA) was used to deliver an impact at 3.0 m/sec generating a 1.0 mm 
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deformation on the posterior cortex. The incision was closed, and animals were assessed in latency 
of foot, tail, and righting reflexes as previously described (Suppl. Figure 1A) 247. Animals were 
allowed to completely recover in a warm chamber before being returned to their home cages. 
Sham‐operated animals received all the analogous surgical procedures except for the craniotomy 
and impact. Animals were monitored thereafter daily for up to 2 weeks. TBI and sham groups 
were n = 4‐6 at each time point and were randomly selected and placed in different time‐point 
groups. 
In Chapter 3, 1 month, 5 day old P301S Tg tau animals and WT littermates (n = 9-
11/group) received a modified closed-head weight drop method, similar to the Wayne State 
weight drop method, and sacrificed either at 1 hour, 1 day, 1 week, 3 months, 6 months, or 8.5 
months. Animal number for the groups was obtained by G-Power analysis 248,249. This weight 
drop method emulates a contact sports athlete, and as examined by Kane et al, fulfills most criteria 
as a CTE-like model, better than others, thereby producing CTE-like results 63,211–214. The 
proposed weight drop method engendered no severe damaging effect (i.e. skull fracture, edema, 
etc.) in mice with 95 g weight at 1 meter 211. Here, we proposed using a mass of 18 g at 82 cm 
height as our method of rmTBI induction in anesthetized P301S and WT animals to study the 
early formation, spreading, and exacerbation of tau in brain following rmTBI. This method was 
the lowest reported weight utilized, to our knowledge. Animals treated with rmTBI were 
anesthetized by isoflurane induction and placed just below a ½ inch diameter PVC cylinder tube, 
which fit perfectly around the skull of the mouse, on a collapsible platform. The 18 g metal weight 
with a beveled end was securely tied from the top of the cylinder tube to prevent any unnecessary 
secondary impacts following initial insult. We performed the rmTBI with 4 impacts in one day 
(being 1 round) with 2 mild impacts given under anesthesia, a 1 hour interval, and 2 more impacts 
under anesthesia. Sham mice were anesthetized following the same as above, thereby 
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experiencing the same fall through the platform but with no impact. Overall, this procedure was 
scaled to fit human cases as previously reported 126. Once again, as according to Figure 11, P301S 
and WT mice were rmTBI or sham-treated at 1 month, 5 days and sacrificed 1 hour (1 rmTBI 
round); 1 day (1 rmTBI round); 1 week (1 rmTBI round); 3 months (2 rmTBI rounds); or 6 months 
(3 rmTBI rounds) post-rmTBI event (Groups 1-5). Mice sacrificed at 8.5 months of age had 4 
rounds rmTBIs (16 total mTBI impacts in time) spread over time to assess exacerbation of AD 
pathology in an “active athlete “ paradigm. Sacrificing at 8.5 months of age was thought to be 
efficient, in our experience, due to the beginning of motor impairment phenotype that can occur 
at later months (as seen in our hands the earliest at 9 months) and due to robust tau pathology in 
the P301S model 109,110. 
Behavioral analysis  
For Chapter 2, Barnes maze was performed 6 months after CCI in both groups (transgenic 
and WT) as well as in the sham group, as previously described 3. Barnes maze is a medial temporal 
lobe dependent task that evaluates spatial learning and memory. Barnes maze consists of a circular 
platform with 40 holes with one being an exit from the arena, and the animal uses spatial cues to 
discover the stationary escape hole in a 3 minute trial. Mice were trained on day 1 with 2 
acquisition trials and then 4 trials per day for 4 days. 7 days later long-term memory (LTM) was 
assessed. Primary latency to the escape hole was used to assess learning and memory. Task 
performance was recorded and analyzed using the TopScan 2.0 tracking software (Clever Sys, 
Reston, VA). Behavioral analysis was done by a single experimenter blinded to subject identities.  
For Chapters 3-4, Splash test was performed to assay anxiety/depressive-like behaviors in 
mice 250. Briefly, animals were sprayed with 10% sucrose solution on the dorsal coat and allowed 
to freely roam a clean home cage for 5 minutes during which the time spent having cephalocaudal 
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motions of grooming was quantified. Nesting is a naturally conserved behavior and has been 
examined in anxiety-related studies. Overnight Nesting was performed by singly housing animals 
with ad libitum food and water and a nestlet (±2.50 g). In the morning, nesting scores were 
assessed from a 1 (no nest) to 5 (structurally complete nest) rank, as done previously 251. Motor 
coordination and activity, grip-strength, and fatigue are all measurements that can be assessed by 
the commonly used behavioral task of RotaRod (Med Associates Inc., Vermont). Here, the animal 
was placed on a horizontal oriented, rotating cylinder that accelerated from 4 to 40 rpm. The 
latency to fall was quantified over 3 trials with 2 minutes interval rest in one day. 6 minutes was 
used as the final cut-off latency to fall measurement. In addition, one difficulty of the task is the 
rodent’s desire to grip the rotating rod to prevent falling; thus, 2 consecutive rotations of the 
animal clinging was considered as a latency to fall measurement. The animals were aided for 30 
seconds in the first trial to prevent unnecessary behavior (i.e. turning and false-positive 
falls/jumps). Open field assessment is a useful and simple task to analyze locomotion, exploration, 
and anxiety behaviors in rodents 252. The open field apparatus is 44 x 44 cm Plexiglas square box, 
which was split into sixteen 11 x 11 cm squares for open field testing. The mouse was transported 
from outside the room into the behavioral testing room in a small box. The animal was placed in 
the middle of the apparatus with this box overturned, and the small box removed at the start of 
the trial. Open field testing was ran over a 5 minute trial. Barnes maze was ran similarly, as above, 
but the LTM assessment was ran 3 days after the final trial. After the LTM trial, reversal learning, 
also delineated as cognitive flexibility, was performed as 3 trials for a total of 3 days. The escape 
hole for reversal learning was placed approximately 180° degrees from the previously learned 
escape hole placement in these trials. The animals were allowed to explore the arena for up to 3 
minutes to discover the novel escape hole. All tasks, except for RotaRod, were video recorded 




In Chapter 2, TBI and sham mice were sacrificed either 1 day, 1 week, 1‐2 months, or 6 
months following CCI trauma. Mice were sacrificed by CO2 inhalation and perfused trans‐
cardially with cold 5mM EDTA+PBS (1X). Brains were removed, post‐fixed into 10% neutral 
buffered formalin fixative solution and embedded in paraffin. Paraffin‐fixed brain tissue was 
sliced coronally by microtome obtaining 10‐μm‐thick serial sections and were processed for 
immunostaining, as previously reported 3. After blocking the endogenous peroxidase activity with 
3% H2O2‐10% methanol for 20 min, sections were incubated overnight at room temperature in 
monoclonal AT8 phospho‐PHF‐tau pSer202+Thr205 antibody (1:100, ThermoFischer). Primary 
antibody was detected by incubating 2 hours with sheep anti‐mouse HRP‐linked secondary 
antibody (General Electric, Pittsburgh, PA), and peroxidase reaction was visualized using DAB 
Kit (Vector, Burlingame, CA) following the manufacturer’s instructions. Finally, all sections were 
dehydrated in graded ethanol, cleared in xylene, and cover slipped with DPX mounting medium.  
In Chapter 3, P301S and WT rmTBI and sham mice were sacrificed, as above, at 1 hour, 
1 day, 1 week, 3 months, 6 months, and 8.5 months of age. In Chapter 4, normal human tau Tg 
(hTau) mice were perfused with 15 ml of PhosStop phosphatase inhibitors (Roche) and Complete 
protease inhibitors (cOmplete™ Protease Inhibitor Cocktail, Millipore Sigma) in 1X PBS, pH 7.4. 
Ten‐μm‐thick serial coronal sections were processed as above and incubated in AT8; MC1 - pre-
tangle PHFs by targeting the N-terminal (amino acids 5-15) and the third microtubule binding 
region (amino acids 312-322) of tau (a gift from Peter Davies, 1:350); and Gallyas silver staining 
for NFTs, as done previously 253,254. For ThS staining, tissue slices were incubated in 0.025% ThS 
solution for 10 min, as done previously 3. For analysis of neuronal loss, anti- cleaved caspase-3 
(Asp175) (5A1) rabbit monoclonal antibody (Cell Signaling Technology, Danvers, MA, 1:1000) 
as caspase-3 is a critical executioner of apoptosis. Primary antibody was incubated multiple days 
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and detected by incubating 2 hours with sheep anti‐mouse/rabbit HRP‐linked secondary antibody 
(General Electric, Pittsburgh, PA), and peroxidase reaction was visualized using DAB Kit. 
Preliminary results for NF-L immunofluorescent staining was obtained utilizing anti-
Neurofilament L antibody (Millipore, Temecula, CA, 1:1000). After heat-mediated antigen 
retrieval in sodium citrate buffer (pH 6.0), the primary antibody was prepared in 2.5% goat serum 
+ 1X PBS with 0.02% Triton X and incubated o/n. Secondary antibody goat anti-rabbit IgG (H+L) 
Alexa Fluor® 594 (Invitrogen) was used for fluorescent detection after cover-slipping with 
VECTASHIELD® Antifade Mounting Medium with DAPI (Vector Laboratories).  
Image analysis and quantification  
Pathological tau burden was quantified using AT8 antibody assessing the overall, 
ipsilateral (Ipsi) and contralateral (Contra) side of CCI impact of the cortex and amygdala (Ctx), 
hippocampal area (Hp), and brain stem (BS). Coronal areas assessed were based on anatomical 
connectivity and cytoarchitectural patterns. The area rostral to the impact covered Interaural (IL) 
± 4.54 mm, Bregma (B) ± 0.74 mm – IL ± 3.46 mm, B ± ‐0.34 mm; the rostral impacted area was 
assessed from IL ± 2.74 mm, B ± ‐1.06 mm to IL ± 1.50 mm, B ± ‐2.30 mm; the caudal impacted 
area included IL ± 1.34 mm, B ± ‐2.46 mm – IL ± 0.00 mm, B ± ‐3.80 mm; whereas the caudal 
area to the impact was analyzed between IL ± ‐1.16 mm, B ± ‐4.96 mm and IL ± ‐3.16 mm, B ± 
‐6.96 mm. 3‐5 sample slides of every 10th section were examined under a bright field microscope 
(DMI6000B, Leica Microsystems, Buffalo Grove, IL, USA) and photomicrographs were taken 
with a digital camera (DFC310 FX Leica), imported into ImageJ 1.45s software (NIH), and 
converted to black and white images. Threshold intensity was used to quantify AT8 burden in 
brain. Threshold intensity was automatically adjusted to remove the background and held constant 
during quantification of all the analyzed animals. Burden was defined as the immunoreactive area 
per total area analyzed in percentage. Likewise, AT8 assessment was measured 5‐7 slides of every 
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10th section and scored from no tau detected (0 score) to highest tau deposition (5 score). This 
semi‐quantitative score was graded by the volume and abundance of AT8 immunoreactivity of 
disease‐associated morphological tau adapted previously 46,100,255. Score values were averaged and 
imported into a custom‐designed heat map software to generate an overall view of tau deposition. 
The experimenter was blinded to the animal identities and groups during processing and 
subsequent quantification methods. For Chapters 3-4, the hemisected brain of mice was coronally 
sliced, and AT8, MC1, and Gallyas silver staining (3-5 sections) burden percentage was quantified 
as done above. Multiple brain regions were assessed in all groups: CTX, HPa, Di, BS, and Cb, 
respectively.  
ELISA quantification  
Additional 3 month old mice (n=3‐4) were CCI‐induced (Leica Impact OneTM Buffalo 
Grove, IL) or sham‐induced by the same parameters above. TBI and sham mice were sacrificed 
after 1 day. The ipsilateral and contralateral sides of the brains were extracted from injured and 
sham mice. Brain hemispheres were homogenized at 10% w/v in PBS containing protease 
inhibitors as previously described 3. Brain homogenates were centrifuged at 32,600 rpm for 1 h at 
4°C in an ultracentrifuge (Beckman‐Coulter). The supernatant was removed, and pellets were 
resuspended in 200 μL of 70% formic acid followed by sonication. Samples were centrifuged for 
30 min under the same conditions, and the supernatant was collected and neutralized in 1 M Tris‐
HCl buffer, pH 10.8 to measure the fraction of insoluble tau in brain following TBI. Levels of 
phosphorylated tau at Ser199 were measured using Human tau [pS199] ELISA kit (Invitrogen) 
per manufacturer’s instructions on an ELISA plate reader (EL800 BIOTEK). As for Chapter 3, 
the other half of brain from P301S rmTBI or sham animals (n = 10/group) sacrificed at 1 hour, 1 
day, 1 week, 3 months, 6 months, and 8.5 months were assessed for insoluble pathological tau by 
ELISA. Before homogenization, the cerebellum was excised from the brain to possibly reduce the 
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dilution of any tau seeds, especially at the earliest time-points. Homogenization and obtaining the 
insoluble or formic acid fraction as well as performing the ELISA was done as discussed in 
Chapter 2.  
Statistical analysis  
Graphs are expressed as means ± standard error of the mean (SEM). For Chapter 2-3, data 
was tested for normal distribution by Shapiro‐Wilk normality test. Student t‐test was used to 
analyze normal data for histological burden and ELISA quantifications as well as non‐parametric 
data was ran with Mann‐Whitney test, respectively. For Chapter 4, the Kolmogorov-Smirnov 
normality test for was performed, due to a lower n-value, to assess data distribution. One-way 
analysis of variance (ANOVA) with Tukey's multiple comparison test or Kruskal-Wallis test with 
Dunn's multiple comparison test was utilized, where applicable, for Splash test, Nesting, Open 
Field test, and RotaRod behavior analysis as well as experimental hTau mice AT8, MC1, and 
Gallyas silver staining quantifications. In Chapter 3, comparison of pathological tau between 
P301S rmTBI and sham mice over time was performed by linear regression analysis, and slopes 
compared by GraphPad Prism 5.0 (GraphPad Software Inc., La Jolla, CA). Two-way ANOVA 
followed by Bonferroni post‐test was used to analyze the Barnes maze learning curve as well as 
with reversal learning analysis, and one‐way ANOVA with post hoc Tukey's multiple 
comparisons test was used for long term memory in all cases. Statistical analyses were performed 
using GraphPad Prism 5.0 software. Statistical differences for all tests were considered significant 
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